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 “There is plenty of room at the bottom”. In this visionary lecture in 1959 Prof. Richard 
Feynman spoke of the interesting ramifications of working with matter at the atomic scale. 
Since then, scientists have worked relentlessly towards realizing his vision. The influence 
of nanobiotechnology on material science and polymer chemistry has given rise to a new 
field called ‘theranostics’, combining drug delivery and diagnostics within the same 
nanostructures, thereby enabling simultaneous diagnosis, targeted drug delivery and 
continued therapy monitoring. Iron oxide nanoparticles (MNPs) are one such class of MRI 
contrast agents that can be converted into theranostic nanomedicines for cancer therapy. 
However, development of a stable theranostic contrast system comprising of MNPs is 
complex and requires a careful balance between the therapeutic diagnostic components.  
 We explored the potential of biodegradable hydrophilic block ionomers such as anionic 
poly (glutamic acid-b-ethylene glycol) and cationic poly (l-lysine-b-ethylene glycol) in 
formulating stable magnetic nanoclusters (MNCs). These MNCs were extensively 
characterized for their composition, colloidal stability and factors influencing their MRI 
capability. Extensive in vitro studies revealed that the anionic cisplatin-loaded MNCs 
showed minimal non-specific uptake, a highly preferred feature for targeted cancer 
therapy. Luteinizing hormone releasing hormone receptor (LHRHr) targeting significantly 
enhanced the uptake of these formulations in LHRHr-positive ovarian cancer cells. LHRHr 
 vi 
targeting also helped improve the theranostic efficacy in cisplatin resistant ovarian cancer 
cells. One the other hand, cationic MNCs were used to demonstrate the potential of MNCs 
to function as stimuli-responsive theranostic systems capable of releasing the payload in 
the acidic milieu breast and ovarian cancer cells. These cationic MNCs also exhibited 
significantly enhanced T2-weighted MRI contrasts at much lower concentrations than the 
anionic counterparts. 
 Finally, we successfully evaluated the feasibility of kinetically controlled flash 
nanoprecipitation technique using multi-inlet vortex mixer (MIVM) to formulate well-
defined MNCs from non-ionic amphiphilic Pluronic tri-block copolymers. In comparison to 
self-assembly techniques, flash nanoprecipitation resulted in significant reduction in 
polydispersity. It was observed that the hydrophobic block-length of the copolymer dictates 
the extent of encapsulation hydrophobic therapeutic agents along with the MNPs. 
exhibited the potential to function as both T1 and T2 contrast agents. 
 In summary, looking at the bigger picture, the work presented here emphasizes on the 
importance of product development in establishing a critical balance between the 
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1.1. THERANOSTIC SYSTEMS FOR SIMULTANEOUS DETECTION AND 
DRUG DELIVERY: AN OVERVIEW 
 For many decades’ clinicians and researchers have desired to develop non-invasive 
strategies for diagnosis, therapy and monitoring of numerous pathological conditions in 
humans. The advent of nanotechnology and the extensive research into its medical 
applications has spawned a new era in the field of pharmaceutics and drug delivery. The 
development of novel nano-vehicles such as liposomes, nanogels, micelles etc. for 
delivery of therapeutic payloads to specific target organs has significantly improved the 
treatment of diseases such as cancer. Their successes in significantly reducing undesired 
side effects in healthy tissues has directed the research towards developing systems 
capable of concomitant detection and localized treatment while allowing for therapy 
monitoring 1-3. Such single-entity nano-platforms capable of simultaneously targeting, 
detecting and treating diseased tissue for a prolonged period of time are much desired in 
clinical settings and thus, the field of ‘theranostics’ has emerged. The term “theranostics” 
has been coined by the combination of the terms ‘therapy’ and ‘diagnostics’ to describe 
this promising new field of research that focuses on the creation of a single therapeutic 
carrier system with integrated diagnostic agents for combined capabilities 4, 5. 
 The theranostic approach promises therapeutic specificity due to the molecular 
characters of the disease and also promises a broader choice of contrast agents to 
objectively monitor therapeutic response. The current focus of theranostic formulations is 
development of systems with stealth properties that enable prolonged circulation times 
 2 
and sustained release of the drug while simultaneously providing noninvasive in vivo 
imaging capability 6, 7. It would be highly beneficial from the pharmacokinetic standpoint if 
the circulation time and organ accumulation of the various nanomedicines could be 
studied in real time. Such systems can also help in formulation characterization by 
studying the in vivo drug release patterns. Targeted theranostic nano-systems go a step 
further in terms of tissue-specificity due to their ability to accumulate preferentially at the 
desired site of action.  As exciting as the potential applications of theranostic nanosystems 
are, the formulation process of such multi-component systems is complex and requires 
meticulous control. The following section briefly describes the different fabrication 
approaches used for different theranostic systems.  
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1.2. DESIGN COMPONENTS OF A THERANOSTIC NANO-FORMULATION 
 
Figure 1.1. Components of a theranostic nanosystem 
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 A typical targeted theranostic nano-particulate system is composed of the following 
components (Figure 1): - 
a) Therapeutic agent, which can include small molecules, protein and peptide 
therapeutics or nucleic acids 
b) Diagnostic/contrast or some other type of imaging agent 
c) Nano-vehicle 
d) Targeting moiety 
1.2.1. DESIGN CRITERIA AFFECTING THE CHOICE OF THE THERANOSTIC 
COMPONENTS 
 Several factors have to be considered in the design of a theranostic nanosystem.  
These include: - 
1. Physico-chemical properties of the therapeutic and contrast agents: Physico-
chemical properties such as the solubilities of the drug and contrast agents affect the 
choice of nano-vehicle, which can carry both the components simultaneously. For 
example, the combination of a water-soluble therapeutic agent such as gemcitabine and 
a hydrophobic contrast agent such as magnetic nanoparticles demands a multi-
component nano-vehicle comprising of both hydrophilic and hydrophobic compartments. 
Multilamellar vesicles such as liposomes and polymersomes serve as superior delivery 
vehicles in such cases.  
2. Pathological condition and target tissue: The disease and physiology of the target 
tissue dictate the choice of contrast agent in terms of circulation time and tissue perfusion. 
For example, positive contrast gadolinium-based imaging compounds are the agents of 
choice for magnetic resonance imaging (MRI) which is known to provide superior contrast 
in soft tissues and is generally preferred in nasopharyngeal and other soft-tissue 
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carcinomas including brain tumors 8, 9. In comparison, blood pool agents, which are a 
special class of MR angiography contrast agents, require significantly longer vascular 
circulation times which is achieved through the use of higher molecular weight compounds 
10, 11. The high molecular weight prevents leakage into interstitial spaces and diffusion in 
the vascular epithelium. This also enables higher relaxivities and a better signal-to-noise 
ratio (SNR) leading to superior images 12. Thus, blood pool agents are usually larger 
molecules such as albumin13 or high molecular weight polymers conjugated to the MR 
contrast agents 14,15.  
3. Biocompatibility and biodegradability:  Biocompatibility and preferably 
biodegradability are an absolute requirement when designing theranostic nanosystems16. 
These factors have proven to be substantial roadblocks in regulatory approval and 
commercial acceptance of nanoformulations. Numerous contrast agents such as Gd suffer 
from low circulation half-lives (t1/2) which then necessitates higher doses of this 
nephrotoxic compound17-20. Hence, several successful attempts were made to enhance 
the t1/2 and simultaneously increase the biocompatibility of such contrast agents by 
conjugating them to materials capable of masking the toxicity21-23. Liposomes have been 
studied extensively and rendered safe as nanovehicles for delivery of various payloads 
including various contrast agents24, 25. Other biodegradable materials such as poly(amino 
acids) serve well as biodegradable building blocks for various nanovehicles such as 
polymeric micelles26-28 and nanogels29, 30. Pluronic®, also generically known as 
poloxamers, are another class of biocompatible tri-block copolymers which are used 
extensively in the design of nanoparticulate drug delivery vehicles31-33. Pluronic® have 
been used to formulate magnetic nanoparticle-based theranostic systems for sustained 
delivery of anti-cancer agents such as doxorubicin34-36. These examples show the variety 
and importance of nanomaterial choice in the design of theranostic nano-systems.   
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1.3  CLASSIFICATION OF THERANOSTIC NANOSYSTEMS 
 The different theranostic systems are classified below based upon the imaging 
modality for which they were designed.  
1.3.1 OPTICAL THERANOSTIC SYSTEMS 
 These nanoformulations constitute the simplest of all the classes of theranostic 
systems that can be developed for simultaneous drug delivery and imaging. The relative 
small molecular size of the various flurophores opens numerous avenues for 
encapsulation. 
1.3.1.1. Organic fluorescent dyes 
 The use of fluorescent probes as ligands on several nanosystems is probably the 
simplest and earliest class of theranostic nanosystems developed by researchers. Even 
today, fluorophore-based formulations are predominantly used in research for in vivo 
animal studies and histological analysis of excised tissue. Fluorescent dyes are used 
extensively in understanding the trafficking of nanoformulations and subsequent 
endocytotic paths followed by the nanoparticles into the cells and various cellular 
organelles. For this purpose, several nanovehicles such as micelles, liposomes, 
dendrimers or simple ionic polyplexes have be developed and studied in great detail for 
their theranostic capabilities. For instance, Kleemann et al. investigated the intracellular 
trafficking of polyplexes comprised of poly(ethyleneimine) (PEI)-plasmid peGFP-N1 
targeted to the lungs by the TAT peptide domain of HIV-1 37. The targeting and transfection 
efficiency of the targeted polyplexes was determined by measuring the fluorescence of 
the green fluorescence protein (GFP) in the plasmid. In a similar study, the intracellular 
trafficking of PEI-DNA polyplexes was studied by confocal laser scanning microscopy. PEI 
and DNA were labeled with Oregon Green 488 and rhodamine respectively and the co-
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localized yellow signal was monitored to determine intracellular fate of the polyplexes. This 
method was used to observe that the polyplexes were intact when entering the nucleus. 
Recently, more sophisticated imaging techniques such as fluorescence resonance energy 
transfer (FRET)38 and fluorescence correlation spectroscopy (FCS)39 have been employed 
to overcome the drawbacks of traditional confocal microscopy such as inherently low 
spatial resolution. These advances have enabled more precise information regarding the 
dissociation of DNA complexes within the cells thereby improving the theranostic efficacy 
of the formulations. For instance, Lucas et al. utilized fluorescence fluctuation 
spectroscopy (FFS) to study the trafficking and intracellular fate of DNA polyplexes labeled 
with Cy5 and rhodamine. FFS enabled the researchers to distinguish between the intact 
and dissociated complexes. It was also observed that the fate of the polyplex was 
dependent on the molecular weight of the cationic polymer. The poly(L-lysine)-
oligonucleotide complexes made from 30 KDa poly(L-lysine) dissociated upon entry into 
the nucleus while the polyplexes comprised of poly (2-dimethylaminoethyl methacrylate) 
(pDMAEMA), a 1700 KDa polymer, dissociated in the cytoplasm itself40. Self-fluorescing 
small molecule therapeutics such as doxorubicin provide a dual functionality and added 
advantage in enabling extensive characterization of the encapsulating nanosystems in 
that the in vivo accumulation and release of the formulation can be monitored continuously 
while also providing therapeutic effect25.  
 However, theranostic nanosystems based on fluorescent dyes, show numerous 
limitations such as photo-bleaching, self-quenching, rapid decay of signal and non-uniform 
labeling of the nanoformulations. Furthermore, certain fluorophores such as Cy5 have also 
been shown to inhibit the ability of the backbone polymer to bind to the nucleic acids41. 
These limitations have been addressed by other imaging agents called quantum dots 
(QDs), which will be discussed next. 
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1.3.1.2. Quantum Dots 
 Quantum dots (QDs) are a novel class of inorganic fluorophores, which are gaining 
widespread recognition as a result of their exceptional photophysical properties. They are 
defined as particles with a crystal size on the order of the size of the exciton Bohr radius42.  
QDs are typically 2-7nm in size and made from semiconductor materials such as 
Cadmium-Selenium composites (CdSe). After excitation by visible light, energy is emitted 
in the form of a photon with a characteristic frequency and wavelength, which is dependent 
upon the QD material and structure. QDs have unique advantages over current 
fluorophores including having broad absorption spectra and narrow emission spectra with 
wavelengths ranging from ultraviolet (UV) to infrared (IR). This enables excitation of 
multiple different colored QDs using a single wavelength. QDs are also easily tunable in 
that altering the particle size, composition and surface stabilizing coatings can easily 
control the emission spectra of QDs. Another highly desirable feature of QDs is their photo 
stability. While conventional organic fluorophores are prone to photo-bleaching after only 
a few minutes, QDs are extremely stable and can undergo many recurring 
excitation/emission cycles while retaining high brightness 43, 44. Comparative studies have 
shown QDs to be significantly more photostable than Alexa-Fluor dyes,45 which are 
regarded as some of the most stable organic dyes available 46.  
 Bare QD nanocrystals are prone to emission irregularities such as fluorescence 
blinking and photochemical degradation which leads to the need for surface stabilization. 
Zinc sulfide (ZnS) capping of the QDs is a widely used process and has been found to 
improve stability and fluorescence. However, for biomedical applications, QDs require 
coating which can render them soluble in physiological fluids, impart stealth properties, 
biocompatibility and enhance in vivo stability and circulation times. These surface 
modifications influence the physico-chemical properties and the toxicity of QDs 47. These 
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stabilizing moieties allow for further functionalization of QDs with targeting ligands. To this 
end, Wu et al.45 used two different QDs conjugated with immunoglobulin G (IgG) and 
streptavidin to label the breast cancer marker human epidermal growth factor receptor 2 
(HER2). QDs have also been successfully co-delivered with therapeutic molecules leading 
to the development of QD-based theranostic systems. One such example involves 
development of D-alpha-tocopheryl polyethylene glycol 1000 succinate mono-ester 
(TPGS) coated multi-functional (theranostic) liposomes, which contained both docetaxel 
and quantum dots (QDs) for cancer imaging and therapy 6. These liposomes were further 
conjugated with folic acid to target the folate receptor overexpressed in a large percentage 
of breast cancers. The inclusion of QDs enabled the researchers to qualitatively track the 
internalization of the liposomes at the target site and also monitor the therapy for an 
extended period of time. Functionalized QDs have also been employed as intracellular 
tracers to monitor plasmid DNA (pDNA) delivery 48.  
 Multimodal contrast agents based on the combination of QDs and MNPs are an 
exciting class of bioimaging nanosystems. With two functionalities integrated in a single 
nanoparticle, a sensitive contrast agent for two very powerful and highly complementary 
imaging techniques (fluorescence imaging and MRI) is obtained. Such magnetic QDs can 
be obtained by four different approaches. In the first, QDs are overgrown as a uniform 
layer on the MNP surface followed by stabilization of the entire particle. Gao et al. reported 
the synthesis of FePt cores with a diameter of 3 nm, surrounded by a 3–5 nm CdSe (QD) 
shell through this method 48.  The second approach involves doping of ions of the magnetic 
material into the QDs to impart magnetic properties to them. Paramagnetic ions that have 
energy states within the QD bandgap introduce ‘trap’ states that determine the wavelength 
and lifetime of the doped QD luminescence. In a study by Santra et al.,49 the use of 
CdS:Mn/ZnS QDs for bimodal imaging was demonstrated prominently for the first time. 
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The third method simply involves co-encapsulation of QDs and MNPs in single 
nanoparticulate structures such as PLGA matrix nanoparticles or mesoporous silica. This 
method was used by Kim et al. to obtain uniform mesoporous silica spheres embedded 
with monodisperse magnetic and semiconductor nanocrystals50. Finally, paramagnetic 
substances such as gadolinium can be chelated into the coordination shells of the QDs. 
Mulder et al.,51 used a lipidic micelle surrounding a QD to incorporate Gd-DTPA 
complexes. Surface coating of this type of multi-modal imaging agents is critical from the 
point of increasing colloidal stability and enhancing solubility as well as reducing 
degradation of the QDs and increasing the biological half-life of the MRI contrast agent. 
 Thus, QDs have significantly superior optical properties than organic fluorophores, 
which makes them a better alternative to the organic fluorescent dyes. However, the 
toxicity of QDs is still a concern and most of the research currently is directed towards 
reducing the toxicity through the use of different coating techniques that will have minimal 
impact on the optical properties. 
1.3.2 RADIO-THERANOSTIC SYSTEMS 
 Radiopharmaceuticals are an important class of therapeutic compounds, which have 
been in clinical use for more than 20 years. Also known as radiotracers, these molecules 
are routinely used in clinical practice either as diagnostics or for treatment of certain 
pathological conditions such as cancer, myocardial infarction and several inflammatory 
conditions 52, 53. Current diagnostic techniques in nuclear medicine include non-invasive 
Positron Emission Tomography (PET) and Single Photon Emission Computed 
Tomography (SPECT).  These techniques utilize positron and gamma ray emitting 
radionuclides respectively for generation of a signal. There is great utility of these 
radionuclides in early detection strategies, first-line therapy and then also prognostic 
follow-up. The ability of a single system to perform all these functions simultaneously is a 
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very desirable feature and constitutes the main rationale behind development of 
theranostic radiopharmaceuticals. To this end, significant amount of data is available on 
the efficacy of theranostic radionuclides in targeting various molecular targets expressed 
in different types of cancers. 
 Numerous physico-chemical factors are considered when formulating such radio-
theranostic agents comprising of separate imaging and therapeutic modalities. First and 
foremost, it is very essential to compare and match the pharmacokinetic properties of the 
compounds. Maximum tolerated doses for critical normal tissues are necessary to know 
so that the maximal possible dose can be given to the tumor cells. One of the critical 
parameters to be considered in designing radio-theranostics is the residence time of the 
molecules. Given the rapid radioactive decay that these radionuclides undergo, it is of 
paramount importance to ensure the time accumulation of formulations in sufficient 
concentrations in the target tissue. Radiopharmaceuticals with short radioactive t1/2 
ranging from as low as several minutes to about two months have been approved for 
radiotherapy in several conditions such as cancer. These include β-particle emitting 
radionuclide molecules such as Iodine-131 (131I; t1/2 193 h), Strontium-89 chloride (89Sr; t1/2 
50 days), Yttrium-90 (90Y; t1/2 64 h) and Lutetium-177 (177Lu; t1/2 161 h) and α-emitters such 
as Astatine-221 (211At; t1/2 7.2h), Bismuth-212 (212Bi; t1/2 1h), Bismuth-212 (213Bi, t1/2 45min), 
Actinium-225 (225Ac; t1/2 10 days), and Thorium-227 (227Th; t1/2 19 days) to name a few 54. 
On the other hand, radionuclides for imaging purposes include 99mTc, 111In, and 123I for 
SPECT or 18F, 64Cu, 68Ga, 76Br, 86Y, 89Zr, 110In, and 124I for PET. Several of these 
radionuclides have been formulated into peptide or monoclonal antibody (mAb) targeted 
cancer therapeutics.  For instance, targeted radionuclide therapy using radiolabeled 
somatostatin analog peptides (177Lu-Octreotate) for treatment of neuroendocrine tumors 
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and radiolabeled anti-CD20 antibodies (90Y-Zevalin) for treatment of chemotherapy-
resistant lymphomas have been used clinically for a long time 55.  
 While research on targeted radionuclides conjugated with synthetic peptides and 
mAbs has been at the forefront of product development efforts in cancer radio-
theranostics, significant amount of work is currently underway towards development of 
radio-theranostic nano-vehicles loaded with or conjugated with different radionuclides. Li 
et al.56 designed and constructed a multifunctional theranostic liposomal drug delivery 
system, which integrated multimodality magnetic resonance (MR), near infrared (NIR) 
fluorescent and nuclear imaging of liposomal drug delivery. The payloads comprised of a 
lipidized NIR fluorescent tracer, IRDye-DSPE and Doxorubicin post-loaded into the 
multifunctional liposomes. The multifunctional doxorubicin-liposomes were further stably 
radiolabeled with 99mTc or 64Cu for SPECT or PET respectively. This multifunctional drug 
carrying liposome system exhibited superior imaging capability in squamous cell 
carcinoma of head and neck (SCCHN) tumor xenografts in nude rats following intratumoral 
injection. NIR fluorescent, SPECT and PET images clearly showed either the high 
intratumoral retention or distribution of the multifunctional liposomes.  Similarly, 
unimolecular micelles were formed by dendritic amphiphilic block copolymers poly 
(amidoamine)–poly (l-lactide)-b-poly (ethylene glycol) (PAMAM–PLA-b-PEG–TRC105) 
and conjugated with anti-CD105 monoclonal antibody (TRC105).57 1,4,7-
triazacyclononane-N, N’, N-triacetic acid (NOTA, a macrocyclic chelator for 64Cu) was 
conjugated as the radiotracer while Doxorubicin was loaded into the hydrophobic PAMAM-
PLA core. The 64Cu-label enabled continuous monitoring of the biodistribution as well the 
therapeutic efficacy of the chemotherapeutic agent. Simultaneous radiotherapy and 
photodynamic therapy (PDT) has also attempted by Sugiyama et al.58 The tumor response 
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to this combination therapy was continuously monitored by use of 3′-Deoxy-3′-18F-
Fluorothymidine radionuclide.  
 Despite the plethora of research efforts, radio-theranostics are still in a nascent stage 
of development due to numerous shortcomings that need to be addressed. Most important 
is the rapid decay of the radionuclides in vivo, which requires rapid uptake of the 
formulations in the target tissue. This necessitates very careful product development 
strategies and choice of radioisotopes, which can compliment each other in terms of their 
biological t1/2. The physical stability, leakage of the payloads and stray exposure of the 
healthy tissue are issues that plague the development of these theranostic agents even 
today, although encapsulation within vesicular nanosystems such as liposomes shows a 
potential solution to this problem. In all, radio-theranostic nano-systems have a 
considerable distance to cover before they find clinical acceptance though current 
research shows promise for the future of this class of theranostic agents. 
1.3.3 PHOTO-ACOUSTIC AND PLASMONIC RESONANCE THERANOSTIC AGENTS 
1.3.3.1. Porphyrins 
 Porphyrins exist abundantly in nature. In humans, the porphyrins in blood (i.e. 
hemoglobin and myoglobin) serve not only as carriers of oxygen, but also as the bright 
red contrast agent that clearly demarcates injury sites. They have proven valuable as 
whole body imaging modalities have emerged, with endogenous hemoglobin porphyrins 
being used for new approaches such as functional magnetic resonance imaging (fMRI) 
and photo acoustic tomography (PAT). Functional MRI has been used effectively in 
detailed three-dimensional volumetric mapping of brain activity. The presence of the 
hemoglobin in abundance enables indirect measurement of intracranial metabolic activity 
and blood changes caused by neural activity 59, 60. Hemoglobin, in the form of oxy-
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hemoglobin, shuttles molecular oxygen to and from the cells for cellular respiration. The 
iron chelated in the center of this hemoglobin can change its valency between Fe2+ and 
Fe3+ to help enable precise oxygen delivery. The differences between oxy and 
deoxyhemoglobin can be detected by fMRI because it has been shown that when 
diamagnetic oxyhemoglobin releases its oxygen, the de-oxyhemoglobin becomes 
paramagnetic, which influences the transverse relaxation rates of water proton spins in 
the immediate vicinity of vessels, resulting in the blood oxygenation level dependent 
contrast 61-63. 
 With the capability for both NIR fluorescence imaging and phototherapy, porphyrins 
were the first exogenous molecules that were used with inherent multimodal theranostic 
properties64. Porphyrins have been used as tumor-specific diagnostic fluorescence 
imaging agents since the early 1920’s,65, 66 as positron emission agents since 1951,67 and 
as magnetic resonance (MR) contrast agents since 1987. In addition, exogenous 
porphyrins such as Photofrin® remain in clinical use for photodynamic therapy 
applications. However, these exogenous porphyrins suffer from the drug delivery issues 
seen with other hydrophobic pharmaceuticals.  Researchers have attempted to address 
these issues using polymeric nano-vehicles, which serve well for stabilization and stability 
enhancement of porphyrins. For example, Hsu et al.68 fabricated a robust polymersome 
nano-vesicle comprising of a 4-armed porphyrin conjugated to poly lactic acid (PLA). The 
so-called ‘porphysomes’ combined the cytotoxicity of PDT with ultra-sound based imaging 
capability thereby serving as an ideal theranostic system for cancer therapy. In another 
study, a porphyrin−phospholipid conjugate with quenched fluorescence was developed to 
serve as both the Raman dye and a stabilizing, biocompatible surface coating agent on 
gold nanoparticles 69. Here the porphyrin molecule was chelated with a central Mn2+ to 
quench the fluorescent properties of the porphyrin while enhanced MR capability. This 
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AuNP-porphyrin conjugate served as a novel surface enhanced Raman scattering (SERS) 
probe capable of being used for cellular imaging. Porphyrins have also been encapsulated 
into stable polymeric micelles systems. For example, micelles made of poly- (ethylene 
glycol)-co-poly (D, L-lactic acid) (PEG-PLA) yielded 85% loading of tetrakis (meso-
hydroxyphenyl) porphyrin (mTHPP) while micelles made from poly(ethylene glycol)-co-
poly(caprolactone) (PEG-PCL) yielded approximately 70% encapsulation efficiency of 
silicon pthalocyanine 4 (Pc 4), a porphyrin derivative 70, 71. 
 Thus to summarize, endogenous porphyrins enable optical and magnetic detection 
serving as an effective natural theranostic agent. Exogenous porphyrins have also been 
developed successfully into stable theranostic nanosystems, with new agents facilitating 
multimodal imaging and therapy for numerous pathological conditions. 
1.3.3.2. Micro/ nanobubbles 
 Microbubbles and nanobubbles are spherical cavities less than 10μm in size that are 
filled with different perfluorocarbon (PFC) gases such as octofluoropropane (C3F8), 
decafluorobutane (C4F10) or sulfur hexafluoride (SF6). Microbubbles are formed by ultra-
sonication resulting in the encapsulation of the sterile PF gases into amphiphilic polymeric 
micelle solutions to form nanoemulsion foams at low temperatures. Advanced techniques 
such as microfluidics have also been employed to produce these microbubbles.72, 73 The 
encapsulated microbubbles undergo oscillations in an acoustic field depending upon the 
field strength. These oscillations result in the generation of strong acoustic signals that 
produce a contrast in comparison to the surrounding medium. The microbubble signal and 
the resulting contrast are dependent on a number of factors such as the bubble size, the 
density and viscosity of the entrapped gas, the density of the surrounding medium, and 
the applied field power and frequency 74. These unique contrast agents have 
revolutionized the field of ultrasound imaging. Microbubbles have been used extensively 
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in imaging blood-flow related conditions such as arterial inflammation, angiogenesis, 
restenosis and even cerebrovascular conditions such as stroke 75, 76. Recently, 
researchers have attempted to go a step further and add a co-therapeutic dimension to 
these imaging systems, resulting in the development of theranostic micro/nanobubbles 
systems. Gao et al.77 successfully incorporated doxorubicin into the polymeric shell of 
perfluoropentane microbubbles prepared from PLA-PEG and poly(ε-caprolactone)-PEG 
(PCL-PEG). The non-targeted microbubbles were shown to accumulate passively in tumor 
tissues and coalesce at physiological temperature to form microbubbles. Under an 
ultrasound field these microbubbles oscillate and collapse to release the encapsulate drug 
while simultaneously enabling visualization of the tumor tissue. 
 Microbubbles have also been studied as potential carriers of oxygen to the hypoxic 
area of tumors.78 This strategy is seen as a means to reduce the hypoxia-induced 
resistance to radiotherapy and photodynamic therapy. Another unique approach, as 
demonstrated by Lukianova-Hleb et al.79 involved the formation of transient plasmonic 
photothermal vapor nanobubbles from gold nanoparticles. When activated by a laser 
pulse, an intracellular AuNP acted as a heat source and generated a transient plasmonic 
nanobubbles (PNBs) in the surrounding medium. PNBs of nanometer-scale size and 
nanosecond-scale duration act as diagnostic probes by scattering light from the probe 
laser. Larger micron-scale PNBs provide a localized therapeutic action through a 
mechanical, non-thermal impact due to their rapid expansion and collapse, thus disrupting 
the cell membrane. Ultrasound imaging of the disruptive PNBs can guide their therapeutic 
action. Thus, the PNBs may combine diagnostics, therapy, and therapy guidance. This 
group of researchers went a step further and demonstrated the theranostic ability of these 
PNBs generated by AuNPs within the liposomes to disrupt liposomal membranes thereby 
enabling optically guided delivery and release of the therapeutic payloads 80.  Another 
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potential application is to use microbubble disruption to accelerate thrombolysis.81 The 
same mechanism that promoted clot lysis in the former case has been applied to 
permeabilize and disrupt the blood–brain barrier, which could be useful for enhancing 
delivery of therapeutic agents to brain tissue while continuously monitoring the therapy by 
ultrasound.82  
 Although a relatively new field in ultrasound imaging itself, micro and nanobubble 
research has rapidly expanded beyond mere ultrasound imaging. The astounding success 
of the initial attempts at developing theranostic micro/nanobubbles are very successful 
and have paved way for the next step in development of targeted theranostic microbubble 
systems. The ability to generate plasmonic nanobubbles within nanovehicles is the first 
step towards directing the bubbles in the desired tissue site.  The main limitation of the 
PNB technology is that it shows less potential in deeper tissues where laser penetration 
is difficult and hence generation of transient PNBs is a perceived challenge. Nonetheless, 
this technology shows tremendous promise as a potential theranostic nano-system. 
1.3.3.3. Carbon nanotubes (CNTs) 
 Over the last decade, carbon nanotubes (CNTs) have attracted the attention of many 
scientists across the globe. These hollow cylindrical nanosized tubes are composed 
entirely of carbon and can be either single walled (SWCNTs) or multi-walled (MWCNTs). 
The uniqueness of the nanotube arises from its structure and the inherent subtleness in 
the structure, which is the helical arrangement of the carbon atoms in hexagonal arrays 
on their surface honeycomb lattices. The helicity (local symmetry), along with the diameter 
introduces significant changes in the electronic density of states, and hence provides a 
unique electronic character for the nanotubes. These novel tunable electronic properties 
create a range of fascinating applications, including those in the biomedical field. 
Numerous studies have shown their ability to carry large payloads, either therapeutic83-86 
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or contrast agents87 alone or a combination of both agents88, 89. There are a few studies 
that have attempted to ‘think outside the box’ and exploit the optical properties of CNTs.  
For example, Zarda et al.90 explored the optical imaging capabilities of SWCNTs in tumors 
planted in murine models. The successfully showed that intravenously administered 
SWCNTs conjugated with cyclic Arg-Gly-Asp (RGD) peptides showed eight times greater 
photoacoustic signal in the tumor than mice injected with non-targeted nanotubes. While 
a very enticing proposition, it remains to be explored whether drug loading can affect these 
photoacoustic properties.  
 What is even more fascinating about the use of CNTs is that surface modification does 
not affect their photoacoustic ability while still rendering them non-toxic and biocompatible; 
a drawback that significantly retarded the pace of research into the biomedical applications 
of CNTs in the initial years of this century. But the current efforts in the direction of 
exploring the diagnostic capabilities of CNTs will definitely usher in a new era in CNT 
biomedical research.  
1.3.3.4. Gold nanoparticles 
 In the last decade, gold nanoparticles (AuNPs) have risen as one of the most 
extensively utilized nanosystems for the imaging, diagnosis, monitoring and treatment of 
various diseases, predominantly cancer. AuNPs have been successfully applied in a 
broad range of biomedical fields such as analytical chemistry, biological sensing and 
immunoassays, optical bioimaging, photothermolysis of cancer cells and targeted delivery 
of drugs, peptides, DNA, and antigens.91 The unique optical properties of AuNPs are 
related to localized plasmonic excitations in metal nanostructures interacting with light 
which cause enhanced optical phenomena such as absorption, Mie scattering, Raman 
scattering, and various nonlinear effects.92 AuNPs have been used as non-fluorescent 
probes owing to their photostability, small toxicity, high light scattering efficiency, and 
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ability to serve as carriers for different molecular cargos.93 AuNPs have also been used in 
designing theranostic nanosystems capable of simultaneous imaging and therapy either 
in the form of photothermal therapy or by co-encapsulating with several conventional 
therapeutic agents. Photothermal therapy involves the use of light and a photosensitizer 
to generate heat for therapeutic purposes. In contrast to conventional photodynamic 
therapy, PTT does not require the presence of oxygen, which may be of importance when 
a tumor is large enough to have a hypoxic center. Moon et al.94 reported development of 
a new theranostic system comprising of hollow AuNPs filled with a low melting point (36-
40°C) phase-changing material (PCM) carrying the therapeutic agent. This system had 
capabilities to both enhance the contrast of photoacoustic (PA) imaging and control the 
release of a chemical or biological effectors by high-intensity focused ultrasound. 
Exposure to the ultrasound caused heating of the AuNPs, which melted the PCM. So long 
as the light was incident on the AuNPs, the molten PCM leached out of the hollow vehicles 
thereby allowing for controlled release of the payload. In another study Heo et al.95 
developed targeted AuNPs conjugated with anti-cancer agent paclitaxel. The biotin-
conjugated formulations were rapidly internalized preferentially in the cancer cells and 
were easily detected as bright areas when observed in dark field microscopy. Similar study 
performed by El Sayed et al.96 reported the diagnostic efficacy of EGFR-targeted AuNPs 
in oral cancer cells. In addition to their photoacoustic properties, AuNPs have also been 
reported to be useful in computed tomography aided imaging studies.97 
 Thus, numerous nanoparticulate systems have been studied for potential theranostic 
applications combining photo acoustic imaging with various forms of therapeutic 
approaches for the diagnosis and treatment of several condition, the primary focus being 
cancer.  
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1.3.4. MRI CONTRAST AGENTS 
 Magnetic resonance imaging (MRI) has become an essential tool for diagnosis and 
evaluation of a broad variety of diseases. This technique was first developed in early 1973, 
thanks to the pioneering work of Paul Lauterbur.98 Briefly, MRI relies on the imaging of 
water molecule protons found in abundance in the tissues in the body. Due to its spin and 
charge, protons have a minute magnetic field and hence, when placed in a magnetic field, 
the protons align themselves either parallel or anti-parallel to the field. Upon application of 
radiofrequency energy of a specific strength (Larmor frequency) the protons originally 
aligned with the field absorb the energy and reverse their direction. Upon removal of the 
field they eventually release this energy and relax back into their original alignment. The 
rates at which this relaxation occurs are known as T1 and T2 relaxation times. These times 
vary with the tissue properties. The relaxation produces a magnetic resonance signal. 
Depending on the imaging technique, magnetic pulse sequence, intensity of the signal 
and the type of relaxation, a specific region of interest (ROI) in the final image is 
represented as a bright or dark spot.99 
 It is particularly helpful in diagnosis of intracranial anomalies.100-102 One important way 
to improve the contrast in MRI is to introduce contrast agents, which are a unique class of 
pharmaceuticals that augment the image contrast between normal and diseased tissue. 
They can indicate the status of organ function or blood flow by increasing the relaxation 
rates of water protons in the tissue in which the agent accumulates.  
1.3.4.1. Basic Principals of MRI 
 Magnetic resonance imaging (MRI) is an imaging technique based on the nuclear 
magnetic resonance phenomenon. Due to its ability to provide images of various soft 
tissues in the body non-invasively, it has continued to be one of the widely used diagnostic 
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techniques for imaging of various organs for nearly last 25 years. In contrast to other 
techniques such as computed tomography (CT) and x-rays MRI provides a stronger tissue 
contrast and minimum energy deposition in the tissues. The development of various 
contrast agents for MRI has further added to the benefits of this technique. Before delving 
the field of biomedical applications of MRI contrast agents, this section will provide the 
necessary background for understanding the fundamentals of MRI. 
 In conventional MR imaging, the main source of signal that generates an image is the 
nucleus of the hydrogen atom (1H) consisting of a single proton and half-integral value of 
this integral spin angular momentum (I = ½), which is abundant in the living tissue in the 
form of water and fat.103, 104 The 1H nucleus has one of the largest magnetic moments of 
all nuclei, resulting in a significant MR signal. The quantum mechanical properties of the 
1H nucleus impart a high magnetic moment to it.105 Such nuclei with net magnetic dipole 
moments have odd number of protons and neutrons.106 When exposed to an external 
magnetic field (B), these protons are aligned parallel and antiparallel to magnetic field. 
This is essentially a quantized system comprising of two energy levels wherein the protons 
with antiparallel spins are at the higher energy level than those with parallel spins. These 
protons constantly move or ‘precess’ around the external magnetic field. The speed at 
which they precess is known as precession frequency. Precession frequency is governed 
by the external magnetic field strength (B).107 The stronger the B value, the higher is the 
precession rate and frequency of the protons. The precession frequency is calculated by 
the ‘Larmor equation’108 
ω0 = γ. B0        …Eqn. 1.1     
where:- 
ω0 is the precession frequency, γ is the gyromagnetic ratio and B0 is the magnetic field 
strength in Tesla (T). 
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 The ω0 value for 1H protons is approximately 42MHz at B of 1T.104, 105 The opposing 
magnetic forces arising from the protons precessing in the opposing directions cancel 
each other. Only the magnetizations along the direction of the magnetic field do not cancel. 
All magnetic moment vectors add up resulting in net magnetization along the direction of, 
or longitudinal to, the applied external magnetic field. This is known as longitudinal 
magnetization (M0).109, 110 Thus, if a patient is placed in an external magnetic field of a 
MRI scanner, (s)he has a net M0 which cannot be measured. The inability to measure the 
static magnetic moment is due to it being in the same direction as that of the external 
magnetic field (B) and very small in comparison. However, it is possible to ‘flip’ the net 
longitudinal magnetization at a right angle to the direction of the external field by using a 
radiofrequency 111 pulse at the ‘Larmor’ frequency. This external pulse provides the energy 
necessary to disturb the equilibrium arrangement of the spins parallel and antiparallel to 
B and transiently point the net magnetization towards a plane transverse to the external 
magnetic field thereby producing a signal, which is recorded by a receiver coil The instant 
this 90° RF pulse is turned off, the newly established transverse magnetization gradually 
decays by dissipating the stored energy to the surrounding (lattice). This dissipation of 
energy results in re-alignment of the magnetization in the longitudinal direction to re-
establish the original equilibrium. This process is known as T1 relaxation.104, 112 Once back 
to the equilibrium state the protons are ready again for a new RF pulse. However, if the 
TR is less (TR < 5.T1), the previous relaxation is not complete and hence the subsequent 
RF pulse generates lower signal. This is the source of T1-based contrast since the tissue 
with a shorter T1 will undergo a more complete recovery, thereby producing a brighter 
signal.  
 Relaxation is a time-dependent process characterized by relaxation time, which is a 
rate constant for this phenomenon. There are two distinct relaxation processes occurring 
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simultaneously namely longitudinal relaxation, also known as spin-lattice relaxation, 
denoted as T1 and transverse relaxation or spin-spin relaxation, denoted as T2. T2 
relaxation occurs due to a complete loss of signal following the RF pulse. It is a 
phenomenon dominated by entropy rather than energy transfer.  While both T1 and T2 
measure the natural energy transfer by an excited proton, they differ in the final disposition 
of the energy. 
a. Relaxation 
 Measurement of magnetic resonance (MR) can be analyzed in terms of energy 
transfer. The process by which the protons release energy absorbed from the applied RF 
pulse is known as relaxation.104 Relaxation is the fundamental property of MR and affords 
the principal mechanism for image contrast or MRI. 
i. Longitudinal (T1) relaxation 
 T1 relaxation time is the time required for the disturbed M0 (M) to return to 63% of its 
original M0. T1 relaxation provides the mechanism by which the protons give up their 
gained energy to return to their original orientation and magnetization (M0). This return of 
magnetization typically follows an exponential growth process. T1 relaxation times in the 
tissues are relatively slow with the values ranging from few milliseconds to several 
seconds.113, 114 In practice pulsed RF energy is applied to the protons repeatedly with a 
delay time (TR) between the pulses, which allows for T1 relaxation to occur. As the protons 
return to their original orientations, a difference is established between protons in the 
parallel and anti-parallel spins. This allows for the energy absorption to recur after the next 
RF pulse. These repetitions cause more dissipation of energy and hence generation of a 
larger signal following repeated pulses. TR is generally insufficient for complete T1 
relaxation to occur. Application of a second RF pulse before complete relaxation causes 
M to flip again in the transverse plane, albeit with a smaller magnitude than the previous. 
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After a few repetitions M returns to its original magnitude prior to the RF pulse, thus 
achieving a steady state value, which depends five parameters namely106, 110, 113 
1. The external magnetic field B. The larger the field, larger is M 
2. Proton density per unit volume of the tissue 
3. The amount of energy absorbed by the protons (flip angle) 
4. The repetition time or rate of RF pulse application 
5. T1 relaxation time 
 The repetition time (TR) is a critical parameter since it controls the efficiency of energy 
transfer. If TR is significantly smaller than T1 relaxation time, the spin will not relax 
completely and hence the next pulse will produce a proportionately smaller magnetization 
signal which will undergo relaxation at a faster rate, thereby producing a brighter signal. 
In practice, each tissue saturates differently due to different T1 relaxation times, which 
affects its maximum potential signal.  
 As discussed previously, spin-lattice relaxation measures the rate of energy transfer 
from an excited proton to the surroundings. Such a transfer also relies on the presence of 
either a vibrational or rotational molecular motion of the lattice in the vicinity of the excited 
protons. The intrinsic frequency of such a motion (ωL) matches ω0. The closer these two 
frequencies are, the sooner do the protons return to their equilibration state.105 Thus the 
presence of several protein structures and metal ions in the tissue greatly influences the 
ωL. Iron (Fe) and Manganese (Mn) have significant magnetic moments that can potentially 
affect the local environment. T1 decreases with decreasing B. However, a larger B does 
not necessarily mean a greater signal since longer T1 times are prone to saturation.113 
ii. Transverse (T2) relaxation 
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 T2 relaxation or spin-spin relaxation time is the time required for the transverse 
component of M to decay to 37% of its initial value, the loss of signal occurring due to 
irreversible processes. As described previously, when a RF pulse is applied, the 
precessing protons absorb this energy and hence the longitudinal magnetization (M0) is 
disturbed and rotates in the transverse plae.103, 105, 106, 113  
 When in the transverse plane, all protons precess with the same Larmor frequency ωO. 
Thus a proton having a similar molecular milieu and precessing with the same frequency 
can absorb the energy being dissipated by its neighboring proton. This transfer of energy 
from between two excited protons of the same kind in a similar environment is called spin-
spin relaxation. The absorbed energy is retained as spin relaxation without being 
transferred to the surroundings as in T1 relaxation. Several inter and intra-molecular 
interactions such a vibrations and rotations cause transient fluctuations, which lead to 
gradual loss of the transverse magnetization. T2 is the time when this transverse 
magnetization is at 37% of this original value immediately after the RF pulse. If the TR is 
faster than the relaxation time, the corresponding M will rotate continuously and while 
doing so gradually decrease in magnitude until it disappears as the proton populations at 
the higher and lower energy levels will equalize leading to zero net magnetization. As a 
result, no signal is produced; a condition known as saturation or magnetization saturation 
(Ms).115, 116 There is a limited amount of energy that the protons can absorb before reaching 
saturation.  If more time relapses, this transverse coherence completely disappears and 
T1 relaxation occurs. One important difference between T1 and T2 relaxation is the 
influence of B. T1 is sensitive to B while T2 is relatively insensitive to B. 
1.3.4.2. Contrast agents 
 MRI revolutionized the field of medical diagnostics. It has perhaps been the most 
powerful method for the non-invasive investigation of human anatomy, physiology and 
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pathophysiology. Compared to other imaging techniques, such as computed tomography 
(CT), MRI does not involve radiation or radionuclides and provides significant amount of 
intrinsic contrast between different tissues, making it widely used in neurological, 
musculoskeletal, cardiovascular, and oncological imaging. This contrast is based upon 
different signal intensities between the adjacent tissues. This contrast is obtained primarily 
due to the differences in the T1/ T2 relaxation times of the different tissues accentuated by 
the chosen parameters such as TR and TE.  
 In spite of this intrinsic contrast between the tissues, distinction between diseased and 
normal tissue can still be challenging as the pathological organ may have similar T1/ T2 
times as that of the adjacent normal tissue. In other situations, the region of interest may 
contain significant amounts of normal tissue, making the contrast low. In either case, a 
promising approach is to increase the signal difference between normal and pathologic 
tissue, which can be achieved successfully by administering a suitable contrast agent. 
 Contrast agents for MRI are indirect contrast agents. Unlike those used in CT (direct 
agents), most MRI contrast agents are indirect agents and not visualized directly in the 
image. Instead, they affect the relaxation times of the numerous water protons in the 
nearby tissue. The concentrations at which these agents are used are also very low, 
thereby explaining the low occurrence of side effects to MRI agents. MRI contrast agents 
can be categorized into three groups with most of them falling into one of two categories: 
T1-agents and T2-agents. T1-agents generally increase the longitudinal (spin-lattice) 
relaxation rates (1/T1) of water protons in tissue more than the transverse (spin-spin) 
relaxation rates (1/T2). With most conventional pulse sequences, this dominant T1-
lowering effect gives rise to increases in signal intensity predominant on T1 weighted 
images; thus, these are positive contrast agents that produce a brighter contrast. On the 
other hand, T2-agents largely increase the 1/T2 of tissue rather selectively, leading to 
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decreases in signal intensity; predominant on T2 weighted images, and thus these 
represent negative contrast agents, which produce a dark contrast. However, non-proton 
agents, such as certain perfluorocarbons, by virtue of the absence of hydrogen, do not 
affect relaxation rates (or the signal) in MRI but produce low signal intensity at completely 
different resonance frequencies (19F) than those of the conventional Gd or iron oxide-
based contrast agents. These represent a third class of MRI contrast agents. Whether the 
contrast agent functions as a T1-agent or T2-agent depends on a function of the imaging 
sequence used, the field strength, the correlation time and how the contrast agent is 
compartmentalized in the tissue. The ability of the agent to reduce the T1- and T2- 
relaxation times are respectively described by the r1 and r2 relaxivity values of the agent. 
The following section describes in brief, the mechanisms of contrast enhancement in the 
presence of T1 or T2 relaxation agents. 
a. T1 contrast agents 
Almost all T1 relaxation agents currently in clinical use are gadolinium-based 
intravenous agents. Gadolinium (Gd) in a rare earth metal with a large magnetic 
moment.117, 118 The primary mechanism of contrast generation for T1 contrast agents is by 
functioning as a relaxation sink for water protons.119 As described previous in this section, 
following a RF excitation pulse, T1 relaxation depends upon the decay of the absorbed 
energy from the proton to the ‘lattice’. For the energy transfer to occur efficiently, these 
protons should be in the coordination sphere, i.e. in the innermost layer of atoms 
surrounding the metal ion.110, 120 Gd-based contrast agents are formulated as Gd chelates 
to reduce the toxicity of Gd as a free metal ion.121, 122 These chelate molecules are 
relatively larger with multiple bonds to the central Gd metal ion,123 which limits free space 
in the inner coordination sphere.110, 113 This limits the fats and other large molecules from 
gaining sufficient proximity to central metal ion for efficient energy transfer. However, the 
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water present in these tissues can penetrate into the coordination space, dissipate its 
energy and subsequently exchange with the bulk tissue water, thus allowing for additional 
water molecules to enter the coordination sphere.110 This process occurs very rapidly and 
hence the water in the bulk tissue is relaxed and available for the subsequent pulse. As a 
result, the tissue water near the contrast agent has a larger net value of M than water in 
the neighboring tissue, thus contributing to a greater and brighter signal in a T1-weighted 
image. The rapid exchange process ensures that a single Gd-complex can affect 
numerous water molecules. This reduces the dose of Gd-based T1 contrast agents. 
In addition to gadolinium (Gd3+), the other most common paramagnetic species in 
nature are metal ions with unpaired electrons, such as manganese (Mn2+, Mn3+), iron 
(Fe2+, Fe3+), lanthanide (La3+) and dysprosium (Dy3+) which have been used in MRI 
contrast agents.124-126 The gadolinium ion Gd3+ is the most widely used paramagnetic ion 
for MRI contrast agents because it has a high magnetic moment and a symmetric 
electronic ground state.  However, paramagnetic metals cannot be used as contrast 
agents in the ionic form due to their undesirable bio-distribution, very short biological half-
lives and relatively high toxicities. To address this issue of short circulation times and 
severe systemic toxicities, Gd chelates with various stabilizing ligands have been 
designed. Acyclic and macrocyclic polyaminocarboxylates, such as 
diethylenetriaminepentaacetic acid (DTPA), 1,4,7,10-tetraazacyclododecane-N,Nl,Nll,Nlll-
tetraacetic acids (DOTA), and their derivatives, have been the main ligand used to 
stabilize Gd. The Gd (III) chelates such as Gd-DTPA (Magnevist, Schering AG, Germany), 
Gd-DTPA-BMA (diethylenetriaminepentaacetic acid-(bismethylamide); Omniscan_, 
Amersham-Nycomed, Norway), Gd-DO3A-HP (1,4,7,10- tetraazacyclododecane-1-(2-
hydroxypropyl)-4,7,10-triacetic acid; ProHance_, Bracco Imaging, Italy), and Gd-DTOA 
(Dotarem_, Guerbet SA, France) are currently in clinical use. Gd-chelates have been 
 29 
further modified to target specific tissues in the body. For instance, the first generation 
MRI contrast agents, such as Gd-DTPA were modified to form neutral molecules, which 
thus exhibit much lower osmolality, longer circulation times and higher safety.127, 128 Some 
suitable residues have been incorporated into either the acetic side arms or the 
diethylenetriamine backbone of Gd-DTPA and Gd-DOTA to obtain tissue or organ-specific 
contrast agents. Thus, Gd-based contrast agents specifically targeted to the liver, tumor 
and blood pool have been developed, which can localize in these target sites thereby 
producing greater signal in the MR images.129 Gd-based positive contrast agents are in 
greater demand and are preferred contrast agents in clinics due to their bright contrast 
that enabled clear demarcation and non-invasive visualization of the disease tissue. 
 Apart from Gd-chelates, Mn-based compounds and ultra-small superparamagnetic 
iron oxide nanoparticles (USPIOs; 3-5nm) have also been used to generate positive 
contrast. Manganese dipyridoxyl-diphosphate (mangafodipir, Mn-DPDP, Teslascan_, 
Nycomed Amersham Imaging, Princeton, NJ) is a contrast agent developed for imaging 
of the hepatobiliary system.130 USPIOs, on the other hand, have been incorporated into 
numerous nanoformulations such as liposomes,131, 132 micelles,133, 134 polymersomes,135 
dendrimers136 to name a few, in order to impart hydrophilicity, enhance stability and most 
importantly increase circulation times. Long circulation times are specifically required 
since these contrast agents are extensively used blood pool agents.15, 129  
b. T2 contrast agents 
T2 or negative contrast agents mainly include superparamagnetic magnetite (Fe3O4), 
maghemite (ϒ-Fe2O3) (collectively referred to as MNPs hereafter) or their composites with 
other ferromagnetic metals such as cobalt (Co), nickel (Ni) and manganese (Mn).137, 138 
Paramagnetic substances such as Gd-based complexes have no net magnetization in 
absence of a magnetic field.110 However, ferromagnetic macromolecular structures such 
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as iron oxide have very high magnetic susceptibility, which can persist even on removal 
of the external magnetic field.139 Magnetic susceptibility is the degree of magnetization of 
a metal in response to an external magnetic field. This persistence of magnetization 
(remnant magnetization) is dependent on the physical properties of the iron oxide such as 
particle size.140 These MNPs lose their magnetization upon removal of magnetic field and 
hence are known as superparamagnetic nanoparticles.141 Likewise, when an external 
magnetic field is applied, due to their high magnetic susceptibility, these nanoparticles 
exhibit a very strong net magnetization resulting in distortion of the local magnetic field in 
their vicinity.142 The microscopic field inhomogeneity causes the nearby water protons to 
dephase more rapidly than the surrounding tissue, thereby leading to significant decrease 
in signal intensity as a result of the shortening of the T2 and T2* relaxation times.  
Biocompatible MNPs such as magnetite have been widely used for in vivo biomedical 
applications including MRI contrast enhancement, tissue specific release of therapeutic 
agents, hyperthermia, and magnetic field-assisted radionuclide therapy. Their slower renal 
clearance and higher transverse (T2) relaxation values compared to the Gd-based contrast 
agents make them more attractive for imaging purposes.143 Biomedical applications 
require that the SPIONs be stable in water, in physiological conditions and not be 
recognized by the body’s phagocytic mechanisms. Various factors such as core size, 
surface charge, surface ligands and chemistry, affect the colloidal stability of the MNPs. 
To control the surface properties, MNPs are commonly coated with a biocompatible 
polymer, a step that significantly controls the size of the resulting MNP clusters while 
preventing formation of large aggregates. In addition, polymer coating can also allow 
binding of drugs and targeting ligands onto the MNP surface. Some MNPs with core sizes 
of 3–6 nm and dextran coating (with 20–150 nm hydrodynamic sizes) such as Feridex 
(discontinued in USA), Endorem, Combidex and Sinerem are approved for MRI in 
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patients.144 Recently, Zhao et al. 145 synthesized octopod-shaped MNPs with extremely 
high T2 relaxivity (six-fold higher) values compared to the spherical counterparts of similar 
chemical composition. These MNPs have significantly higher values than all the 
commercial MNPs currently available. In addition, drug loaded MNPs have also been 
surface-modified with various targeting ligands and can be guided to the desired target 
area using an external magnetic field while simultaneously tracking the biodistribution of 
the particles.146  
 Composites of iron oxide nanoparticles are obtaining by replacing a mole fraction of 
the Fe moiety by other metals, which exhibit significantly higher (T2) relaxation values. 
Magnetite composites with Co having T2 relaxivity values almost 4-fold higher than pure 
MNPs have been reported.147 Similar observations have been made with Ni-based MNP 
composites.148 However these composites have, so far, suffered from significant toxicity 
and biocompatibility issues. Although surface-modification has helped reduce the toxicity 
considerably, when compared with pristine MNP formulations these composite cores are 
inherently toxic and degradation of the cores has been shown to contribute significantly to 
formulation toxicity. Thus, given the extensive research in the field of magnetic 
nanoparticles, iron oxide based MNP formulations continue to show tremendous promise 
in development as theranostic nanosystems. The fact that these MNPs are already 
available for clinical use in European nations and still continues to be used on a proprietary 
basis in US further adds to the optimism. 
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1.4. THERAPEUTIC AREAS WITH POTENTIAL BENEFITS FROM ‘NANO-
THERANOSTICS’ 
 Therapeutic and technological advances in medicine have enabled prompt diagnosis 
and improved precision in therapy for many pathological conditions. However, there is a 
tremendous scope and an increasing need for improvement in management of certain 
diseases.  
1.4.1. NON-MALIGNANT NEUROLOGICAL DISORDERS 
 Nanovehicles capable of carrying multiple payloads present distinct advantages in 
targeting the hard-to-reach areas of the brain. Nanoparticles can be surface-functionalized 
to readily transmigrate across the blood-brain barrier (BBB), which otherwise posed a 
near-impermeable barrier to the delivery of therapeutics to the brain.149 The ability to tailor 
nano-formulations as per the requirements of specific pathological conditions is a highly 
desired feature. To this end, liposomes serve as the ideal nano-delivery vehicles capable 
of carry multiple payloads simultaneously for brain targeting and bioimaging with imaging 
agents such as Gd/ MNP-based MRI agents or quantum dots.150, 151 One such example of 
brain disorders where nanomedicine and theranostics show tremendous promise is 
traumatic brain injury (TBI). Affecting almost 2 million patients annually in the US alone, 
there are no FDA approved treatments for TBI. Numerous clinical trials focusing on 
conventional single drug therapy have failed.152 Technological advances in proteomics 
have enabled the identification of therapeutic pathway-specific biomarkers of TBI. 
Although indirect and involving multiple steps, biomarker driven methods of detection and 
diagnosis have paved the way for timely and personalized treatment of such patients. 
Stroke or cerebral ischemia is another dreaded cerebrovascular condition with very limited 
treatment alternatives. The use of theranostics capable of timely treatment and 
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subsequent maintenance therapy along with continuous therapy monitoring is considered 
to be a very valuable approach to stroke management. To this end, Agulla et al. have 
designed stealth immunoliposomes targeted towards HSP72 protein in the peri-infarct 
region with dual imaging capabilities (fluorescence and MRI). Loaded with citicoline, these 
dual modal theranostic immunoliposomes showed a 30% decrease in lesion volume when 
compared to non-encapsulated drugs. Encapsulation of Gd-DTPA-BSA enabled a 
continuous monitoring of the targeting efficiency of the formulation, tissue accumulation 
and progression of therapy over a period of 7 days.153  
 During the last decade, there has been an unprecedented increase in the number of 
cases of neurodegenerative conditions such as Alzheimer’s disease (AD) and Parkinson’s 
disease. The primary hurdle in the management of these conditions is early diagnosis. 
CdSe-ZnS quantum dots (QD) conjugated to dihydrolipoic acid have be demonstrated to 
successfully detect the amyloid plaques, block their growth and thus reduce the fibrillation 
process along with detection.154 Skaat et al.155 used fluorescent maghemite nanoparticles 
coated with LPFFD peptide for simultaneous detection, treatment and therapy monitoring. 
These theranostic MNPs inhibited the associated fibrillation, which could be monitored by 
MRI. In addition, numerous biomarkers such as the new 79-amino acid Alzheimer’s 
associated protein ALZAS67 have been identified156, which can aid in early detection of 
amyloid plaques, thereby enabling preventive measures against further development of 
the condition. 
 Commercial blood pool agent Endorem® has been used as a marker for long-term 
noninvasive MR tracking of transplanted bone marrow and embryonic stem cells in rat 
brain and spinal cord.157 In this study, the migration of mesenchymal stem cells labeled 
with Endorem could be tracked successfully to the injured site for a prolonged period of 
time. While these are only a few representative examples of the relentless efforts currently 
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being made towards the development of theranostic systems for brain, they do highlight 
the advantages of theranostic nanosystems in several pathological conditions of the brain. 
1.4.2. CARDIOVASCULAR DISEASE 
 Cardiovascular disease is the leading cause of morbidity and mortality all over the 
world. Several theranostic nanosystems have been studied for several cardiovascular 
conditions with interesting and encouraging findings. Numerous studies have successfully 
demonstrated the potential of several theranostic nanosystems in detection and treatment 
of atherosclerosis. Certain molecules such as αvβ3-integrin are overexpressed on the 
endothelial cells in the atherosclerotic plaques. These molecules serve as direct targets 
for long-circulating targeted nanoparticles. Functionalization of nanoparticles to target 
macrophages or oxidized low-density lipoproteins (LDL) within the plaques. The ability to 
target these processes allows for simultaneous targeting of therapeutic agents as well as 
contrast agents. The applicability of theranostic nanosystems was evaluated as follows:  
a. Nanoparticulate contrast agents co-delivered with conventional therapeutics to 
evaluate the efficacy of the therapy: USPIO’s, popularly used as blood pool agents, 
have been shown to have significantly high uptake in macrophages in atherosclerotic 
plaques both pre-clinically 158, 159 and clinically160. Morris et al. exploited this finding to 
demonstrate the potential of USPIO-enhanced MRI in monitoring the therapeutic efficacy 
of p38 kinase inhibitor in mouse model of atherosclerosis. MR images showed reduction 
in contrast in the aortic area of animals treated with p38 indicating reduced accumulation 
of macrophages in the atherosclerotic plaques in the treatment group.161 This approach 
was used successfully for the first time in humans to non-invasively evaluate the efficacy 
of treatment of atorvastatin in carotid plaques. 162, 163 Theranostic nanosystems can also 
be used in monitoring the treatment of peripheral artery disease. ανβ3-integrin-targeted 
perfluorocarbon nanoparticles were used to monitor the effect of dietary L-arginine in 
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decreasing the symptoms of peripheral artery disease by increasing arteriogenesis. 164 19F 
MRI using perfluorocarbons has been used effectively for the detection of inflammation 
due the efficient uptake of these emulsified contrast agents into monocytes and 
macrophages, which in turn infiltrate the affected tissue. 165 Targeting of the nanoparticles 
to the ischemic tissue enhanced the signal and contrast two-folds in comparison to the 
nontargeted nanoparticles thereby significantly improving the ability for non-invasive 
monitoring of therapy progression and success wherein oral dietary L-arginine resulted in 
significant development of collateral blood vessels in the affect tissue. 
b. Nanoparticulate therapeutics co-delivered with free contrast agents to evaluate 
efficacy of nanotherapy: Stenotic arteries formed due to progression of atherosclerosis 
are often dilated by balloon dilation followed by placement of a metallic stent. However, 
restenosis in such arteries often leads to other complications such as myocardial damage 
and impeded peripheral circulation. Drug eluting stents, which are often used for such 
conditions, can add to the complications by interfering with the healing of the endothelial 
membrane. 166-168 αvβ3-targeted rapamycin loaded169 nanoparticles co-encapsulating 20% 
(v/v) perfluorooctylbromide and 30 mol% Gadolinium diethylene-triamine-pentaacetic 
acid-bisoleate as the paramagnetic components successfully reduced the extent of 
stenosis in the related arteries. This improvement was tracked by MR angiograms over a 
period of two weeks. Perfluorocarbon-containing nanoparticles conjugated with Phe [D]-
Pro-Arg-chloromethylketone (PPACK), a molecule with high affinity for thrombin, were 
studied in the treatment of thrombosis in a mouse model of thrombosis. The site-specific 
accumulation of the 160nm nanoparticles was observed by 19F MRI imaging.170 In another 
approach, paclitaxel (PTX)-loaded MNPs were employed to replenish the drug-depleted 
stents. While MNPs were used exclusively to aid in targeting and accumulation in the 
desired region, fluorescent probes were conjugated on the nanosystems to evaluate the 
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therapeutics efficacy as observed by delayed cell proliferation.171 This approach has also 
been used to demonstrate improved perfusion of the affected tissue in peripheral artery 
disease. Gold nanoparticles carrying vascular endothelial growth factor (VEGF) were 
targeted to the ischemic tissue in order to promote angiogenesis and increase perfusion 
in a murine hind limb ischemia model. The therapeutic effects of the targeted gold 
nanoparticles were visualized by laser Doppler perfusion imaging. The targeted 
nanoparticles helped increase the circulation half-life of VEGF while reducing the 
undesired side effects. Similarly, adenosine-loaded liposomes administered intravenously 
significantly reduced myocardial infarction in murine model.172 Fluorescent ligands 
decorated on the liposome surface were used to track the accumulation of the 
nanoformulations at the affected site. This formulation was specifically beneficial from the 
point of significant reduction in the unwanted side effects of free adenosine when 
administered intravenously.  
c. Co-encapsulated therapeutic and contrast agents for simultaneous diagnosis 
and treatment and subsequent monitoring of therapy: Co-encapsulated theranostic 
nano-systems provide significant advantages in terms of spatio-temporal delivery of both 
the essential components without measurable loss. This approach helps improve the 
treatment and overall management of previously mentioned conditions such as restenosis. 
Successful attempts have been made to inhibit the smooth muscle proliferation in the 
stented blood vessels. Perfluorocarbon nanoemulsions loaded with anti-proliferation 
drugs doxorubicin (DOX) as well as PTX were targeted to tissue factor on the smooth 
muscle cells in the restenotic artery walls. In this in vitro study, the uptake of the particles 
was detected by T1-weighted MRI imaging while 19F MRI helped further enhance the 
contrast and distinguish the tissue from the nanoparticles. The pattern of DOX 
fluorescence was monitored to observe and study the pattern of drug release over time.173 
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PFCs encapsulated within nanoformulations have shown significant improvement in site-
specific signal enhancement in all cardiovascular conditions associated with inflammation. 
The very first study to demonstrate the advantages of co-encapsulation in treatment of 
atherosclerosis used perfluorocarbons along with anti-angiogenic drug fumagillin.174 PFCs 
were encapsulated in nano-emulsions stabilized by a surfactant co-mixture of lecithin, 
polyethylene glycol (PEG)2000- phosphatidylethanolamine, phosphatidylethanolamine and 
gadolinium diethylene-triamine-pentaacetic acid-bis-oleate. Fumagillin partitioned into the 
surfactant layer surrounding the paramagnetic perfluorocarbon molecule. The therapeutic 
response of the drug could be monitored over an extended period of time. Theranostic 
nanosystems have also been studied using multiple modes of visualization of a single 
contrast agent. Such an approach helps to separate the tracking of the nanosystems from 
evaluating the therapeutic efficacy.  Labotto et al.175 developed Gd-containing liposomes 
co-loaded with anti-inflammatory glycoprotein PLP. The liposomes produced significant 
T1-weighted contrast by dynamic contrast enhanced MRI (DCE-MRI), which was used to 
monitor the delivery and accumulation of the formulations in the atherosclerotic plaques 
while 18F-fluoro-deoxy-glucose (18F-FDG) was injected separately to study the therapeutic 
efficacy of the liposomal formulation by PET/CT. In another study, a multi-modal nano-
theranostic agent comprising of dextran-coated MNPs and near-infrared fluorophore 
AF750 with phototoxic capacity was prepared. These nanoparticles were readily 
internalized by murine macrophages as observed in the in vitro experiments. The in vivo 
studies revealed preferential accumulation of the nanoparticles in macrophage-rich 
inflamed atherosclerotic lesions as visualized by intravital fluorescence microscopy. When 
irradiated by 650nm light, AF750 was activated resulting in phototoxicity in the 
atherosclerotic area, causing significant reduction in inflammation and lesion stabilization. 
Such a theranostic system provided for simultaneous imaging and therapeutic response 
by a single multi-purpose NIR fluorophore.176  
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 While many of the above-mentioned theranostic nanosystems are still in the 
experimental stages and thus need further characterization, quality control and 
toxicological evaluation, there is no doubt that compared to conventional formulations and 
contrast techniques, such theranostic nanosystems have proven to be superior in terms 
of therapeutic efficacy as well as continuous monitoring of therapy in several 
cardiovascular conditions, predominantly atherosclerosis and stroke.  
1.4.3. CANCER 
 Cancer is steadily growing into a global public health problem and is feared to take 
over cardiovascular diseases and obesity as the disease with the highest mortality and 
morbidity rates. Cancer statistics of 2014 estimated over 1.6 million new cases and over 
500 thousand deaths in the United States itself.177 These numbers justify the federal 
emphasis on research aimed at prevention, early diagnosis and therapy of cancer. Given 
the diverse nature of the disease, every new case is unique in terms of the diagnosis, the 
molecular markers expressed and the response to therapy. These complexities have 
spurred concerted efforts in the direction of personalized therapy wherein each patient’s 
biomarker profiling is recommended to design and optimize the therapeutic strategy. 
Nanomedicine, via its extensively target-centric approach, has opened new avenues, 
which can enable early diagnosis and highly personalized anti-cancer therapy.  The ability 
to functionalize nanoparticles to target different types of diagnostic and therapeutic 
payloads exclusively to the malignancy helps reduce the dose, enhance accumulation of 
the therapeutic and also significantly reduce the incidence of unwanted side effects that 
plague conventional cancer treatments.  The need to detect the malignancy in early 
stages, treat it and simultaneously monitor the progression of therapy noninvasively is a 
highly desired feature in cancer chemotherapy.  This has given rise to what is termed as 
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‘cancer theranostics’, i.e. simultaneous therapy and non-invasive diagnostic monitoring of 
the disease.  
 The development of a theranostic nanosystem for cancer is guided by numerous 
factors. The location and stage of the disease is a primary factor which dictates the type 
of contrast agent to be selected. With that in mind, several potential theranostic anti-
cancer nanoformulations have been reported so far. Radio-theranostic nanosystems 
(discussed in section 1.3.2.) are the most versatile since the diagnostic component is not 
quenched in deeper tissues and can be consistently monitored. Radiopharmaceuticals 
can be used for the treatment of the deepest tissues in the human body such as for 
treatment and imaging of bone metastasis.178 Recently, nanobodies radiolabeled with 
99mTc were generated against the paratope of M-protein expressed in multiple myeloma 
cells as a tool to image multiple myeloma progression using SPECT/microCT. Targeted 
radionuclide therapy using a 177Lu-labeled anti-5T2 MM nanobody led to an inhibition of 
disease progression.54 Optical theranostic nanosystems have also been shown to be 
successful. Zhang et al.179developed a multifunctional nanocomposite by loading copper 
sulfide (CuS) into Cy5.5-conjugated hyaluronic acid nanoparticles (HANP), obtaining an 
activatable Cy5.5_HANP/CuS (HANPC) nanocomposite. Cus quenched the Cy5.5 
fluorescent signal inside the intact particles. Upon complete degradation by hyaluronidase 
present in the tumor stroma, strong fluorescence signals delineated the tumor. Thus, CuS 
with strong NIR absorbance appears to be an excellent contrast agent for photoacoustic 
(PA) imaging and an effective PTT agent. 
 Ultrasound mediated imaging is another technique with potential for applications in 
different types of cancer, given the ability of ultrasound to penetrate deep in the body 
tissues.180 Carson et al. demonstrated the use of targeted ultrasound microbubbles in 
squamous cell carcinoma for detection and burst-initiated siRNA release and therapy.181 
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Liposomes have been used extensively in ultrasound-assisted anti-cancer therapy. 
Microbubbles conjugated with paclitaxel (PTX)-loaded liposomes were targeted towards 
breast cancer.182 Other optical theranostic nanosystems such as porphyrins have also 
been successfully shown to inhibit tumors. Shi et al.183 successfully investigated the 
potential of a 64Cu-containing nanosystem comprising of porphyrin-peptide-folate 
nanoprobe for simultaneous PDT and PET imaging. However, it must be noted here that 
PDT application are limited to superficial cancers such as those of the head and neck 
since activation of the porphyrin in deeper tissues is difficult. Similar argument can be 
made for theranostics with AuNPs for photothermal therapy combined with photoacoustic 
imaging. Lastly, MRI contrast agents are another extremely versatile choice across all 
types of cancers. The advances in MRI technology enable whole body scans with 
excellent contrast between malignant and healthy tissues, including those in the brain. In 
the next section we exclusively discuss these applications of magnetic (iron oxide) 
nanoformulations. 
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1.5. APPLICATIONS OF MAGNETIC NANOPARTICLES (MNPS) IN CANCER 
THERANOSTICS 
 The biocompatibility and biodegradability of magnetic nanoparticles, particularly of 
those made from magnetite, coupled with its MRI capability makes them ideal candidates 
for numerous biomedical applications. The ease of stabilization and case-specific 
functionalization (personalization) of these MNPs finds use in cancer diagnosis, 
therapeutics and therapy monitoring.  Here we review the different applications of MNPs 
and their nanoformulations in overall management of cancer. 
1.5.1. MAGNETIC FLUID HYPERTHERMIA (MFH) AND IMAGING 
 When MNPs are exposed to an alternating current (AC) magnetic field, the resulting 
eddy current, hysteresis, and energy losses due to Neél and Brownian relaxation 
mechanism experienced by the MNPs result in localized heating in the associated tissue 
around the nanoscale source.184 It is known that cells, when exposed to elevated 
temperature of about 42-45 °C for sufficient time period initiate apoptotic processes 
leading to cell death.185 The capacity to combine MRI capability and therapy in the form of 
hyperthermia as well as the possibility of functionalizing particles specific to a patient’s 
biomarkers has directed research in this direction to further advance the use of magnetic 
nanoparticles in cancer treatment. Classical hyperthermia is known to induce a reversible 
damage to cells and tissues and has been known to work very effectively as an adjunct 
treatment to conventional radiotherapy or chemotherapy. Maier Hauff et al. studied the 
efficacy of intratumorally administered MNPs and radiotherapy on patients with recurrent 
gliobloastoma multiforme.186 It was observed that pre-treatment with field –induced 
hyperthermia followed by radiotherapy led to longer overall survival following diagnosis of 
the first tumor recurrence. The efficacy of the treatment regimen was monitored by regular 
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MRI and CT scans. Another study conducted in prostate cancer patients evaluated the 
ability of transperinially administered MNPs in monitoring the therapeutic responses of 
repeated magnetic fluid hyperthermia (MFH) by CT.187 Simultaneous MFH and MRI 
imaging faces challenges related to the properties of MNPs.188 For successful MFH is it 
essential that MNPs be localized in the target tissue in high enough concentration. 
However, this interferes with ability of MR scanners to produce clear images. At high 
enough concentration MRI images are not without any artifacts and hence CT is the 
preferred technique in such cases.  This has prompted the development of composite 
MNPs wherein Fe is doped with high metals such as Co, Mn or Ni in order to increase the 
specific absorption rate (SAR) of the resulting MNPs. Such an approach is driven on the 
hypothesis that composite MNPs, due to their high SAR will be able to generate sufficient 
localized heating at significantly lower concentrations, which can aid in obtaining better 
images by MRI itself. Nonetheless, the application of MNPs in simultaneous 
hyperthermia and targeted chemotherapy has been successfully tested in human trials as 
well189-191 which has renewed the interest in applying MNPs for dual therapy in cancer. 
1.5.2. SIMULTANEOUS CHEMOTHERAPY AND MRI 
 Over the last decade, the availability of a broad range of polymeric and other 
biodegradable and biocompatible has led to an explosion in the research in the direction 
of development of magnetic nanoparticle-based theranostic systems capable of carrying 
a therapeutic payload and simultaneously enabling MR imaging. The ease of 
functionalization of these nano-systems has made it possible to target them to patient-
specific biomarkers. Extensive research in cancer genetics has shown that cancers show 
significant heterogeneity and hence the concept of ‘one size fits all’ cannot work at least 
here.192, 193 This has brought about a paradigm shift in the process of oncological drug 
development. The focus is now on designing targeted or personalized therapies as per 
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the genetic constitution of the disease in every patient. A classic example is breast cancer 
wherein different cases present with different biomarkers or, still worst, none at all.194 The 
human epidermal growth factor receptor overexpressed in several cases of cancers has 
many subtypes namely HER1/EGFR, HER2, HER3 and HER4.195 Accordingly, the 
therapeutic strategies differ. For instance, Tarceva® (erlotinib) is the preferred line of 
therapy to target HER1 in patients with non-small cell lung cancer (NSCLC). HER2, 
overexpressed in breast and ovarian cancer is targeted using mAb Herceptin® 
(trastazumab).  
 Theranostic nanomedicine shows tremendous potential in not only targeting, but also 
controlling the release of the payload and monitoring the therapeutic response. Schleich 
et al.196 compared the different in vivo targeting strategies of PLGA nanoparticles co-
loaded with PTX and MNPs. They concluded that dual targeting (i.e. active targeting of 
αvβ3 integrin via RGD grafting along with magnetic targeting) resulted in maximum 
accumulation of nanoparticles which in turn enhanced therapeutic and MRI contrast 
efficacy. Thermoresponsive anti-cancer nanosystems have also been developed to 
control the release of the therapeutic payload via the hyperthermic potential of MNPs. 
Purushotham et al.197 developed core-shell magnetite (Fe3O4)–poly-n-(isopropyl 
acrylamide (pNIPAM) composite MNPs loaded with DOX. In an alternating magnetic field, 
the MNPs generated heat leading to localized temperature rise. Above the lower critical 
solution temperature of PNIPAM, the nanostructure released DOX thus acting as an on/off 
switch to control drug release. Clares et al.198 reported the development of 
magnetoliposomes loaded with 5-fluorouracil (5-FU) for the colon cancer. These non-
targeted formulations showed thermo-responsive release of 5-FU in response to local 
hyperthermia in AC field.  
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 Physiological stimuli-responsive MNP-based theranostic systems have also been 
designed to control the drug release form the nanocarriers. Luo et al.199 exploited the 
presence of intra-cellular redox conditions to trigger drug release from MNP-cyclodextrin 
nanoformulations loaded with camptothecin. Li et al.200 went a step further by developing 
folate-targeted magnetic bovine serum albumin microcapsules loaded with coumarin-6. 
The microcapsules exhibited redox-responsive enhancement in drug release. The pH 
difference between healthy tissues and tumor microenvironment has also been utilize pH 
responsive theranostic nanosystems. Sahoo et al.201 designed DOX-loaded theranostic 
MNPs comprising of pNIPAM. These systems showed preferentially release of DOX 
conjugated via a pH labile linker only under physiological temperature. Another interesting 
attempt was made by Gan et al., who developed ‘MNP-gated’ mesophorous silica 
nanoparticles. In this system, MNPs capped the pores on the drug loaded silica 
nanoparticles via pH labile linkers. At acidic pH the MNPs opened the pores thereby 
causing controlled release of the payload. 
 Several successful attempts have been made to employ low frequency non-heating 
AC magnetic field to release the drug from the theranostic MNPs. In one such example, 
polymersomes were loaded with USPIOs and DOX were tested for field-responsive in vitro 
drug release and cytotoxicity in HeLa cells.135 They observed that when exposed to 15mT 
fields at 750 KHz, the formulation exhibited 18% increase in cytotoxicity. It was postulated 
that in response to Neel relaxation mechanisms, the MNPs dissipated heat, which was 
sufficient enough to cause poration in the polymersomal membrane and thus release the 
therapeutic agents. In the last of their series of four publications demonstrating the 
application of various stimuli for drug release from ‘gated mesoporous silica 
nanoparticles’, Thomas et al.202 demonstrated that in presence of external AC magnetic 
field having a frequency of 500kHz and 37.4 KA/m field strength, Zn-doped MNPs 
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generated local heat, which caused the cucurbit(6)uril nanovalves on the pores to open 
and release DOX. Controlling the duration of the applied AC field pulse could control the 





 Theranostics is emerging as a new field that combines the modalities of therapy and 
diagnostic imaging. Nanotechnology holds the key to the fructification of this vision. The 
ability to ‘pack’ therapeutic and diagnostic modalities in a single carrier helps overcome 
unwanted differences in biodistribution, selectivity thereby ensuring the simultaneous 
presence of both the components in the desired site. The eventual aim of the field of 
theranostics is to gain the ability to image and monitor the diseased organ, drug delivery 
kinetics, and therapeutic efficacy, eventually being able to tune the therapy and dosing as 
per the needs of the patient. Clinicians are increasingly advocating such personalization 
of therapy. In fact, numerous cancer treatment centers across the US, have started 
studying the genetic make-up of the patients in order to design a treatment strategy on a 
case-by-case basis.  However, given the short response time available once diagnosed 
with fatal diseases such as cancer, it is an uphill task to formulate a personalized 
formulation with required precision. Hence the onus is now on researchers in the field of 
Pharmaceutics and drug delivery to device techniques for addressing this need. As 
exemplified in this overview, tremendous efforts are underway in the direction of 
development of theranostic nanoformulations for numerous pathological conditions. In 
terms of imaging modalities, there are various options available, from simple fluorescence 
based systems to complex ultra-sound based photoacoustic agents, each with its 
advantages and disadvantages. However, in case of MNP-based theranostic 
nanosystems, thanks to the relentless efforts for the last two-three decades, the 
advantages outweigh the limitations. The ability to tune almost every character of MNPs, 
from their magnetic properties to addition of various targeting moieties makes them a 
favorable choice, especially for cancer management.  One factor that still plagues this 
class of theranostic systems is their systemic stability and associated toxicity.  
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 We aim to design highly stable and completely biodegradable MNP-based theranostic 
nanoclusters capable of targeted drug delivery and MR imaging. Given that the primary 
requirement in a theranostic system is to strike a right balance between the amounts of 
therapeutic and contrast agents carried by the nanocarrier, development of such a 
nanosystems is a very complicated process. Through the next chapters we demonstrate 
the challenges faced and the strategies employed to meet these challenges in 
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CHAPTER 2 
LHRHR-TARGETED MAGNETIC NANOCLUSTERS STABILIZED 
BY BIS-PHOSPHONATE-MODIFIED POLY (GLUTAMIC ACID)-B-
POLY (ETHYLENE GLYCOL) FOR OVARIAN CANCER 
THERANOSTICS 
2.1. INTRODUCTION 
 Recent advances in nanomedicine have shown the capability to realize the 
long-desired spatio-temporal delivery of drugs, genes and imaging agents. Enhancement 
in material sciences has enabled the design of nano-carriers capable of releasing their 
payload in response to specific biological stimuli such as pH1-3, temperature4-6, redox 
potential7-9 etc. Over the last two decades, superparamagnetic iron oxide nanoparticles 
(MNPs) have been studied comprehensively and used in a wide variety of fields ranging 
from high capacity data storage and water purification10 to numerous biomedical 
applications such as protein and antibody detection11-13, protein14 bacteria15 and toxin16 
separation and most importantly as magnetic resonance imaging (MRI) contrast agents15. 
The ability of MNPs to interact with protons of water molecule and shorten their transverse 
(T2) relaxation times produces dark T2-weighted negative contrasts in the accumulating 
tissues. The MRI capacity of MNPs had been applied clinically for diagnosis of several 
diseases. MNP formulations have been designed and used clinically as blood pool agents 
in magnetic resonance angiography (MRA)17, 18 for imaging of the aortoiliac region and 




 The first-generation commercial MNP-based MRI contrast agents such as Feridex® 
showed a higher propensity for aggregation in vivo and rapid systemic clearance.20, 
21.Rapid clearance necessitates an increased dose to achieve the desired contrast, which 
in turn induces toxicity. All these factors seem to have led to the withdrawal of Feridex®22 
in the United States. To be clinically relevant, negative contrast agents depend on higher 
transverse (T2) relaxivity. Transverse relaxivity is governed by several factors such as 
MNP core size, chemical nature, oxidation state, applied magnetic field, site-specific 
uptake and proximity of the metal ions to the water. A formulation that enables deeper 
penetration of the water molecules towards the magnetic core allows for faster relaxation 
of the protons and a higher T2-relaxivity. Clusters of magnetic nanoparticles experience a 
greater force than single, well separated MNPs in a magnetic field gradient.23 Several 
successful attempts have been made to functionalize MNPs with therapeutic agents for 
specific disease. Such ‘theranostic’ systems, as they are termed, present a desirable 
improvement in cancer chemotherapy due to their ability to target the tumor and 
simultaneously allow noninvasive visualization and treatment24 25. Development of a MNP-
based theranostic nanosystem is an intricate task as it requires correct balance of the 
diagnostic and therapeutic components. For example, biodegradable polymersomes 
loaded with MNPs and doxorubicin exhibited magnetic field-responsive drug release along 
with excellent MRI contrast.26.Similarly MNP clusters stabilized by Pluronic® F127 and 
loaded with doxorubicin have been shown to exhibit a sustained drug release in vivo while 
simultaneously enabling MR imaging of the target tumor tissue.27 However, formulation-
related issues such as colloidal stability and toxicity still hinder the clinical development of 
such MNP-based ‘theranostic’ systems.  
 Selection of an appropriate polymer for coating is critical to ensure colloidal stability, 




biocompatibility and biodegradability of the polymer further limits the choices. Block 
ionomers comprising of biodegradable charged poly (amino acid) chains can serve as 
ideal stabilizing agents for formation of MNCs. Each year there are about 22,000 new 
cases and over 14,000 deaths annually due to ovarian cancer in the US.28 In spite of the 
dose limiting nephrotoxicity and other severe side effects,29 cisplatin still remains the first 
line of treatment for ovarian cancer. To address the severe toxicity, several successful 
attempts have been made at loading cisplatin into nanoparticles and targeting it 
exclusively to the malignancy via several targeting ligands. For instance, previously, 
cisplatin was incorporated within folate-receptor targeted nanogels to successfully treat 
folate-receptor-positive ovarian cancer xenografts in mice.30 The membrane receptor for 
Luteinizing hormone releasing hormone (LHRHr) is overexpressed in more than 70% 
human ovarian cancers31-33. Luteinizing hormone releasing hormone peptide (LHRH), a 
synthetic analogue of the nautral hormone has been used to successfully target 
chemotherapeutic agents to LHRHr overexpressed on the tumor tissue.34, 35 LHRH-
targeted nanogels conjugated with cisplatin were used to enhance the in vivo cytotoxic 
efficacy in treatment of LHRHr-positive ovarian cancer xenografts in mice.36 In a separate 
study MNPs were conjugated directly with LHRH-peptide in order to improve the uptake 
in LHRH overexpressing breast cancer cells.37  
  Herein we report a simple process for formulation of theranostic MNCs for anti-cancer 
therapy and simultaneous MR imaging. The MNCs were prepared by stabilization with 
anionic bisphosphonate-modified poly (glutamic acid)-b-(ethylene glycol) (PLE-b-PEG) by 
an entirely hydrophilic route. The MNCs were loaded with cisplatin though electrostatic 
interactions and LHRH was conjugated to the MNCs surface as targeting moiety. Stable 
cisplatin-MNC conjugates (PtMNCs) exhibited selective uptake, cytotoxic efficacy 




overexpressing A2780-wild type (A2780-WT) and cisplatin-resistant (A2780-CisR) ovarian 
cancer cells. The LHRHr targeted MNCs is an effective T2 contrast agent for simultaneous 
chemotherapeutic efficacy in LHRHr-positive tumors. 
2.2. EXPERIMENTAL SECTION 
2.2.1. MATERIALS 
Chemicals: Poly (glutamic acid)-b-poly (ethylene glycol) block copolymers with different 
poly (glutamic acid) 38 block lengths namely PLE10-b-PEG113, PLE50-b-PEG113, PLE100-b-
PEG113 and poly (aspartic acid)100-b-PEG113 (PLD100-b-PEG113) and the respective 
homopolymers were purchased from Alamanda Polymers (Huntsville, AL). Here and 
below the numbers in subscripts after the copolymer blocks define the number of the 
repeating units (r.u.) in the respective block. The free end of PEG contained methoxy 
groups. Alendronate sodium trihydrate was purchased from Ultratech (Navi Mumbai, 
India). 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC), N-hydroxysuccinimide 
(NHS), iron (III) acetylacetonate (Fe(acac)3), benzyl alcohol (anhydrous), nitric acid 
(TraceSELECT), hydrochloric acid (TraceSELECT), ICP grade standards for Fe, Pt and P 
(Fluka) and 3-(4,5-dimethylthiazol -2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were 
purchased from Sigma-Aldrich (St. Louis, MO). Acetone (histology grade), n,n-
dimethylformamide (DMF), cisplatin, Pyridine, DMSO and all other anhydrous HPLC grade 
organic solvents were purchased from Thermo Fisher Scientific (Waltham, MA). N-
hydroxysulfosuccinimide (S-NHS) was purchased from Covachem (Loves Park, IL). D-
Lys-6-LHRH (Glp−His−Trp−Ser−Tyr−DLys−Leu−Arg−Pro−Gly) peptide was purchased 
from American Peptide Company (Sunnyvale, CA). Alexa Fluor®-647, Lysotracker Green 




Cell lines: A2780 wild-type human ovarian cancer cells were purchased from American 
Type culture collection (ATCC, Manassas, VA). Cisplatin-resistant A2780 human ovarian 
cancer cells were derived from the wild-type cells by repeated exposure to sub therapeutic 
concentrations of cisplatin over a prolonged period.  
2.2.2. METHODS 
2.2.2.1. One-pot Synthesis of Magnetite Nanoparticles 
 Magnetite nanoparticles (MNPs) were synthesized by thermal decomposition of iron 
(III) acetylacetonate (Fe (acac)3) in benzyl alcohol with minor modifications to the method 
developed by Pinna et.al.39 Briefly, 6.2 μmoles of Fe (acac)3 was charged to a three-
necked flask containing 45mL anhydrous benzyl alcohol. The reaction mixture was heated 
at 110°C for 1h to ensure complete evaporation of water. The size of the MNPs was tuned 
by subsequently varying the heating rates of the reaction. Four different heating profiles 
were employed as described below and depicted in Figure 1.  
Profile A: The reaction mixture was heated gradually at 0.4°C/min to 205°C. Once at 
reflux the temperature was kept constant for 40h.  
Profile B: The mixture was heated to 150°C at 4°C/min and kept isothermal at 150°C for 
2h following which the temperature was raised to reflux at 4°C/min and heated for 40h at 
reflux.  
Profile C: The reaction mixture was heated to 180°C at 4°C/min and kept isothermal at 
180°C for 2h after which the temperature was raised to reflux at 4°C/min and heated for 
40h at reflux.  
Profile D: The reaction mixture was heated quickly at 5°C/min to reflux and heated at 




 All the reactions were conducted under inert atmosphere. After cooling, the 
nanoparticles were precipitated and washed in acetone. The final product was collected 
by magnetic separation, dried under vacuum and stored for further use under vacuum in 
a sealed vial filled with argon. The benzyl alcohol content in the final product was 
estimated by thermogravimetry (TGA; TGA Q50, TA Instruments, DE). Briefly, 20 mg 
sample was heated at 5°C/min to 1000°C. Benzyl alcohol content was obtained by 
subtracting the weight of the residue from the initial weight of the sample. The saturation 
magnetization (M; emu/g) of the smallest and the largest particles obtained was 
determined by SQUID-VSM (Quantum Design Co.) at 300 K.  
2.2.2.2. Alendronate Conjugation to PLE50-b-PEG113 
 Prior to ALN conjugation, PLE50-b-PEG113 sodium salt was de-protected by dissolving 
in de-ionized water and acidified by slow addition of 0.1N HCl to restore the carboxylic 
acid functionality. The precipitate was dialyzed overnight against de-ionized water and 
lyophilized to obtain the de-protected polymer. For the conjugation reaction, 5μmoles of 
the de-protected polymer was dissolved in 3mL DMSO. In a separate vial, 0.16 mmoles 
EDC and 0.8 mmoles NHS were dissolved in 0.5mL DMSO and added to the polymer 
solution. The reaction mixture was stirred for 4h at RT. 0.44 mmoles ALN.Na was 
dissolved in 4mL de-ionized water followed by adjustment of the pH to 9.5 by addition of 
NaOH. The EDC-NHS-activated PLE50-b-PEG113 in DMSO was added dropwise to the 
aqueous solution of ALN and the reaction was stirred for 48h. The unconjugated ALN as 
well as the reaction by-products were removed by centrifugal filtration through 3000 
MWCO PES centrifugal membrane filters (Sartorius, NY) and the resultant ALN-
conjugated PLE50-b-PEG113 was lyophilized. The ALN conjugation was confirmed 
qualitatively by 31P-NMR. The degree of conjugation (Dconj) was quantified from 1H-NMR 




conjugated ALN at 3.0 – 3.22 ppm with the broad singlet of the H-atom on the chiral carbon 
of PLE block at 4.0 – 4.34 ppm (Figure 2.5) and by inductively coupled plasma mass 
spectrometry (ICP-MS).40 Briefly, a standard curve was prepared from commercial 
standard solution of phosphorus (Fluka) in the 50 – 500 ppb concentration range. The 
lyophilized polymer was dispersed in 1 ml of DI water at a concentration of 1mg/mL. 50 
μL concentrated HCl (TraceSELECT) was added to it and the mixture was incubated at 
70°C for 12h. The sample was allowed to cool to room temperature (RT) after which the 
volume was adjusted to 2mL with DI water.  The final solution was filtered through 0.2μm 
nylon syringe filter and analyzed by ICP-MS to quantify the bisphosphonate end groups in 
the polymer using argon and oxygen carrier gases. 
2.2.2.3. Preparation of Polymer-Stabilized MNCs  
a. 30-40nm MNCs: Briefly, the polymer was dissolved in 10 mL alkaline water (pH 9-9.5) 
and added to a 10 mL MNP dispersion in alkaline water (pH 12) in a 2:1 (w/w) ratio.  
b. 65-85nm MNCs: Larger sized MNCs were obtained by dissolving the polymer and 
MNCs in 5mL of respective solvents. 
 The mixture was then stirred for 12-15h followed by extensive dialysis for 72h, with six 
water changes. To obtain the final product, the dialyzed mixture was further purified by 
filtration through 0.45 and 0.22 μm Whatman Anotop syringe filters, lyophilized to dryness 
and stored under vacuum in a sealed vial filled with argon for further studies.  
2.2.2.4. Preparation of Cisplatin-Loaded MNCs  
 Cisplatin was loaded by electrostatic interactions onto the free carboxyl groups of the 
PLE block of the MNCs. Briefly, prior to loading the number of moles of carboxyl groups 
available were quantified by potentiometric titration. The MNCs were dispersed in 




NaOH. Cisplatin (equivalent to 50 or 75 mol% of the available carboxyl groups in the 
formulation) was dissolved in n,n-dimethylformamide (DMF) and added under stirring to 
the colloidal MNCs. The solution was stirred for 48h in the dark. The unconjugated cisplatin 
was separated by centrifugal filtration (2000-MWCO, Sartorius, location USA) and the final 
product was lyophilized and stored in vacuum at -20°C for further use. 
2.2.2.5 Preparation of LHRH-conjugated MNCs 
  DLys6-LHRH was conjugated to the free carboxylic groups on MNCs by EDC/sulfo-
NHS coupling reaction via the D-lysine group on the peptide. Briefly, 10mg lyophilized 
MNC or PtMNC formulations were dispersed in MES buffer (pH 6; 0.05M) at a 
concentration of 20 μg/mL. EDC/sulfo NHS (3 equiv/6 equiv) at RT was used to activate 
5 mol% of the total available carboxylic groups (concentration of carboxylic groups was 
calculated by potentiometric titrations) for 2h. The excess of the unreacted chemicals was 
neutralized by 2-mercaptoethanol (20mM). (D-Lys6)-LHRH was dissolved in PBS (20mM, 
pH 7.4) at a concentration of 10mg/mL. 0.4mL of this solution was mixed with the activated 
MNC and PtMNC formulations. pH of the mixture was adjusted to 7.4 and the solutions 
were stirred for 7h at RT. The dispersions were purified by centrifugal filtration (3000 
MWCO; 3 washes) to remove the unreacted peptide and other reactants. The final 
formulations were lyophilized and stored under vacuum at -20°C for further use. 
2.2.2.6. Physiochemical Characterization of MNCS 
a. Dynamic light scattering (DLS). The z-average hydrodynamic diameter (Deff), 
polydispersity index (PDI) and ζ-potential was determined by DLS using a Malvern 
Zetasizer (Malvern Instruments, MA, and USA). The concentration of the dispersed phase 
was 1 mg/mL  




thermogravimetric analysis (TGA). Briefly, 5-10mg of the lyophilized unloaded-formulation 
was placed on the tared TGA pan. The formulation was dried in the furnace at 110°C in 
order to remove the moisture followed by steady heating at 5°C/min to 1000°C. The 
obtained thermogram was analyzed using the Universal Analysis software (TA 
Instruments, DE) to deduce the total loss of the organic components 41 and amount of 
MNPs per mg of MNCs. The content of benzyl alcohol coating was determined by loss of 
organic components upon thermal decomposition of MNPs by TGA. The LOI of MNCs 
was corrected by subtracting the content of benzyl alcohol in the MNPs to obtain the 
content of polymer in the MNCs.  
c. Relaxation measurements: A Bruker Biospec MRI and spectroscopy (MS) system 
(7T/21 cm, Bruker, Karlshure, Germany) was used to determine the longitudinal (r1) and 
transverse (r2) relaxivities of the different MNC formulations. The sequence used for T2 
mapping was a CPMG phase cycled single slice multiecho sequence. One 1 mm thick 
coronal image was acquired with an acquisition matrix of 256 x 128, 40 mm field of view, 
32 echoes at 10 ms first echo time and 10 ms echo spacing, repetition time of 3000 ms, 
one average, for a total acquisition time of 6.4 min. The stabilized colloidal particle 
dispersions were diluted to 0, 0.018, 0.045, 0.09, 0.18, 0.27 and 0.36 mM Fe with distilled 
water and 20mM PBS. T1 and T2 relaxation times were measured and converted to their 
corresponding relaxation rates (R1 and R2; 1/T; s-1). The r1 (longitudinal relaxivity) and r2 
(transverse relaxivity) values (s-1.mM-1) were obtained as the slope of the plots of R1 or R2 
versus the corresponding Fe concentrations. 
2.2.2.7. Determination of Drug Release from Cisplatin-Loaded MNCS  
 The drug release of the anionic formulations was studied in pH 7.4 phosphate buffered 
saline (PBS; 20mM) and pH 5.5 sodium acetate buffered saline (50mM). Briefly, 




tubes (3.5 – 5KDa MWCO; 1ml capacity; Spectrum Labs, USA). The volume in the tube 
membrane was adjusted to 1mL and the assembly was placed in a 24ml dissolution 
medium and stirred at approximately 125 rpm for five days. At specific time points during 
the study, 0.5ml aliquots were removed from the dissolution medium outside the dialysis 
membrane and replaced with same volume of fresh buffer. The cumulative release of 
cisplatin was quantified by ICP-MS and plotted against time.  
2.2.2.8. Cellular Uptake of MNCS  
a. Quantitative determination by ICPMS: A2780-WT and A2780-CisR cells (106 cells/ 
well) were treated with a 2ml colloidal dispersion of the different formulations (equivalent 
to Fe concentration of 5μg/ml) and incubated for 24h. At various time points during the 
incubation period the medium was removed from the wells and the cells were washed 
three times with ice-cold PBS and acid saline (pH 3). The cells were harvested and the 
viability was determined by trypan blue assay and centrifuged to form a pellet. The 
supernatant was removed completely and 0.5ml of a100ppb solution of Iridium in 2% 
HNO3 was added to the pellets. The cells were then lysed mechanically by probe-
sonication. 50μl concentrated nitric acid (TraCERT; Fluka) was added to the lysate, which 
was then digested overnight at 70°C. The digested samples were then appropriately 
diluted to 5ml with 2% HNO3. The cell debris was separated by ultra-centrifugation at 
10000rpm for 30 mins. The supernatant was further filtered through 0.2um syringe filters 
and analyzed by Nexion 300-D ICP-MS equipped with collision cell and auto sampler 
(Perkin Elmer, USA). The intensities of the 57Fe and 195Pt isotopes were considered for 
quantification of the uptake. The final Fe or Pt content was normalized to the total protein 
content of the cells (as determined by standard BCA assay) and uptake was expressed 
as μg per mg of total cellular protein.  




to study the cellular localization pattern of the different fluorescent-labeled MNCs. A2780-
WT and A2780-CisR cells were incubated with Alexa Fluor®-647 labeled MNCs for 1, 3 
and 24h followed by visualization under a LSM 710 (Zeiss, CA) confocal microscope 
equipped with a live-cell imaging stage. 
2.2.2.9. In Vitro Cytotoxicity of PtMNCs  
 The cytotoxic potential of the cisplatin-conjugated PtMNCs was estimated in vitro in 
A2780-WT and A2780-CisR human ovarian carcinoma cell lines. Briefly, the cells were 
cultured in complete RPMI 1640 medium in conditions mentioned previously. Twenty four 
hours after seeding about 3000 cells per well in 96-well plates, the cells were treated with 
either free drug cisplatin, blank MNCs or PtMNCs (+/- LHRH) at different concentrations. 
The cells were then incubated for 24 and 72h. At the end of each time point the culture 
medium was replaced with complete RPMI and the cells were further incubated for 12h. 
Finally, the cell viability was estimated by standard MTT assay. Briefly, 0.02mL of a 
5mg/mL solution of MTT in PBS was added to each well and the plates were incubated 
for 4h. The plates were then centrifuged and the supernatant was removed. The resulting 
formazan crystals were dissolved in DMSO and the color intensity was measured at 
560nm using Spectramax M3 plate reader.  The cell viability was determined by comparing 
the different treatment groups with the control (untreated) wells.  
2.2.2.10. In Vitro Determination of MR Potential  
 Approximately 10 million A2780-WT and A2780-CisR cells were incubated with LHRH-
conjugated and unconjugated particles at Fe concentrations of 0.045, 0.09 and 0.18 mM 
for a period of 24h. Following incubation, the cells were collected and cell viability was 
determined by trypan blue assay. 9 million viable cells were re-dispersed in 0.5mL PBS 
and mixed carefully with equal volume of hot 4% w/v agar solution. The samples were 




cells were used. Phantom gels were scanned in Siemens Magnetom TIM Trio 3T human 
MR scanner. Images of the phantom gels were obtained by using a multigradient echo 
pulse sequence at a 1.64ms/3000ms TE/ TR and 40° flip angle for T1 and 112.5ms/ 
3000ms TE/TR for T2. The cellular phantoms were compared with phantoms of similar 
concentrations of formulations without any cells. 
2.2.3. STATISTICAL ANALYSIS 
 Statistical analysis was performed using IBM SPSS 23 statistical software. 
Experimental designs with two groups were analyzed by student’s t-tests. Designs with 
more than two groups were analyzed by appropriate ANOVA test followed by Bonferroni 





2.3. RESULTS  
2.3.1. SYNTHESIS AND CHARACTERIZATION OF MAGNETITE NANOPARTICLES 
(MNPS) 
Figure 2.1. Various heating regimes during the synthesis of MNPs by thermal 
decomposition of Fe(acac)3 
 At the onset of this work we concluded that it was important to control and fine-tune 
the sizes of the MNPs as these sizes could affect the properties of the resulting MNCs. In 
the modified one-pot solvent-controlled synthesis of magnetite nanocrystals39, 42 benzyl 
alcohol acts as a solvent and reducing agent as well as a ligand or a mild surfactant. In 




surrounding Fe(acac)3 precursor while Ostwald’s ripening or oriented attachment 
mechanisms are not observed.43, 44  
Figure 2.2. Effect of the heating patterns on the diameter of magnetite nanoparticles 
(MNPs). A1-D1: UV-absorption spectra of the reaction mixtures under different heating 
patterns as depicted in Figure 2.1. Aliquots of the reaction mixture were collected at 
specific time intervals, precipitated in acetone, centrifuged to separate any formed MNPs 
and absorbance spectrum of the supernatant was measured to determine the nucleation 
and growth phases during the synthesis of MNPs. The solid lines correspond to 
measurement taken at the start of the incubation periods where the reaction mixture was 
kept isothermal for two hours. The dashed lines are spectra taken 2 h after incubation of 
the system at a given temperature except for D1 where the spectra were taken at the start 
of reflux. A2-D2: Amount of unreacted Fe(acac)3 in the reaction mixture at the 
corresponding temperatures during the ramp phase of the heating process as measured 
by ICPMS. A3-D3: TEM images of the MNPs synthesized by different heating patterns. 
Particle size distributions are shown in the respective insets. Diameters of the MNPs were 
calculated from the TEM images using Image J software. 
 Notably, the thermal decomposition of Fe(acac)3 in benzyl alcohol allows good control 
over the nucleation and growth stages of the colloidal nanocrystals of magnetite and yields 
MNPs with a narrow size distribution as compared to the widely used co-precipitation 
technique.39 The rate of decomposition of Fe(acac)3 and therefore the onset, rate and 
extent of the nucleation phase in nanocrystallization of magnetite from the organometallic 




mixture. To determine the rate of decomposition of the precursor during the MNPs 
nucleation and growth phases, 5-μL aliquots of the reaction mixture were collected, diluted 
with HPLC-grade acetone, centrifuged and the supernatant was analyzed by UV 
spectroscopy in the 250-600 nm wavelength range. The broad peaks at 355 and 435 nm 
correspond to the precursor while the sharp peak at 330 nm corresponds to the colloidal 
nuclei in the reaction mixture.45 The Fe content in the supernatant was also quantified by 
ICP-MS. Several heating regimes were evaluated as depicted in Figure 2.1. 
1). Slow heating: As the temperature was raised slowly at 0.4°C/min (Figure 2.1A) the 
nucleation stage was initiated very early (at ~150°C), as indicated by the attenuation of 
the precursor peaks intensities at 355 and 435 nm and elevation of the colloidal nuclei 
peak intensity at 330 nm (Figure 2.2A1). Approximately 75% of the precursor was 
converted into colloidal nuclei at around 160-180°C (Figure 2.2A2). As the temperature 
approached reflux (205°C), the remaining precursor in the reaction mixture was entirely 
consumed for the growth of the nuclei as shown by a complete loss of the absorbance 
(Figure 1A1). The mean size of the resultant MNPs was 7 ± 4 nm (Figure 2.2A3). 
2). Step-wise heating at 150°C: In this regime the reaction mixture was heated to 150°C 
at 4°C/min and then the temperature was kept constant at 150°C for 2 hours to prolong 
the nucleation stage compared to the regime 1) by slowing down the precursor 
decomposition (Figure 2.1B). Under those conditions approximately 70 wt% of the 
precursor was consumed during the nucleation stage (Figures 2.2B1 and B2) resulting 
in nearly monodisperse MNPs with a mean diameter of 9 ± 2 nm (Figure 2.2B3). 
3). Step-wise heating at 180°C: In this regime the reaction mixture was heated at 4°C/min 
to 180°C and then the temperature was kept constant for 2 hours at 180°C (Figure 2.1C). 
As a result, the nucleation phase was shortened compared to regimes 1 and 2. Under 




particles growth on the existing nuclei as demonstrated by the attenuation of the peak 
intensity at 330 nm (Figure 2.2C1). After 2 hours at 180°C, a significant amount of nuclei 
had undergone growth and precipitated as discrete MNPs (Figure 2.2C2). Larger MNPs 
with a mean diameter of 11 ± 4 nm and a broader size distribution were obtained using 
this regime (Figure 2.2C3).  
4). Rapid heating: In the final regime the temperature was increased rapidly at a rate of 
5°C/min until the reaction mixture refluxed (205°C) and this was followed by 40 hours of 
annealing (Figure 2.1D). Rapid heating of the mixture resulted in an overlap of the 
nucleation and growth phases leading to availability of large excesses of the precursor to 
promote rapid growth of the formed nuclei (Figures 2.2D1 and D2). This regime resulted 
in particles with a mean diameter of 14 ± 7nm (Figure 2.2D3), 
Figure 2.3. Magnetization saturation of MNPs with two different core sizes synthesized by 





 The rapid increase in temperature and prolonged high temperature annealing is known 
to provide a higher degree of control over the crystal size.46 Specifically, high temperature 
annealing was shown to enhance the saturation magnetization (MS) of the 
superparamagnetic single domain MNPs synthesized by thermal decomposition.47, 48 
 The magnetic properties of the 7 nm and 14 nm diameter MNPs were studied by 
measuring the saturation magnetization (Ms) at 300K (Figure 2.3). The magnetization 
curves did not show any hysteresis which is consistent with the superparamagnetic 
properties of the MNPs.49 As the particle size increased from 7 nm to 14 nm their MS nearly 
doubled from 36.2 emu/g to 65.5 emu/g while their superparamagnetic behavior was 
preserved. Larger MNPs, due to their lower surface-volume ratio, have smaller numbers 
of atoms at the surface thereby leading to decreased surface effects such as spin-spin 
canting and spin-glass-like behavior.50 As a result, the number of atoms contributing to the 
magnetic moment of the MNPs increases leading to higher MS values.51 Increase in MS 
also leads to an increased T2 relaxation capability of the MNPs.49, 52 Therefore, from the 
theranostic perspective, the 14-nm MNPs were  expected to have higher T2 relaxivity and 
darker negative contrast. 
2.3.2. PREPARATION AND CHARACTERIZATION OF POLYMER-STABILIZED MNCS 
 MNCs stabilized by PLE-b-PEG block copolymers were formed via electrostatic 
binding of pendant carboxylate groups of the PLE blocks and the MNP surface (Scheme 
2.1). In this study the length of the PEG block of the PLE-b-PEG was kept constant, while 
the PLE block length was varied. The hydrodynamic diameters of the resulting clusters 
(Figure 2.4) varied in the range of 40 to 70 nm depending on the length of the PLE block 
(Table 2.1). All MNCs were negatively charged as was evident from their ζ-potential 
values. In this study we also prepared MNCs stabilized by PLE100 homopolymer as well 




ionized water had relatively small particle size (under 100 nm), and negative ζ-potential 
(Table 2.2). 
Scheme 2.1. Formulation process for preparation of MNP nanoclusters stabilized by 













Table 2.1: Physicochemical characteristics of MNCs stabilized by anionic PLE-b-PEG block copolymers having different PLE block 
lengths 
Formulation (a) Abbreviated 
designation 
Composition  (wt%) (b) DLS characteristics (c) 
Organic content MNP Deff (nm) PDI ζ-potential 
(mV) Polymer BA (d) 
PLE10-b-PEG113/MNP E10-MNC 19 6.7 74.3 51.4 ± 11.3 0.334 ± 0.01 -20 
PLE50-b-PEG113/MNP E50-MNC 65.7 4.6 29.7 45.2 ± 4.3 0.171 ± 0.01 -26 
PLE100-b-PEG113/MNP E100-MNC 56.2 5.5 38.3 68.8 ± 7.8 0.222 ± 0.04 -36 
(a) The size of the MNPs in all formulations was 6 nm as quantified by Image J software from TEM images 
(b) The composition of the MNCs was determined by TGA. 5-8 mg MNCs was heated to 110°C at 5°C/min. The temperature was maintained at 
110°C for 10 min. and then elevated to 1000°C at 5°C/min. The polymer content was determined by subtracting the benzyl alcohol ligand content 
on the MNP from the overall organic fraction content. 
(c) DLS characteristics were measured in de-ionized water at 0.5 mg/ml MNCs at 25°C. 
(d) BA, benzyl alcohol. 
Table 2.2: Physicochemical characterization of MNCs stabilized by homopolymers PLD, PLE, and PLD100-b-PEG113. 
Formulation a Abbreviation 
DLS Characteristics b 
Deff (nm) PDI ζ-potential (mV) 
PLE100/MNP hE100-MNC 27.3 ± 4.8 0.171 ± 0.03 -34.6 
PLD100-b-PEG113/MNP D100-MNC 94.8 ± 4.2 0.189 ± 0.01 -24.7 
PLD100/MNP hD100-MNC 67.2 ± 3.4 0.168 ± 0.03 -47.2 




Figure 2.5. Colloidal stability of E100MNC as a function of (A) pH and salt composition (20 
mM each), (B) concentrations of phosphate buffer, pH 7.4 and (C) NaCl concentration in 
10 mM phosphate buffer, pH 7.4 All samples were prepared at a concentration of 0.5 





  Pegylated polymers are preferable in our work because they impart stealth properties 
and enhance systemic circulation of nanofomulations.53, 54 PLE-b-PEG was chosen 
because of more facile lysosomal biodegradation of PLE compared to PLD and the 
respective block copolymer.55, 56 PLD100-b-PEG113 and the corresponding homopolymer 
based MNCs were anticipated to undergo degradation at a slower rate and hence were 
not developed further. 
 For the PLE-b-PEG stabilized MNCs, altering the PLE block length affected the 
polydispersity and composition of the clusters. Interestingly, the greatest MNPs content in 
the clusters, as determined by TGA, was observed in E10-MNC formed using copolymers 
with the shortest PLE chain (10 r.u.). As the ionic block length increased, the MNP content 
decreased to ~30-40 wt % in E50-MNCs and in E100-MNC compared to ~74 % in E10-MNC. 
The presence of the PEG block also appears to have sterically hindered increased 
coordination of MNPs with the PLE block in E100MNCs, which may have controlled the size 
of the resulting MNCs. Irrespective of the length of the PLE block in the copolymer used 
for cluster formation, the MNCs showed considerable sensitivity to the environmental pH, 
as well as the concentration and/or composition of the elementary salts in the solution. 
For example, E100-MNC appeared to be less stable in magnesium sulfate, pH 6.0 than in 
sodium acetate, pH 5.0, sodium bicarbonate, pH 7.2 or disodium phosphate, pH 7.4 
solutions (Figure 2.5A). This is possibly explained by the coordination of the divalent 
magnesium cation with the PLE block57 resulting in detachment of this block from the 
MNPs surface. In the phosphate buffer (pH 7.4) the E100-MNC stability strongly depended 
on the concentration of the disodium phosphate (Figure 2.5B) or NaCl (Figure 2.5C). This 
was attributed to a relatively weak attachment of the pendant carboxylate groups of the 
PLE to the MNP surface that can be substituted by the phosphate ions or disrupted by 




2.3.3. ALN CONJUGATION ON PLE50-b-PEG113 POLYMER 
  
 Introducing anchor groups such as dopamine58-60 or bisphosphonate-containing 
compounds that form very strong coordination complexes with the MNPs42, 61 can enhance 
binding of the block copolymer to the MNP surface and increase stability of the resulting 
MNCs under physiological conditions. Towards this goal we conjugated ALN to the PLE 
chain of PLE50-b-PEG113 by EDC/NHS chemistry in DMSO-water system (Scheme 2.2). 
The product of the reaction was confirmed by 1H-NMR (Figure 2.6) and 31P-NMR (Figure 
2.7). The number of ALN groups linked to the PLE chain, termed here “degree of 










Figure 2.6. 1H-NMR in D2O of (A) PLE50-b-PEG113, (B) ALN and (C) ALN-modified 
PLE50-b-PEG113. Peak assignments are as follows: (A) δ ppm= 1.85 (2H, m, -CH2-; c), 
2.2 (2H, m, CH2; b), 4.2 (H, t, -CH-; a); (B) δ ppm= 1.88 (2H, m, -CH2-; e), 2.9 (2H, t, -
CH2; d); (C) δ ppm= 2.9 - 3.1 (2H, m, -CH2-; d), 4.28 (H, d, -CH-; a). 
 
Table 2.3. Quantitation of ALN conjugation by 1H-NMR  















Figure 2.7. 31P-NMR in D2O of (A) unconjugated ALN (δ ppm: 17.73) and (B) ALN-






Table 2.4. Physicochemical characteristics of MNCs stabilized by ALN-conjugated PLE50-b-PEG113 copolymers. 
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(a)  Number of ALN molecules per polymer chain was quantified by ICP-MS except for A6-MNC (*) wherein the number of ALN units per polymer 
chain were estimated from 1H-NMR. 
(b)  Carboxylic acid (COOH) groups concentration was determined by potentiometric acid-base titration on formulation diluted to 0.1 mg/mL in DI 
water. 
(c)  The average MNP sizes were estimated from TEM images by measuring a minimum of 400 core particle sizes with Image J software. 
(d)      The composition and DLS characteristics of the MNCs were determined as explained in Table 1, except for the last two columns where the DLS 





 The cluster size was altered by increasing the concentration of the polymer and MNP 
solution by two-folds. The number of ALN groups also strongly influenced the size of the 
resulting MNCs (Table 2.5).  The A6-MNC and A12-MNC formed using copolymers with 
Dconj equal to 6 and 12 respectively were relatively small (~33 – 35 nm). As Dconj increased 
to 19 in A19-MNC-1 the particle size increased nearly two fold. Interestingly, TEM images 
suggest that A19-MNC-1 particles appear to be more elongated and display greater 
proportion of chain-like structures compared to A12-MNC (Figure 2.8). Using the 
copolymer with Dconj = 19 and MNPs with different particle diameter (9 and 12 nm) we also 
produced two types of clusters, A19-MNC-1 and A19-MNC-2.  
Figure 2.8. TEM images of (A) A12-MNC and (B) A19-MNC-1 formulations 
 
 Despite the difference in their MNPs sizes the resulting clusters had practically the 
same overall particle size. Similar to above described non-stabilized clusters, the MNCs 
obtained using the ALN copolymers were negatively charged as was evident from the high 
absolute values of their negative ζ-potential (Table 2.5). Perhaps, the greatest difference 
between these clusters was in their stability in physiological ionic strength conditions. Thus 




When compared with each other the A6-MNC and A12-MNC having smaller number of ALN 
groups per copolymer were relatively less stable upon storage and aggregated over time 
in contrast, A19-MNC-1 was stable in both DI water and PBS at RT and 37°C displaying 
little if any change in particles size upon incubation for at least 30 days (Figure 2.9). 
Figure 2.9. Colloidal stability of (A) A6-MNC and (B). A12-MNC formulations in DI water 
(DW) and 20mM pH 7.4 PBS at RT and A19-MNC formulation in DW and PBS at (C). RT 
and (D). 37oC 
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Table 2.5. Physicochemical characteristics of cisplatin-loaded MNCs. 












DI Water PBS pH 7.4 
Deff (nm) PDI 
ζ-potential 
(mV) 
Deff (nm) PDI 
A6E50-PEG113 /MNP Pt-A6-MNC 38.6 ± 8.2 0.261 ± 0.03 -28.3 36.4 ± 11.4 0.348 ± 0.06 24 3.8 
A12E50-PEG113 /MNP Pt-A12-MNC 41.7 ± 11.3 0.243 ± 0.03 -36.1 43.3 ± 8.2 0.267 ± 0.03 32.7 5.2 
A19E50-PEG113 /MNP Pt-A19-MNC -1 69.3 ± 9.3 0.255 ± 0.02 -35.4 70.2 ± 7 0.203 ± 0.04 37.3 8.4 
A19E50-PEG113 /MNP Pt-A19-MNC -2 86 ± 5.1 0.218 ± 0.02 -43.4 83.8 ± 7.2 0.211 ± 0.01 40 17.6 
(a) The loading procedure is described in Materials and Methods. 
(b) DLS characteristics were measured in DI water or PBS, pH 7.4 at 0.5 mg/mL MNCs at 25°C. 
(c) The loading efficiency (LE) was determined by ICP-MS as the percent of the drug incorporated in MNCs vs. the drug added during loading.  
(d) The loading capacity (LC) was determined as the weight percent of cisplatin per the dispersed phase. Briefly, the drug-loaded MNCs were 






2.3.4. LOADING OF CISPLATIN IN MNCS 
 Cisplatin was loaded into the MNCs via the formation of a coordination complex of 
drug molecules with the carboxylate groups of PLE chains at pH 9.5. The technique 
employed for the drug loading was similar to that previously described by us for the loading 
of the cross-linked anionic nanogels.30, 62 In addition, the bisphosphonate groups 
introduced on the polymer chain are also likely to have a higher binding affinity towards 
cisplatin than the carboxylates.63 We targeted 70 mol% of the total carboxylate groups 
available in MNCs, assuming that each mole of cisplatin reacts with two moles of the 
carboxylate groups. Four different types of ALN-stabilized MNCs described in the previous 
section were used in these experiments. The characteristics of the resulting cisplatin-
loaded MNCs are presented in Table 2.6. In all cases from 24 to 40 % of the drug used 
for the loading was actually incorporated in the MNCs. Both, the loading efficiency (LE) 
and loading capacity (LC) appeared to increase as the number of ALN moieties elevated 
in the following order A6-MNC < A12-MNC < A19-MNC-1. As mentioned earlier, increase in 
the bisphosphonate groups (two bisphosphonates introduced per each carboxylate group 
attached) is also very likely to contribute to this trend in LE and LC due to higher affinity 
for cisplatin. However, in A19-MNC-2, as the size of the MNP grains increased, there was 
nearly two-fold increase in the LC compared to A19-MNC-1. Although these two unloaded 
clusters had similar particle size, the greater phosphonate and carboxylate groups content 
in A19-MNC-2 compared to A19-MNC-1 probably explained the difference in the LC 
between them (Table 2.6). Notably, the particle size of all clusters in DI water noticeably 
did not change upon loading (Tables 2.5 and 2.6). However, and quite interestingly in all 
cases the ζ-potentials of the loaded clusters appeared to become more negative after 
loading, which might seem counterintuitive as the ionic groups are partially consumed by 




thickening of the effective Stern layer that, as previously discussed30 in the nanogel-like 
particles, can span throughout the entire particle volume. Coordination of the drug is likely 
to displace the counter ions from the interior of the MNCs to the more “hydrodynamically 
mobile” surface and periphery layers, resulting in an effective increase in the density of 
the uncompensated negative charge and absolute ζ-potential value of the particles. 
Figure 2.10. Release of cisplatin from Pt-A6-MNC, Pt-A12-MNC and Pt-A19-MNC-1 at (A) 
pH 7.4 and (B) pH 5.5. Data are mean ± SD (n = 3); Statistical analysis performed by 
ANOVA using SPSS statistical software, * p <0.05; ** p< 0.01. The graphs in the insets 





2.3.5. RELEASE OF CISPLATIN FROM MNCS  
 Cisplatin release was studied at 37°C at pH 7.4 (PBS; 0.14M NaCl) and pH 5.5 acetate 
buffered saline (ABS; 0.14M NaCl), that mimic conditions in extracellular media and 
endosomal compartments, respectively. As shown in Figure 2.10., both pH and Dconj of 
the MNCs affected the drug release. In all cases the fastest release kinetics was observed 
in Pt-A6-MNC having the smallest number of ALN anchor groups in the copolymer and 
lowest LC. As the Dconj increased, the release rate decreased, lowest being in in Pt-A19-
MNC-1. For all systems the release was faster at pH 5.5 than pH 7.4 although this 
difference was the smallest in Pt-A6-MNC and the greatest in Pt-A19-MNC.  
Figure 2.11. Colloidal stability of cisplatin loaded Pt-A19-MNC formulation before and after 
cisplatin release from the formulation. The particle size (Deff) of the samples used for 
release kinetics study (Figure 2.10) was determined by DLS before and at the end of the 
release study 
 The pKa of the protons on the phosphonate groups of ALN may also play an important 
role in the drug release. The third pKa of alendronic acid is 6.4.64 Hence, at pH 5.5, the 
respective phosphonate groups of ALN can become protonated and if these groups 




 Interestingly, Pt-A19-MNC-1 at pH 7.4 displayed a complex release kinetics with very 
slow release of the drug during the first two days followed its by acceleration thereafter. 
The slow phase could be possibly attributed to the initial compact morphology of the 
cluster, which becomes looser as the drug loading decreases, thereby facilitating drug 
diffusion out of the particle. Notably, the slow release phase was not seen at pH 5.5 with 
the drug release being overall much faster and monotonic. It is noteworthy that the 
formulations did not aggregate of lose colloidal stability over the entire period of the study 
in either buffer systems (Figure 2.11). 
2.3.6. RELAXOMETRY MEASUREMENTS OF MNC FORMULATIONS  
Figure 2.12. r1 (longitudinal) and r2 (transverse) relaxivity measurement of different 
unloaded (A, B) and cisplatin loaded (C, D) MNCs in PBS. Formulations with maximum 
relaxivity values were further dispersed in 4% agar and relaxivities were measured in the 
resulting phantom gels (E, F). Relaxivity is the linear slopes of the plots of relaxation time 
(R1/ R2) vs. Fe concentration (mM) and expressed as S-1.mM-1 (See Table 2.7) 
 











































































 The use of contrast agents for MRI depends on their ability to shorten the relaxation 
times of the surrounding protons.65, 66 Positive contrast agents reduce T1 relaxation times 
to give a brighter signal while negative contrast agents reduce T2 resulting in a darker 
signal. The reciprocals of the relaxation times are called the relaxation rates, R1 and R2, 
with the effectiveness of contrast agents expressed as relaxivities, r1 and r2, which are 
determined from the slope of the relaxation rate curves expressed as a function of total 
Fe concentration (mM) (Figure 2.12). In all cases the r1 relaxivity values of MNCs in PBS 
pH 7.4 values were relatively low and did not change or decrease upon drug loading 
(Table 2.6).  
 










A6-MNC 0.694 ± 0.07 31.3 ± 2 
Pt-A6-MNC 0.66 ± 0.04 56 ± 4.7 
A12-MNC 1.91 ± 0.11 48.3 ± 2.2 
Pt-A12-MNC 1.02 ± 0.06 86.5 ± 2.8 
A19-MNC-1 1.23 ± 0.05 87.8 ± 4.4 
Pt-A19-MNC-1 1.02 ± 0.16 154.8 ± 11.5 
A19-MNC-1 (b) 1.12 ± 0.1 72.2 ± 4.02 
Pt-A19-MNC-1 (b) 0.9 ± 0.04 120.8 ± 3 
A19-MNC -2 1.34 ± 0.08 81.4 ± 3.3 
Pt-A19-MNC -2 1.18 ± 0.07 140.3 ± 12 
(a) Data are mean ± SD (n = 3) 
(b) Relaxivity measurements of phantom gels in 2% v/v agar. All other measurements were conducted in 
PBS pH 7.4. 
 In contrast the r2 values of MNCs increased progressively as the Dconj value increased 
A6-MNC < A12-MNC < A19-MNC-1 (Table 2.7). Notably for each empty and drug loaded 
MNCs the r2 value appeared to be higher as the particle size was larger. But quite 
unexpectedly for all MNCs the r2 value increased considerably, ~1.6 to 1.8 times after the 




significantly. For example, Pt-A19-MNC-1 had r2 values of 154.8 s-1.mM-1 vs 87.8 s-1.mM-1 
for the unloaded A19-MNC-1. The T1 and T2 relaxivities of A19-MNC-1 and Pt-A19-MNC-1 
were further measured in buffered (PBS pH 7.4) 2% w/w agar gel. Phantom agar gel is 
commonly used as reference material to mimic biological tissues due to similarities of its 
T1 and T2 values to those of biological tissues.67 In the gel the r1 and r2 values of both the 
loaded and unloaded MNCs showed only a minor decline compared to these values in 








































Figure 2.13. FTIR spectrum of LHRH-conjugated LH-Pt-A19-MNC formulation showing 
a. N-H stretch of the primary amine of cisplatin at 3280 cm-1 b. carbonyl stretch of 
carboxylic acid on the polymer at 1730 cm-1 c. C-O stretch of PEG at 1110 cm-1 d. N-H 
bend of primary amines 1650 cm-1 e. C-N stretch of aliphatic amines at 1260 cm-1 f. 
formation of secondary amide bonds following conjugation of LHRH on the PtMNC at 




2.3.7. SYNTHESIS OF LHRH-TARGETED MNCS 
 Unloaded A19-MNC-1 and Pt-A19-MNC-1 (41 wt% MNP and 8.4 wt% cisplatin) were 
used in this work as representative MNCs for LHRH conjugation. Similar to our previous 
publication on cisplatin containing nanogels36 (D-Lys6)-LHRH was conjugated through its 
lysine primary amino group to the free carboxyl groups of the A19-MNC-1 and Pt-A19-MNC-
1 using EDC/S-NHS coupling chemistry.  
 The conjugation was confirmed by an HPLC assay68 by measuring the amount of the 
free (D-Lys6)-LHRH in the filtrate after purification of the modified clusters by centrifugal 
filtration (3000 MWCO). Only 13.3% and 28.7% of the total reagent added in the reaction 
mixtures was present in the filtrates of A19-MNC-1 and Pt-A19-MNC-1 samples, 
respectively. The apparent greater yield of conjugation of the peptide to A19-MNC-1 
compared to Pt-A19-MNC-1 was explained by availability of a greater number of free 
carboxylate groups prior to loading of the drug. The FTIR spectra (Figure 2.13) of the 
LHRH-conjugated Pt-A19-MNC-1 (LH-Pt-A19-MNC-1) suggested formation of a secondary 
amide bond between the primary amino group of the (D-Lys6)-LHRH and the carboxylic 
acid groups of the PLE. 
2.3.8. UPTAKE OF LHRH-TARGETED CISPLATIN-LOADED MNCs IN OVARIAN 
CANCER CELLS 
 The cell uptake of the unloaded LHRHr-targeted (LH-A19-MNC-1) and untargeted (A19-
MNC-1) MNCs was studied by confocal microscopy in LHRHr overexpressing A2780-WT 
and A2780-CisR human ovarian cancer cells. A2780 human ovarian cancer cells are 
known for LHRHr over-expression. Numerous studies have characterized LHRHr 
expression by Western Blot analysis.34-36 As seen in Figure 2.14, untargeted MNCs 




resistant cells. The internalized MNCs were localized in the lysosomal compartments of 
the cells visualized by the bright yellow punctate regions in the overlay images. 
Conjugation of LHRH significantly enhanced the LH-A19-MNC-1 cellular uptake. In the 
A2780-WT cells the LH-A19-MNC-1 were seen localized along the cell membrane (red) 
and within the lysosomes (yellow punctate regions) as early as at 1-hour post incubation. 
Although the uptake of LH-A19-MNC-1 in A2780-CisR cells was slower, a significant red 
fluorescence of the labeled clusters was observed in the cells at as early as 3 hours. 
Interestingly, literature reports suggest that certain cisplatin-resistant cancer cells (e.g. 
ovarian epidermal carcinoma) exhibit significant reduction in non-receptor mediated fluid-
phase endocytosis compared to their wild-type counterparts while the receptor-mediated 
endocytosis remains unaffected.69 The observed increased uptake of LH-A19-MNC-1 in 
A2780-CisR cells specifically, is in line with these reports and strongly suggests that 
receptor-mediated targeted therapy is an effective strategy for achieving a faster onset 
and selective enhancement of cellular uptake in drug resistant tumors as it circumvents 





Figure 2.14. Confocal microscopy of the wild-type A2780-WT and cisplatin resistant 
A2780-CisR human ovarian cancer cells at different time points during their incubation 
with non-targeted A19-MNC-1 and LHRH-conjugated A19-MNC-1. Live cells were exposed 
to the said Alexa-Fluor 647 labeled (RED) MNCs and stained with the lysotracker green 
(GREEN) and Hoechst nuclear stain (BLUE) for 30 min. The colocalization of the labeled 








Figure 2.15. Uptake of LHRH-targeted and untargeted cisplatin-loaded MNCs in A2780-
WT and A2780-CisR cells as quantified by ICP-MS and presented as (A) Fe levels, (B) Pt 
(cisplatin) levels and (C) cisplatin / Fe ratio over time. Data are mean ± SD. Statistical 
analysis done by ANOVA using SPSS software. Statistical significance denoted as: * 





 The uptake was further quantified by ICP-MS. In this case the cells were incubated 
with Pt-A19-MNC-1 and LH-Pt-A19-MNC-1 for up to 24 hours and the Fe and Pt content in 
the cells was normalized per mg of cellular protein and plotted over time (Figure 2.15). 
Similar to the trend observed in the confocal images, LHRH conjugation resulted in an 
almost 2-fold increase in intracellular Fe concentration in the A2780-WT cells (Figure 
2.15A). In the A2780-CisR cells there was also a significant increase in the uptake of 
targeted LH-Pt-A19-MNC-1 compared to untargeted Pt-A19-MNC-1 although, as expected 
the overall uptake was slower than that in the WT cells. A similar pattern was observed 
for the intracellular Pt content also (Figure 2.15B). It is important to note that LHRH 
targeting significantly improved the rate of uptake of the cisplatin-loaded MNCs during the 
first few hours, thereby decreasing the effect of the release of free cisplatin in the culture 
medium. This was apparent in the analysis of the ratios of the cisplatin/Fe cell levels 
(Figure 2.15C). In the case of the non-targeted Pt-A19-MNC formulation the cisplatin/Fe 
ratio in both cell lines decreased significantly after 3 hours over time indicating that a 
significant amount of drug was released into the media during the incubation time. For the 
targeted LH-Pt-A19-MNC-1 formulation this ratio although steadily decreased over time but 
remained much higher than that for Pt-A19-MNC-1. This was consistent with more rapid 






Figure 2.16. Inhibition of intracellular uptake of (A) Fe and (B) Cisplatin (Pt) in A2780-WT 
and A2780-CisR cells pre-incubated with D-Lys-6-LHRH peptide for 1h followed by 6h 
incubation with targeted and non-targeted PtMNC formulations. Statistical significance: * 
p<0.05, ** p<0.01, *** p<0.001 (n=3). 
 
 Finally, pre-incubating both cell lines with 100 nM free D-Lys-6-LHRH peptide for 1 h 
before adding the MNCs greatly diminished the uptake of LH-Pt-A19-MNC-1 and had little 
if any effect on Pt-A19-MNC-1 (Figure 2.16). This suggests that the free peptide 
competitively inhibited the uptake of LHRH-targeted LH-Pt-A19-MNC-1 and reinforces the 






















































































































Figure 2.17. Formulation toxicity of unloaded non-targeted A19-MNC-1 and targeted LH-
A19-MNC-1 formulations in (A) A2780-WT and (B) A2780-CisR cells. Cells were seeded 
in 96-well plates at a density of 3•103 cells/well and incubated at 37°C in 5% CO2. After 
24 h, they were treated with various concentrations of the said formulations and further 
incubated for 24h or 72h. At the end of each treatment period cell viability was measured 
by MTT assay. Mean ± SD (n = 12). 
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2.3.9. ANTI-CANCER OF LHRHr-TARGETED CISPLATIN-LOADED MNCS IN 
OVARIAN CANCER CELLS 
Figure 2.18. Cytotoxic efficacy of cisplatin and LHRH-targeted and untargeted cisplatin-
loaded MNCs in (A, B) A2780-WT and (C, D) A2780-CisR cells exposed for drugs for 
(A, C) 24 h and (B, D) 72 h. Data are mean ± SD (n = 6). 
 Prior to evaluating the anticancer activity of drug formulations the toxicity of unloaded 
MNCs was determined in A2780-WT and A278-CisR cells. The cells were incubated with 
various concentrations of A19-MNC-1 and LH-A19-MNC-1 for 24 h and 72 hours and cell 
viability was measured by a MTT assay. The unloaded formulations did not show toxicity 
in a broad range of concentrations (Figure 2.17) and they were further used to assess the 
anticancer activity of the drug loaded MNCs. 
The anticancer activity of LHRH-targeted and untargeted cisplatin-loaded MNCs was 
determined in A2780-WT and A278-CisR cells after 24 and 72-hour treatments. The two 
time points were used initially to exclude possible effects of the release of the drug into 










































































the extracellular media from the untargeted and targeted MNCs. However, the observed 
trends in cytotoxicity were essentially the same for both exposure times. As expected, the 
untargeted Pt-A19-MNC-1 was several folds less active compared to the free cisplatin in 
both A2780-WT and A2780-CisR cells (Figure 2.18 and Table 2.8). LH-Pt-A19-MNC-1 
was more active compared to untargeted Pt-A19-MNC-1 in both cell lines. Although LH-Pt-
A19-MNC-1 was still less active than the free drug in the resistant cells, its IC50 was close 
to that of cisplatin (10.9 μM vs 7.9 μM; 72 h). This trend in activity of MNC formulations is 
consistent with the slow and low cellular uptake of the untargeted MNCs and somewhat 
faster uptake of the LHRH targeted particles. Since, as discussed above, during the cell 
exposure time the free drug may release from nanoparticles into the extracellular media 
and contribute to cytotoxicity, the “actual” difference in the activity of the targeted and 
untargeted MNCs could be even greater than revealed herein. 
Table 2.7. IC50 values of different treatment groups in A2780-WT and cisplatin resistant 
A2780-CisR ovarian cancer cell lines. 
Exposure 
time(a) Treatment 
IC50 values (μM) 
A2780-WT A2780-CisR (μM) 
24 h 
Cisplatin 1.1 9.1 
Pt-A19-MNC-1 6.8 28.6 
LH-Pt-A19-MNC-1 3.2 18.3 
72 h 
Cisplatin 0.9 7.9 
Pt-A19-MNC-1 4.4 16.7 




2.3.10. IN-VITRO EVALUATION OF THE MRI POTENTIAL OF MNCS  
Figure 2.19: In vitro evaluation of MRI potential of different formulationsT1 and T2 images 
of phantom gels of A2780-WT and A2780-CisR cells incubated with different 
concentrations of (A) A19-MNC-1, (B) LH-A19-MNC-1 (C) Pt-A19-MNC-1 and (D) LH-Pt-A19-
MNC-1. The image contrasts are compared with those obtained from serial dilutions of 
A19-MNC-1 and Pt-A19-MNC-1 in the absence of cells (top). The signal-to-noise (S/N) 
ratios for the different sets of contrasts were plotted against the corresponding Fe 
concentrations to quantitatively compare the contrasts obtained by the four different 
formulations A-D. The comparisons of S/ N ratios of T1 and T2-weighted contrasts of 
formulations A and C in phantoms with no cells are represented in Figures E and F 
respectively. Figures G and I represent the S/N ratios of T1 and T2-weighted contrasts in 
phantoms of A2870-WT cells while Figures H and J represent the same of A2780-CisR 






 The effect of LHRHr targeting on the MRI capability of the formulations was studied in 
both cell lines. Following 24 hours of incubation with different unloaded and cisplatin 
loaded MNCs A19-MNC-1, LH-A19-MNC-1, Pt-A19-MNC-1 and LH-Pt-A19-MNC-1 at various 
Fe concentrations, the cells were washed with 1X PBS, harvested and. 9•106 live cells per 
group were molded into agar and scanned in the Seimens 3T human MR scanner to obtain 
T1 and T2-weighted contrast images (Figure 2.19). MNPs are predominantly used as 
negative (T2) contrast agents. The negative contrast was indeed more prominent and 
showed a dose-dependent increase. LHRH conjugation promoted cellular uptake of LH-
Pt-A19-MNC-1 and resulted in greater T2 contrast and this was more profound in the 
A2780-WT cells that took up more material than A2780-CisR. In line with the relaxivity 
values, the presence of cisplatin resulted in greater contrasts irrespective of the presence 
of LHRH. This was more obvious in the case of A2780-CisR cells than in A2780-WT cells 
due to overexposure in the latter. Overall, when compared to the contrast obtained with 
the phantom gels the targeted MNCs provided significant T2 contrast even after 






 Thus, to summarize, we have developed the new superparamagnetic 
nanoformulations for drug delivery and MRI and demonstrated 1) their use as carriers for 
a chemotherapeutic drug, cisplatin, 2) their targeted receptor mediated delivery into drug 
resistant and sensitive ovarian cancer cells and 3) and their potential use as MR contrast 
agents for future theranostic applications. Structurally, these systems are distant relatives 
of previously described nanogels or polymeric micelles with cross-linked polyion cores and 
PEG shells that have been synthesized using the anionic block copolymers, including 
PLE-b-PEG.30, 36, 70, 71 However, instead of chemical crosslinks the polyion chains of the 
block copolymers are physically cross-linked through ionic interactions with the magnetite 
MNPs that bind these chains to each other. 
 To synthesize the MNPs we employed a well-established method of thermal 
decomposition of Fe(acac)3, which is a simple one-pot technique allowing to access 
relatively uniform MNPs having good magnetization properties. In this method the solvent 
serves as a mild surfactant as well as a reducing agent.39 The sizes of the MNPs are 
governed by the rate of heating while magnetic properties depend on the annealing 
temperature and duration of the reaction.72, 73 High boiling point solvents such as benzyl 
ether (298°C) are known to allow for shortening of the duration of synthesis but require 
additional surfactants and reducing agents.74 We show herein that in spite of a relatively 
lower reflux temperature in benzyl alcohol, the nucleation and growth phases could be 
effectively controlled in this solvent by altering the rate of reaction thereby enabling control 
over the core size.  
 Formation of nanoclusters by unmodified block copolymers was governed by the PLE 
block length. There exists a complex interplay of the electrostatic interaction between the 




of the bulkier PEG block during the cluster formation step. The increase in the number of 
anchoring groups has been shown to reduce aggregation due to incomplete surface 
coating of the MNPs and form more stable clusters of MNPs. 75 The shortest block 
copolymer PLE10-PEG113 resulted in interactions of single polymer chain with different 
MNPs resulting in higher degree of catenation as well as more MNPs per cluster. The 
steric hindrance due to the PEG block eventually curbed the cluster formation process. 
However, the so formed E10-MNC nanoclusters had incomplete surface coverage and 
hence were also the least stable. Colloidal stabilities of the MNPs of defined size obtained 
by this method in aqueous dispersion were obtained by using biodegradable ALN-modified 
PLE-b-PEG block copolymer.70 Hydrogels of carboxylated polymers are known to exhibit 
significant swelling behavior at physiological pH due to the presence of charged 
carboxylate groups.76-78 In the case of crosslinked nanogels formed by anionic block 
copolymers such as PLE-b-PEG, swelling results in significant increase in the particle size 
that is varied by changing the crosslinking degree. Moreover, crosslinking can significantly 
enhance the colloidal stability of nanogels and define the rate of the release of the 
encapsulated payload.70, 79   
 In this work we have demonstrated that MNCs, can be successfully stabilized by 
introducing sufficient amount of ALN bis-phosphonate groups onto the PLE block that 
tightly anchor the copolymer to the MNP surface. Cisplatin loading in the MNCs was 
successfully achieved by coordinating the drug with a fraction of the remaining carboxylic 
and phosphonate groups of the PLE chains. The presence of MNPs did not hinder the 
loading as was evident from the relatively high LC values.  The drug loaded MNCs 
exhibited sustained drug release profiles that were altered by changing the number of bis-
phosphonate “cross-links” between the polymer and the MNPs. The utilization of a few 




formulations. The samples were intact and did not undergo any aggregation throughout 
the study period. In addition, we postulate that cisplatin loading can, in fact, further 
increase the stability and integrity of the formulation by simultaneously crosslinking the 
polymer chains within the cluster.  
 Recently, Pothayee et al.80 developed theranostic MNCs by adsorbing the polyacrylate 
block of an amino functional poly(ethylene glycol-b-acrylate) (H2N-PEG-b-PAA) copolymer 
onto magnetite MNP and loaded these MNCs with a cationic antibacterial drug, 
gentamycin through electrostatic interactions. Despite some similarities that can be found 
with this prior work there were major differences with our nanoformulations. First, in 
contrast to H2N-PEG-b-PAA the PLE-b-PEG used here has a biodegradable PLE block, 
which is essential for the use of this nanoformulation for systemic drug delivery. Second, 
H2N-PEG-b-PAA chains were covalently cross-linked via non-degradable PEG diacrylate 
oligomer to form the nanoclusters. In this work we introduced controlled levels of 
bisphosphonate groups onto the PLE block via ALN addition. The bisphosphonates form 
stronger links to both the magnetite and the Pt from cisplatin than having only carboxylates 
present. These interactions allow for facile non-covalent self-assembly of MNCs. Such 
clusters based on ALN-modified PLE have stable colloidal sizes in physiological pH and 
ionic strength. Selection of an appropriate polymer coating is critical to ensure colloidal 
stability, high drug loading capacity, biocompatibility and biodegradability and long 
circulation time of the MNP-based nanoformulations. Block copolymers comprising 
biodegradable charged polyaminoacid chains can serve as ideal stabilizing agents for 
formation of MNCs. In our case, the resulting MNCs contained an excess of carboxyl and 
bisphosphonate groups that were used to load an anticancer drug, cisplatin. Since the 




the amount of these groups was increased and achieved a maximum of 17.6%, which is 
an excellent LC value for a nanoformulation used in cancer therapy.   
 A key element in our nanoformulation design is the decoration of MNCs with a 
targeting moiety to increase accumulation of the MNCs and their payload in ovarian cancer 
cells. Ovarian cancer represents a major health problem accounting for about 22,000 new 
cases and over 14,000 deaths annually in the US alone.28 In spite of the dose limiting 
nephrotoxicity and other severe side effects,29 cisplatin still remains the first line of 
treatment for ovarian cancer. To address the toxicity and delivery issues of cisplatin the 
drug has previously been loaded into various polymeric nanocarriers.71 Attempts of 
targeted delivery of cisplatin have also been reported. For example, cisplatin has been 
incorporated within the folate-decorated crosslinked PEG-b-polymethacrylate (PEG-b-
PMA) nanogels to treat the folate receptor positive ovarian cancer tumor in mice.30 Here 
we targeted LHRHr that is overexpressed in more than 70% of human ovarian cancers as 
well as several other cancers.31, 32, 81 These receptors are not present in most visceral 
organs, which could help reducing the off-target delivery of the nanoformulations to normal 
tissues and decrease side effects. The LHRH peptide, a synthetic analogue of the natural 
hormone has successfully been used to improve delivery of chemotherapeutic agents to 
LHRHr overexpressing tumors.74 We also previously used this approach with LHRH-
decorated PEG-b-PMA nanogels loaded with cisplatin to target LHRHr-positive ovarian 
cancer in mice.36 In a separate study MNPs were conjugated directly with LHRH-peptide 
in order to improve the uptake of such MNPs in LHRH overexpressing breast cancer 
cells.37  
 As expected, decoration of the MNCs with LHRH resulted in the increased uptake of 
both MNPs and the drug presumably due to the LHRHr-mediated endocytosis of the 




nanoformulated drug in both cisplatin-sensitive and resistant cancer cells. Notably, 
cisplatin loaded in untargeted nanoformulations was also active albeit much less than the 
free drug. The differences between the free and nanoformulated drug were minimal in the 
drug resistant cell line. Interestingly, our targeted nanoformulations were somewhat more 
active in A2780 cells in comparison to previously reported LHRH-decorated PEG-b-PMA 
nanogels loaded with cisplatin (24 h IC50 ≈ 30 μM).36 We attribute the enhanced efficacy 
of our new nanofomulation to the biodegradability of PLE-b-PEG in the lysosomal 
compartments, which can enhance the drug release.71 As MNCs accumulate in 
endosomal-lysosomal organelles, the drug release is triggered by acidic pH in these 
organelles. Hydrolysis of the neutral cisplatin molecule inside the cells results in aquation 
of the molecule involving displacement of the chlorine ligand with water. LHRH targeting 
further increases influx of the drug-loaded MNCs in the targeted cancer cells where the 
paucity of chloride ions facilitates drug activation. The activated cationic mono- and di-
aqua complexes of cisplatin are thereby released and trapped within the target cells where 
they intercalate with the N7 atoms of the purines in the DNA base pairs, which prevents 
DNA repair and DNA replication and leads to cell death.71, 85, 86 By incorporating cisplatin 
in the targeted MNCs one can protect the drug from premature aquation in the blood that 
is responsible for undesired side effects and more selectively affect tumor cells. 
 Interestingly we also show here that targeting can improve the MRI imaging of cancer 
cells, which is consistent with increased uptake of LHRH-decorated MNCs in these cells. 
This result reinforces the importance of tissue specific targeting in designing successful 
theranostic nanosystems, which can enable diagnosis as well continuous monitoring of 
therapy. The MNP-based MR contrast agents have been in commercial clinical use in 
several countries for almost a decade.87, 88 To be clinically relevant, negative contrast 




by several factors such as MNP core size, chemical nature, oxidation state, applied 
magnetic field, site-specific uptake and proximity of the metal ions to the water.89-92 A 
formulation that enables deeper penetration of the water molecules towards the magnetic 
core allows for faster relaxation of the protons and a higher T2-relaxivity.82 Clusters of 
magnetic nanoparticles experience a greater force and magnetic moment than single, well 
separated MNPs in a magnetic field gradient resulting in an increase in saturation 
magnetization.23 Clustering of several MNP cores into compact agglomerates has been 
shown to be beneficial especially in the case of T2 relaxivity.93, 94 It was previously reported 
that aggregates comprising few closely held MNPs measured with long pulse-echo times, 
can result in greatly improved T2-relaxivity.95, 96 Berret et al.97 have shown that ionic block 
copolymers having an opposite charge to that of the MNPs can be successfully used to 
formulate stable MNCs wherein the aggregation number of the MNPs can be controlled 
by altering the copolymer block length. The MNCs discussed herein exhibited a similar 
trend, where T2 relaxivity was governed by the cluster size and MNP loading in the 
clusters. In contrast the T1 relaxivity was only marginally affected either by cluster 
formation or increased uptake since the primary factor governing T1-weighted positive 
contrast is the MNP core size. Only ultra-small superparamagnetic iron oxide 
nanoparticles (less than 5-6 nm in size, are known to exhibit positive contrast 
enhancement as well.98 Hence, the 9 nm MNP cores were expected to produce only 
marginal changes in T1 images. 
 Unexpectedly, we discovered that cisplatin loading in the MNCs considerably 
increased the T2 relaxivities for all of our nanoformulations. It is well known that platinum 
(Pt) has paramagnetic properties and incorporation of Pt in MNPs results in significant 
enhancement in relaxivities of FePt alloys.99 Although our MNPs are comprised of 




magnetite MNPs can play a similar role. Each mole of cisplatin can interact with two moles 
of carboxylate and bisphosphonate groups on the polymer chains. This can cause 
additional intra or inter cluster crosslinking, thereby leading to further immobilization and 
stabilization of the MNCs and an increase in T2 relaxivity. Several metal-cluster 
compounds, made of different metals such as Pt and Ni closely held together via 
coordination complexes by organic ligands containing carbonyl anchor groups, have been 
shown to exhibit significant increase in magnetic susceptibility of the resulting clusters. 100 
The magnetic moments of these ‘metal-carbonyl’ clusters increased with increase in 
metallic composition of the clusters with larger clusters. Pt in particular contributed to a 
small but significant increase in the net susceptibility of these clusters.   The cisplatin-
loaded MNCs formulated in this paper closely mimic such metal-carbonyl clusters and the 
loaded Pt (~8wt%) can contribute significantly to the net susceptibility and hence relaxivity 
of the superparamagnetic MNCs. Lastly, incorporation of cisplatin can also enhance water 
penetration in close proximity of the MNPs by diminishing the hydrophobicity around the 
core, which can also further enhance the T2 contrast capability of the cisplatin-loaded MNC 
formulation. This effect, nonetheless, deserves further study and could play positive role 






 We have produced stable MNCs by reacting magnetite MNPs with the biodegradable 
PLE50-PEG113 block copolymer having ALN anchor groups attached to some of the 
carboxylic group of the PLE via polymer-analogous modification. The resulting MNCs were 
loaded with cisplatin using remaining carboxylic and bisphosphonate groups of the PLE. 
The MNCs were decorated with the LHRH as the targeting groups to enhance delivery of 
the nanoformulations to ovarian cancer cells overexpressing LHRHr. The LHRH 
modification enhanced uptake of the MNCs and their drug and MNP payload in the wild-
type as well as cisplatin-resistant ovarian cancer cells. Enhanced uptake further translated 
into superior MRI contrast and significant enhancement in cytotoxicity of the 
nanoformulated drug. Thus, theranostic nanoformulations were developed here that can 
be applied for simultaneous MR imaging and targeted drug delivery in cancer cells. The 
encouraging in vitro results certainly warrant further investigation of the in vivo efficacy of 





2.5. FUTURE DIRECTIONS 
Our in vitro studies have demonstrated that MNCs formulated with ALN-modified PLE50-
b-PEG113 polymer are relatively non-toxic as carriers of potent anti-cancer agents such as 
cisplatin. The results of in vitro cytotoxicity studies of the LHRHr-targeted formulations in 
ovarian cancer cells are very encouraging and we have initiated steps in the direction of 
in vivo evaluation of the formulation. Apart from that, further studies will be aimed at 
increasing the loading capacity of MNPs and therapeutic payloads in the formulation. We 
aim to do this by employing a polymer with a longer PLE block such as PLE100. Further 
refinements in the bisphosphonate conjugation procedure have enabled us to achieve 
higher Dconj on PLE100-b-PEG113 polymer. For theranostic formulations such as these it is 
extremely important to strike a correct balance between the contrast agents and the 
therapeutic agents. Finally, we aim to extend the application of these theranostic MNCs 
by exploring potential targeting to other malignancies such as glioblastoma and prostate 
cancer. Our choice of these types of cancers is guided by the fact that till MRI is one of 
the most efficient contrast systems for imaging of the brain with maximum details. We aim 
to study, if our biocompatible and biodegradable MNC formulations can address this need, 
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CATIONIC MAGNETIC NANOCLUSTERS STABILIZED BY POLY 




  Poly-L-lysine (PLK) is a cationic polypeptide that has been used as a modifier for 
drug-loaded nanoparticles and has been shown to enhance the cellular uptake of drugs1 
by increasing the permeability of various compounds.2-4 This property of PLK-based 
polymers has been effectively exploited in designing non-viral vectors for gene and protein 
delivery. Cationic polymer-based non-viral vectors have been considered as favorable 
candidates for clinical gene therapy due to their advantages over viral vectors in numerous 
vital properties including low immunogenicity, easy fabrication, low cost, ease of 
modification and functionalization such as incorporation of targeting ligands. They were 
commonly used to package plasmid DNA (pDNA) into nanoscale polyplexes, which can 
protect pDNA from enzymatic degradation and transport genes into target cells through 
an endocytic pathway. In addition to PLK, numerous other polymeric gene delivery vectors 
have been investigated, including poly (ethyleneimine) (PEI)5-7, chitosan8-10, poly(amino 
ester)11, 12, dendrimeric poly(amidoamine) (PAMAM)13-15, and their block or graft 
copolymers with poly(ethylene glycol) (PEG). Among all, PEI and PLK are two of the 
mostly studied polymers as gene carriers. Both polymers possess high charge density 




 The success of magnetic nanoparticles (MNPs) as theranostic agents relies on their 
ability to generate superior soft contrasts in the tissue of interest while simultaneously 
delivering a therapeutic dose to the organ. Both require significant accumulation in the 
organ. The type of stabilizing agent used to render hydrophilicity and stability to the 
otherwise hydrophobic and unstable MNPs dictates tissue accumulation of MNPs. In the 
previous chapter we discussed strategies of enhancing tissue specific uptake of anionic 
magnetic nanoclusters (MNCs) stabilized by PLE-PEG polymer modified with 
bisphosphonates. The high charge density of PLK-PEG block ionomers has also been 
employed to form stable aggregates of magnetic nanoparticles (MNPs), which have been 
successfully tested for a variety of biological applications. For instance, PLK-labeled 
MNPs have been extensively used in labeling specific cells such as stem cells16, dendritic 
cells17 and non-phagocytic T cells18. Wang et al.19 observed a specific peroxidase-like 
activity within PLK-modified MNPs that could greatly reduce intracellular peroxide activity 
in labeled cancer stem cells derived from glioblastoma. The ability to introduce different 
functionalities on the side-chain amino groups makes PLK-stabilized MNPs a smart choice 
for simultaneous drug delivery and MRI. 
 In this study, we evaluated the efficacy of different PLK-PEG polymers in forming 
stable magnetic nanoclusters (MNC). Moreover, we modified the available side chain 
amino groups to conjugate anti-cancer agent doxorubicin onto the stable clusters via a pH 
sensitive hydrazone linker (DOX-MNC). This end group modification reduced the positive 
charge density on the clusters, which reduced the uptake-driven toxicity of the PLK-based 
magnetic nanoparticles. This DOX-MNC formulation exhibited excellent MRI potential with 
significantly high T2 relaxivities. The stimuli-responsive drug delivery helped achieve a 
sustained release exclusively in an acidic environment only, thereby preventing premature 




uptake of the formulations. The formulations were preferentially localized in the acidic 
lysosomal compartments (~pH 4.5 – 5.5)20 of A2780 and MDA-MB-231 cancer cells where 
the pH-driven cleavage of the hydrazone bond resulted in drug release and significant 
cytotoxicity.  
3.2 EXPERIMENTAL SECTION 
3.2.1 MATERIALS 
Chemicals: Poly (L-lysinex-b-ethylene glycol113) polymer (PLK-PEG; x = 10, 50 and 100) 
was purchased from Alamanda Polymers (Huntsville, AL). N-Succinimidyl 3-[2-
pyridyldithio]-propionate (SPDP), iron (III) acetylacetonate (Fe(acac)3), benzyl alcohol 
(anhydrous), nitric acid (TraceSELECT), hydrochloric acid (TraceSELECT), 
Fluorescamine and 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
were purchased from Sigma-Aldrich (St. Louis, MO). Acetone (histology grade), n,n-
dimethylformamide (DMF), 3, 3´-N-[ε-Maleimidocaproic acid] hydrazide (EMCH), 
trifluoroacetic acid salt, dithiothreitol (DTT), 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB), 
DMSO and all other anhydrous HPLC grade organic solvents were purchased from 
Thermo Fisher Scientific (Waltham, MA). Doxorubicin hydrochloride salt was purchased 
from LC Laboratories (Woburn, MA). Alexa Fluor®-647, Lysotracker Green and Hoechst 
33342 were purchased from Life Technologies (Carlsbad, CA).  
Cell lines: Triple negative MDA-MB-231 breast cancer cells and wild-type A2780 ovarian 
cancer cells were purchased from American Type Culture Collection (ATCC, Manassas, 
VA). MDA-MB-231 cells were maintained in DMEM (high glucose) supplemented with 10% 
fetal bovine serum (FBS) and 1% penicillin/streptomycin from Thermo Fisher Scientific 




10% FBS and 1% penicillin/streptomycin.  All cell cultures were maintained in 37°C and 
5% CO2 atmosphere.  
3.2.2 METHODS 
3.2.2.1 Synthesis of Magnetic nanoparticle cores (MNPs). 
 Magnetic nanoparticles were synthesized by thermal decomposition of iron (III) 
acetylacetonate (Fe (acac)3) in benzyl alcohol by two methods: 
a. Ramp-soak method. This method was similar to Profile B described in section 2.2.2.1 
of the Chapter 2, except for a minor change in the initial heating rate from 110°C to 150°C. 
Briefly, 6.2μmoles of Fe(acac)3 precursor was mixed with 45mL anhydrous benzyl alcohol. 
The reaction mixture was initially heated at 110°C for 1h to ensure complete removal of 
moisture. The reaction temperature was gradually increased to 150°C at 2°C/min and 
maintained constant for 2h. After 2h the mixture was further heated under reflux to 205°C 
at a rate of 4°C/min and maintained at that temperature for 40h. 
b. Hot injection method. This method differed from the previous methods described here 
and in 2.2.2.1 of the Chapter 2. While in the other methods Fe(acac)3 was dissolved in 
benzyl alcohol and the entire mixture was heated to reflux at different heating rates, in in 
this method, only 80% (35mL) of the total solvent without any Fe(acac)3 was heated to 
reflux. Separately, 6.2μmoles Fe(acac)3 was dissolved in remaining 20% (10mL) benzyl 
alcohol at RT and rapidly injected into the hot solvent at reflux with the help of a glass 
syringe. The reaction mixture was allowed to regain the reflux temperature and further 
heated for 40h under reflux. 
 The final product was obtained by precipitation and washing in acetone followed by 




TGA and SQUID to determine their particle size distribution, surface benzyl alcohol 
content and magnetization saturations, respectively. 
3.2.2.2 Preparation of cationic magnetic nanoclusters (MNCs).  
 Cationic MNCs were prepared by the same method as described in Chapter 2 section 
2.2.2.3a and depicted graphically in Scheme 2.1. Briefly, 40mg of PLL-b-PEG polymers 
with different PLL block-lengths were dissolved in de-ionized (DI) water at a concentration 
of 4 mg/mL. The pH of this solution was adjusted to 10.5 with 1N NaOH. MNP cores were 
dispersed separately in 10mL of alkaline water (pH 11.9-12.1) at a concentration of 2 
mg/mL to obtain a colloidal dispersion. The polymeric solution was added to the magnetic 
colloidal dispersion under constant stirring. The mixture was further stirred overnight on a 
magnetic stirrer at approximately 400 - 500 rpm. The excess polymer was then filtered by 
extensive dialysis in DI water for 72h with six water changes. The dialyzed intermediate 
was filtered serially through 0.45 μm and 0.22 μm Anotop filters to obtain the final product. 
The cationic nanoclusters thus obtained were lyophilized and stored under vacuum until 
further use.  
3.2.2.3 Physico-chemical characterization of MNCs. 
a. Size and ζ-potential. 
 The hydrodynamic diameter (z-average) and ζ-potential of the formulations were 
determined by dynamic light scattering using a Malvern Zetasizer (Malvern Instruments, 
Malvern, UK). The formulations were diluted to 1mg/mL of total formulation before 
measurements were performed in clear disposable zeta cells. 
b. MNC composition. 
 The composition of the unloaded nanoclusters was determined by thermogravimetric 




temperature was raised at 5°C/min to 110°C and kept isothermal for 10 minutes in order 
to remove the moisture followed by steady heating at 5°C/min to 1000°C. The obtained 
thermogram was analyzed using the Universal Analysis software (TA Instruments, DE) to 
deduce the total loss of the organic components (LOI) and amount of MNPs per mg of 
MNCs. The content of benzyl alcohol coating was determined by loss of organic 
components upon thermal decomposition of MNPs by TGA. The LOI of MNCs was 
corrected by subtracting the content of benzyl alcohol in the MNPs to obtain the content 
of polymer in the MNCs. 
c. Relaxivity measurements 
 Longitudinal (T1) and transverse (T2) relaxivity measurements of the different 
formulations were conducted using a Bruker Biospec MRI and Spectroscopy (MS) system 
(7T/21 cm; Bruker, Karlshure, Germany).  The stabilized colloidal dispersions were diluted 
to 0, 0.018, 0.045, 0.09, 0.18, 0.27 and 0.36 mM Fe with distilled water and 20mM PBS. 
T1 and T2 relaxation times were measured and converted to their corresponding relaxation 
rates (R1 and R2; 1/T; s-1).  The sequence used for T2 mapping was a CPMG phase cycled 
single slice multiecho sequence. One 1 mm thick coronal image was acquired with an 
acquisition matrix of 256 x 128, 40 mm field of view, 32 echoes at 10 ms first echo time 
and 10 ms echo spacing, repetition time of 3000 ms, one average, for a total acquisition 
time of 6.4 min. The r1 (longitudinal relaxivity) and r2 (transverse relaxivity) values (s-1.mM-
1) were obtained as the slope of the plots of R1 or R2 versus the corresponding Fe 
concentrations. 
d. Colloidal stability of MNCs. 
 The different formulations were dispersed in 20mM PBS (pH 7.4) at a concentration of 
1mg.mL-1 and their colloidal stability was measured at RT for one month during which 




3.2.2.4 Preparation of pH sensitive doxorubicin-conjugated MNCs  
 Doxorubicin was conjugated by a pH-labile hydrazone linkage at the ε-amino end 
group of the PLL block on the MNCs via a hetero-bi-functional linker SPDP. The 
conjugation procedure is described in brief as follows. 
a. Synthesis of activated DOX-hydrazone linker.  
 The 13-keto position on the doxorubicin (DOX) molecule was targeted by activating 
DOX with EMCH (3,3´-N-[ε-Maleimidocaproic acid] hydrazide).21 Then, 0.1 mmol of 
DOX.HCl was dissolved in 15mL anhydrous methanol in a dry 25mL round bottom flask. 
EMCH (0.2 mmol) was dissolved in 2mL methanol and added to the DOX.HCl solution. 
Two drops of trifluoroacetic acid were added to the reaction to catalyze the conjugation of 
the hydrazide to the 13-keto position of the DOX. The reactants were stirred at room 
temperature in the dark for 8h. The reaction solution was concentrated by rotary 
evaporation to 4mL and the DOX-HZN conjugate was obtained by precipitation in ice-cold 
anhydrous acetonitrile. This purification step was repeated thrice. The product was 
collected by centrifugation and dried under vacuum. The DOX-HZN was characterized by 
1H-NMR and stored at -20°C till further use. 
b. Formation of SH-MNC intermediate 
 First, the available primary amine groups in the formulation were quantified by 
Fluorescamine assay.22 Briefly, 2mg of MNC-4 formulation was dispersed in DI water at a 
concentration of 0.05mg/mL. Fluorescamine reagent was dissolved separately in acetone 
at a concentration of 3mg/mL. About 0.15mL of the formulation was placed in a flat-bottom 
black-walled 96-well plate. 50μL of the Fluorescamine reagent was added to each sample 
and mixed vigorously for a minute. The fluorescence was measured immediately at ex/em 




of –NH2 group) solution of PLK10-PEG113 polymer was diluted at concentrations equivalent 
to 0.01, 0.05, 0.1, 0.25, 0.5, 1 and 2 μmoles of –NH2 group, mixed with Fluorescamine 
and fluorescence intensities were measured to obtain the standard curve.  
 Of the total available -NH2 groups, 25, 50 and 75 mol% were targeted for conjugation 
with the heterobifunctional linker SPDP. Briefly, the formulation was dispersed in DDW at 
10 mg/mL and divided into three parts of 5mL each. 15mg (48μmoles) SPDP was 
dissolved in DMF to obtain a 20mM solution and volumes corresponding to 5, 11 and 16 
µmoles of SPDP were added to the three vials containing the MNC-4 formulation. The 
reaction was stirred in dark for 4h followed by centrifugal filtration (3000 MWCO) and three 
washings to remove the unreacted SPDP and resuspended in PBS. DTT was dissolved 
in PBS at 10 mg/mL. 0.2mL of this solution was added to each sample and stirred for 8h. 
Excess DTT was quickly removed by centrifugal filtration. The sample was washed twice 
and re-suspended in water to obtain the stable SH-MNC intermediates. The success of 
the conjugation reaction and conversion of the disulfide to free thiol was assessed by 
DTNB assay for free thiol.23 
c. Formation of DOX-MNCs 
 DOX-MNCs were synthesized by conjugation of the activated DOX-HZN to the SH-
MNC intermediate. Briefly, DOX-HZN was dissolved in methanol and added to the SH-
MNC at a 2:1 molar ratio. The reaction was stirred overnight in dark. The final DOX-MNC 
formulations namely 4a, 4a and 4c were obtained by centrifugal filtration and extensive 
washing in PBS to remove the unbound drug. The conjugation efficiency (%CE) was 




3.2.2.5 Doxorubicin release study 
 Doxorubicin release from the final formulation was studied in sodium acetate buffer 
solution pH 5.5 (ABS), sodium phosphate buffered saline pH 7.4 (PBS) and in a 
combination of PBS (1 day) followed by ABS (4 days). Briefly, the MNC-4B formulation 
was diluted to concentration equivalent to 10μg/mL DOX in respective buffers. 1mL of 
each dilution was placed in Float-a-Lyzer dilution membrane tubes and placed in an amber 
colored vial (30mL) containing 24mL of the corresponding buffer at 37°C as the release 
medium. The samples (n = 3 per pH group) were stirred at 100rpm. 0.2mL aliquots were 
collected from the release medium at regular time points and replaced by same volume of 
fresh buffers. The drug release was quantified by fluorimetry at Ex/ Em of 480/ 580 nm 
respectively. For the combination group, after 24h in pH 7.4, the release medium in the 
vial was replaced by same volume pH 5.5 ABS and the study was continued for 4 more 
days. 
3.2.2.6 Determination of Formulation toxicity 
 The effect of amine-group modification on toxicity of the empty formulations was 
studied in A2780 human ovarian cancer and MDA-MB-231 triple negative human breast 
cancer cells by MTT assay. Briefly, 3x103 cells per well were seeded in 96 well plates and 
allowed to adhere for 24h. The cells were then treated with different concentrations of 
each of the three SH-MNC-4 formulations and incubated for 24h and 72h. At the end of 
each time point, the supernatant medium was replaced with fresh complete medium and 
the cells were incubated further for 12h to allow the cells to revive. Finally, the cell viability 
was measured by standard MTT assay. Briefly, 20μl of a 5mg/mL solution of MTT dye in 
PBS was added to each well and incubated for 3.5h. The supernatant was then removed 
and the formed formazan crystals were dissolved in DMSO. Formazan concentration was 




the untreated control to obtain viability percentage values. The cell viability of the modified 
formulation was compared with that of the unmodified MNC-4 formulation.  
3.2.2.7 Cellular uptake of MNCs 
 A2780-WT ovarian cancer cells and MDA-MB-231 triple negative breast cancer cells 
(6 million cells/ flask) were treated with a 5mL colloidal dispersion of the different DOX-
MNC formulations (equivalent to Fe concentration of 5μg/mL) and incubated for 24h. At 
various time points during the incubation period the cells were washed once with ice-cold 
PBS and acid saline (pH 3) and harvested. The viability was determined by trypan blue 
assay and then the cells were centrifuged to form a pellet. The supernatant was removed 
completely and 0.5mL of a 100ppb solution of Iridium in 2% HNO3 was added to the pellets 
as an internal standard. The cells were then lysed mechanically by probe-sonication. 50μL 
concentrated nitric acid (TraCERT; Fluka) was added to the cell lysates and the samples 
were digested overnight at 70°C. The digested samples were then appropriately diluted to 
5mL with 2% HNO3. The cell debris was separated by ultra-centrifugation at 7500 rpm for 
10 min. The supernatant was further filtered through 0.2μm syringe filters and analyzed 
by Nexion 300-D ICP-MS equipped with collision cell and autosampler (Perkin Elmer, 
location USA). The intensity of the 57Fe isotope was considered for quantification of the 
uptake. The final Fe content was normalized to the total protein content of the cells (as 
determined by standard Bicinchoninic acid (BCA) assay) and MNC uptake was expressed 
as μg of Fe per mg of total cellular protein.  
Simultaneously, live-cell confocal microscopy was performed to study the cellular 
localization pattern of the different fluorescent-labeled DOX-MNC formulation. A2780-WT 
and A2780-CisR cells were incubated with Alexa Fluor®-647 labeled DOX-MNCs for 1, 3 
and 24h followed by visualization under a LSM 710 (Zeiss, CA) confocal microscope 




3.2.2.8 In vitro Cytotoxicity of DOX-MNCs 
 The in vitro cytotoxic potential of the DOX-MNC formulations was estimated in A2780-
WT human ovarian carcinoma and MDA-MB-231 triple negative human mammary 
adenocarcinoma cell lines. Briefly, the cells were cultured in complete DMEM in conditions 
mentioned previously. Cells were seeded at a density of 5x103 per well in 96-well plates 
24h before treatment. The cells were treated with free DOX, blank MNCs or the three 
DOX-MNC formulations at different concentrations. The cells were incubated for 24h and 
72h. At the end of each time point the cells were washed, the culture medium was replaced 
with fresh complete DMEM and the cells were further incubated for 12h. Finally, the cell 
viability was estimated by standard MTT assay and described previously in Chapter 2.  
3.2.2.9 In vitro determination of MR potential 
 Approximately 10 million A2780-WT and MDA-MB-231 cells were incubated with DOX-
MNC-4c formulation at Fe concentrations of 0.009, 0.018 and 0.09 mM for a period of 24h. 
After incubation for specified time points, the cells were harvested and cell viability was 
determined by trypan blue assay. Approximately, 9x106 viable cells were re-dispersed in 
0.5mL PBS and mixed carefully with equal volume of hot 4% w/v agar solution taking care 
to prevent entrapment of air bubbles in the solidified gel. The samples were cooled to RT 
for to allow the formation of a solid matrix. As a control 9x106 un-treated cells were used. 
Phantom gels were scanned in Siemens Magnetom TIM Trio 3T human MR scanner. 
Images of the phantom gels were obtained by using a multi-gradient echo pulse sequence 
at a 1.64ms/3000ms TE/ TR and 40° flip angle for T1 and 112.5ms/ 3000ms TE/ TR for T2. 
The cellular phantoms were compared with phantoms of similar concentrations of 












 Core MNPs with two different mean particle sizes were synthesized by thermal 
decomposition of Fe (acac)3 in benzyl alcohol using two different techniques. In the first 
ramp-soak method wherein the reaction mixture was kept isothermal at 150°C for 2hrs, 
MNP cores of mean size 9.3 nm (Figure 3.1A) were obtained with a broad size distribution 
(Figure 3.1B). In comparison, the hot injection method yielded MNPs with a larger core 
size of 14.4nm (Figure 3.1C) with a very narrow size distribution (Figure 3.1D) and a 
significant fraction of the MNP population above 13nm. The magnetization potential of 
MNP cores was further studied by SQUID magnetometer. MNPs synthesized by hot 
injection exhibited significantly higher magnetization saturation (Ms) of 74.3 emu/g 
compared to 24.7emu/g for 9.3nm particles (Figure 3.1E). 
Figure 3.1. Synthesis of core MNP particles from thermal decomposition of 
Fe(acac)3. TEM images of MNPs synthesized by A. ramp-soak and B. direct 
injection method of thermal decomposition and respective size distributions C 





3.3.2 PREPARATION AND CHARACTERIZATION OF CATIONIC MNCS 
 Poly (l-lysine)x-PEG113  polymers of different poly (L-lysine) block lengths (x = 10, 50 
or 100) were used to stabilize the MNPs into clusters by a process described previously 
in Chapter 2. The physico-chemical characteristics of the different formulations are shown 
in Table 3.1.  The cluster formation was effected by electrostatic interactions between the 
MNP surface and the positively charged ε-primary amine end group of the cationic PLK 
block. As seen in Figure 3.2, the cluster size was affected by the poly (L-lysine) block 
length as well as the size of the core MNPs. 9.3nm MNPs stabilized by PLK10-PEG113, 
PLK50-PEG113 and PLK100-PEG113 had hydrodynamic diameters (Deff) of 36.4, 44.2 and 
82.1 nm respectively. MNC-1 formulation showed the maximum MNP content of 29.2 wt%. 
On the other hand, MNC-4 formulation, comprising of 14.4nm MNP had Deff of 121.3 nm 
with 28.3 wt% MNP content. The size (r.u.) of the PLK block of the cationic copolymer and 
the resulting polymer content in the MNCs, together dictated the colloidal stability of the 
clusters (Figure 3.3). While all the formulations maintained colloidal stability over a one-
month period in PBS (20mM, pH 7.4), MNC-1, stabilized by PLK10-b-PEG113 showed a 












































MNC-1 9.2 66.9 3.9 29.2 36.4 ± 6.3 0.211 ± 0.01 +20.5 
32.3 ± 







MNC-2 9.2 74.7 3.1 22.2 44.2 ± 4.1 0.183 ± 0.01 +28.3 
43.1 ± 






-MNP-9 MNC-3 9.2 73.3 3.8 22.9 82.1 ± 6 0.209 ± 0.03 +35.4 
76.2 ± 











± 2.4 0.137 ± 0.02 
a) The average core size was estimated from TEM images by measuring a minimum of 400 core particle sizes with Image J software. 
b) Composition of the MNCs was determined by TGA 
c) Benzyl alcohol: Briefly, the content of benzyl alcohol coating on the MNPs was determined by loss of organic components upon thermal 
decomposition of MNPs. The total loss of the organic components upon thermal decomposition of the MNCs was corrected by subtraction of 
the content of BA to determine the polymer content of the MNCs 
d) DLS characteristics were measured at 25°C at a concentration of 1 mg/mL in DI water and 10mM PBS at pH 7.4 in clear disposable zeta cell 












Figure 3.2. TEM images of A. MNC-1, B. MNC-2, C. MNC-3, D. MNC-4 clusters 




























Figure 3.3. Colloidal stability of different MNCs stabilized by PLK-b-PEG with 
different r.u. of PLK. 
Figure 3.1. Relaxivity measurements of different MNC formulations in PBS. R1 
(A) and R2 (B) Relaxation rates of were plotted against Fe concentration to obtain 
r1 and r2 relaxivities (s-1.mM-1; Table 2) as the slopes of the linear curves so 











MNC-1 0.9 ± 0.04 93.2 ± 2.2 
MNC-2 0.62 ± 0.02 177.3 ± 6.5 
MNC-3 1.28 ± 0.02 294.1 ± 2.1 
MNC-4 1.02 ± 0.01 358.5 ± 7.4 
MNC-4 in gel 1.01 ± 0.08 313 ± 12.9 
 
Relaxivity measurements of the different MNCs were performed in DI water and 
PBS on a 7T MRI scanner (Figure 3.4). The ability of MNPs to decrease the relaxation 
time of the surrounding water protons is quantified as relaxivity i.e. the slope of the 
plots of longitudinal (R1) or transverse (R2) relaxation rates vs. Fe concentrations. As 
tabulated in Table 3.2, the transverse relaxivity (r2) of the different formulations 
increased with the cluster size and as a function of the total MNP content of the 
formulations with the exception of MNC-1 formulation, which in spite of having a high 
MNP content of 29.2 wt%, had the lowest r2 of 93.2 ± 2.2 s-1.mM-1. This can be 
attributed to the smaller cluster size of 33nm as well as the lack of compactness of the 
clusters (Figure 3.2). MNC-2 and MNC-3 clusters had identical MNP content of 23 
wt%, but the MNC-3 showed significantly higher relaxivity (358.5 ± 7.4s-1.mM-1) than 
MNC-2 (294.1 ± 2.1 s-1.mM-1), which had nearly half the Deff as that of MNC-3. MNC-
4 formulation, with the core MNP size of 14.4nm, largest cluster size and evidently a 
higher MNP content of 28 wt% had the maximum r2 relaxivity of 358.5 ± 2.2 s-1.mM-1. 




phantom agar gels. As noted in Chapter 2, agar gel is widely used to mimic soft tissues 
in in vitro assessment of MRI contrast agents. Given the physical characteristics of the 
MNPs used for MNC preparation, none of the formulations exhibited high longitudinal 
relaxivity (r1). 
3.3.4 DOXORUBICIN CONJUGATION ON MNCS VIA PH SENSITIVE LINKER 
 MNC-4 formulation was selected for all further studies due to its excellent colloidal 
stability and high relaxivity in physiological buffer (PBS). Doxorubicin HCl (DOX) was 
conjugated onto the formulation via the heterobifunctional pH sensitive linker SPDP in a 
stepwise manner. Firstly, DOX was activated at its 13-keto position with EMCH, a 
heterobifunctional hydrazide linker in presence of trifluoroacetic acid as a catalyst as 
shown in Scheme 3.1A. The activated DOX-HZN molecules were characterized by 1H- 
Scheme 3.1. Doxorubicin conjugation to MNC-4 formulation via hetero-bi-




NMR (Figure 3.5). In a separate reaction, the side-chain primary amine groups of the poly 
(l-lysine) block were conjugated to another heterobifunctional linker SPDP. Following 
successful conjugation to the MNCs the disulfide linkage on the other end was reduced 
by DTT and DOX-HZN was conjugated to the MNCs via a thioester bond to the SPDP 
molecule (Scheme 3.1B). Three different target conjugation efficiencies were attempted 
as tabulated in Table 3.2. 
 
Figure 3.5. 1H-NMR of (A) free DOX and (B) DOX-HZN. Selected peak assignments 
common to both (A) and (B) are as follows: δ ppm = 1.7 (2H, m, -NH2, 4), 3.39 (3H, s, -
CH3, 2), 4.69 (2H, d, -CH2, 5), 5.37 (1H, s, -OH, 3), 7.65 (1H, s, -CH, 1). Additional peak 
assignments of the modified DOX-HXN are as follows: 1.32 (2H, s, -CH2, 7), 4.0 (2H, s, -




 Depending on the number of primary amino groups targeted for DOX-HZN, all three 
formulations showed a %CE of approximately ~5 wt%. Formulation DOX-MNC-4c 
exhibiting the maximum %LC of 2.48 wt%. DOX conjugation had no effect on the cluster 
size as well as PDI of the formulations. However, this modification significantly reduced 
the zeta potential of the final formulations. MNC-4 formulation had a zeta potential of +44 
mV before DOX conjugation, which reduced to less than +25 mV (Table 3.3) following 
DOX-HZN conjugation, which we anticipated would help reduce the charge-induced 








Table 3.3: Physico-chemical characteristics of DOX-MNC conjugates 
 
Formulation 
Target Conjugation (Eq. 
mol % of available primary 
amino groups (a) 
DLS Characteristics in DDW(b) %CE 
(C) 
%LC 
(d) Deff PDI ζ-potential (mV) 
DOX-MNC-4a 15 129.7 ± 4.2 0.163 ± 0.005 21.5 5.3 0.93 
DOX-MNC-4b 30 121.7 ± 5.3 0.161 ± 0.004 17.7 4.2 1.51 
DOX-MNC-4c 50 125.7 ± 2.7 0.153 ± 0.002 13.8 4.6 2.48 
a) The total primary amino groups (μmoles) available for DOX conjugation per mL of the MNC formulation was determined by 
Fluorescamine assay. 
b) Physical characteristics of the final DOX-MNC formulations was determined by DLS 
c) Conjugation efficiency: Defined as the %fraction of the targeted μmoles of primary amino groups that was conjugated by DOX. 
DOX content per mL of the formulation was quantified by fluorimetry at Excitation/ Emission wavelengths of 480nm/ 580nm 
d) Loading Capacity was determined as the weight percent of DOX.HCl per the dispersed phase. Briefly, the drug-loaded MNCs were 
lyophilized and the amount of DOX.HCl per mg of the formulation was determined by fluorimetry. Briefly 0.2mL of the final DOX-
loaded formulations was lyophilized. The lyophilized formulation was weighed and dispersed in pH 4.5 acetate buffer for 48h 
followed by sonication for 1h and ultra- centrifugation at 10,000 rpm for 15 minutes. The fluorescence of the supernatant was 





3.3.5.  PH RESPONSIVE RELEASE OF DOX FROM MNCS 
 The efficacy of the acid-labile hydrazone linkage in achieving a  physiological stimuli-
responsive drug release was studied on DOX-MNC-4b formulation, which had the 
intermediate %LC of the three formulations. We evaluated DOX release separately for a 
period of five days in pH 7.4 PBS, pH 5.5 ABS. In addition, we also studied the effect of 
sequential exposure to both pH conditions. For this study the formulation was placed in 
PBS for 24h after which the release medium was changed to pH 5.5 ABS and the release 
was  further monitored for the remaining four days. The last approach was adopted 
specifically to evaluate the potential effect of pre-exposure to physiological buffer may 
have on the release rate of the drug in acidic pH.  



















pH 7.4  PBS
pH 5.5 ABS
pH 7.4/ pH 5.5
****
Figure 3.6. Release of DOX from MNC-4b formulation at different pH conditions. DOX 
release was measured in either 50mM pH 5.5 sodium acetate buffer (ABS), 10mM pH 
7.4 PBS or sequentially in pH 5.5 ABS buffer for 24h followed by pH 7.4 PBS for a total 
of 5 days Drug release was quantified at regular time points by fluorimetry at Ex/Em 




 As expected, the acid-labile hydrazone bond efficiently prevented the release of DOX 
from the clusters (Figure 3.6). Only 4.3% drug was release in PBS in the first day and 
overall only 23.3% DOX was released in PBS over a five-day period. On the other hand, 
formulation in pH 5.5 ABS responded favorably to the acidic environment and 22% of the 
conjugated DOX in the first 24h. Over a five-day period 92% release was achieved in ABS. 
Formulation exposed sequentially in PBS for 1day followed by ABS for four days did not 
show any aberration in the release profile following changeover to ABS medium from PBS 
after 24h.  
 Thus, DOX conjugation on the MNCs via acyl hydrazone linkage allows for controlled 
release in response to pH stimuli inside the cell. However, it is noteworthy that hydrazone 
hydrolysis occurs rather slowly even at pH 5.5, a condition similar to that found in 
subcellular compartments. In summary, the rate of drug release appears to be determined 
primarily by the intrinsic rates of hydrazone hydrolysis and is governed by pH changes 
only. 
3.3.6 FORMULATION TOXICITY STUDIES 
 Cationic polymers such a poly (L-lysine) and nanocarriers thereof present with one 
major challenge; that of charge induced toxicity of the polymer itself.  It is now known that 
molecular weights as well as the cationic charge density of the polycations are the key 
parameters for the interaction with the cell membranes and consequently cell damage. 
24
 
Studies on poly(ethyleneimine) (PEI) polymer revealed that the polymer does not cause 
apoptosis but rather a necrotic cell reaction.  Nonetheless, cationic polymers are 
exclusively used in gene delivery wherein condensation of the negatively charged DNA 






 In order to determine the toxicity of our formulation before DOX conjugation we 
conducted toxicity studies on the unloaded MNC-4 formulations (SH-MNC-4a-c) in the two 
cancer cells lines, namely MDA-MB-231 triple negative breast cancer cells and A2780 wild 
type ovarian cancer cells.  Cells were exposed to different concentrations of SH-MNC 
formulations for 24h and 72h. At the end of each time point, the treatment was removed, 
the cells were washed with heparinized PBS (0.2 mg/mL Heparin sulfate) and allowed to 
grow for additional 12h in fresh media. The cell viability was measured by MTT assay as 
described in Section 2.2.2.9 of Chapter 2. SPDP conjugation and subsequent reduction 
of the disulfide bond significantly reduces the toxicity of the cationic MNC-4 formulations 






























































Figure 3.7. Toxicity of SH-MNC formulations prior to DOX-HZN conjugation in 




(Figure 3.7). Depending on the extent of SPDP conjugation on the side-chain primary 
amine, the formulation toxicity decreased as SH-MNC-4a > SH-MNC-4b > SH-MNC-4c. 
The formulations exhibited marginally higher toxicity in A2780 cells at 24h compared to 
MDA-MB-231 cells. However, at the end of 72h both the cell lines showed similar toxicity 
profiles. Overall, all the modified formulations were well-tolerated up to concentration 
equivalent to 10 μg/mL of Fe with cell viabilities being above 80% in all cases. Formulation 
SH-MNC-4a showed relatively higher toxicity at 25 μg/mL of Fe. Nonetheless, compared 
to the unmodified MNC-4 formulation, all the SH-MNC-4 formulations showed marked 
reduction in charge-induced toxicity. 




 Intracellular uptake of the cationic formulations was studied by ICPMS and confocal 
microscopy in A2780-WT ovarian cancer and MDA-MB-231 triple negative breast cancer 
cells. We first evaluated the effect of SPDP conjugation on the cellular uptake of the three 
SH-MNC formulations by ICPMS. It was observed that the degree of modification inversely 






























































Figure 3.8. Cellular uptake of SH-MNC formulations in A. 2780 (wild type) and B. 
MDA-MB-231 cells over a period of 24h quantified by ICPMS Data represented as 




affected the cellular uptake. Thus, SH-MNC-4a formulation, which had the least SPDP 





Figure 3.9: Qualitative estimation of cellular uptake of DOX-MNC-4c formulation over a 
period of 24h in A2780-WT ovarian cancer and MDA-MB-231 cancer cells by confocal 
microscopy. Cells were incubated with DOX-MNC-4c formulation (Orange) conjugated 
with Alexa-Fluor 647 (Red) for different time intervals followed by incubation with 
Lysotracker (Green) and Hoechst nuclear stain (Blue). Colocalization of the MNCs in 




 lines. The other two formulations did not show a significant difference in cellular uptake. 
Between the two cell lines, uptake rate was faster in the ovarian cancer cell line. At the 
end of 24h ovarian cancer cells showed an uptake equivalent to 8.4 μg/mg of total protein 
while the breast cancer cells showed an uptake of 6.6 μg/mg of total protein (Figure 3.8).  
 Of the three DOX-loaded formulations, DOX-MNC-4c was further selected for confocal 
microscopy studies to qualitatively evaluate the uptake of the formulation and also to study 
the cellular localization pattern of the formulation. For this study the cells were seeded in 
8-Chamber confocal slides and allowed to grow for 24h. The cells were then incubated 
with Alexa-Fluor 647-labelled DOX-MNC-4c formulation for 1h, 3h and 24h. At end of each 
time period the cells were washed thoroughly and further incubated with lysosomal marker 
lysotracker green and Hoechst nuclear stain for 1h and 30min respectively. As seen in 
figure 3.9 cationic formulations (red/ red + orange) were associated with the cell 
membrane immediately (1h) post incubation. As time progressed, the membrane-
associated MNCs were internalized and localized within the lysosomes as seen from the 
yellow overlay images. DOX, either bound with the formulation or as a free drug (orange 
punctate either by itself or embedded in red MNC fluorescence) was also seen localized 
within the lysosomes. Confocal microscopy confirmed the results of ICPMS wherein 




3.3.8 IN VITRO ANTI-CANCER EFFICACY STUDIES OF DOX-MNC FORMULATION 
Figure 3.10: Cytotoxic efficacy of different DOX-MNC-4 formulations in MDA-MB-231 (A, 
B) A2780-WT (C, D) cells at 24 and 72h. Data represented as Mean ± SD (n = 6)  
Table 3.4: IC50 values (μM) of the different DOX-MNC-4 formulations in A2780-WT 
ovarian cancer and MDA-MB-231 breast cancer cells  
Group 
A2780-WT MDA-MB-231 
24h 72h 24h 72h 
DOX.HCl 0.024 ± 0.013 0.014 ± 0.003 0.496 ± 0.028 0.08 ± 0.009 
DOX-MNC-4a 0.145 ± 0.01 0.059 ± 0.006 -- 0.371 ± 0.021 
DOX-MNC-4b 0.103 ± 0.006 0.038 ± 0.01 -- 0.382 ± 0.019 
DOX-MNC-4c 0.162 ± 0.002 0.042 ± 0.008 1.55 ± 0.024 0.223 ± 0.016 
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 The in vitro therapeutic efficacy of the three cationic DOX-MNC-4 formulations with 
different %LC of DOX was determined in A2780-WT and MDA-MB-231 cells by MTT 
assay. As anticipated, all formulations showed higher IC50 values than free DOX. The 
cytotoxicity was dependent on the rate of uptake of the formulations. Also, DOX release 
was guided by a pH-dependent mechanism wherein the drug could be released and 
available for activity only in the lysosomal pH.  Likewise, all formulations showed lower 
cytotoxicity at the end of 24h, particularly in MDA-MB-231 cells wherein only DOX-MNC-
4a formulation exhibited at least 50% toxicity (Figure 3.10 and Table 3.4). At 72h, 
however, the formulations exhibit toxicity proportional to %LC of DOX in each. Thus, DOX-
MNC-4b and 4c formulations had similar IC50 of 0.038 and 0.042 μM respectively in 
A2780-WT cells. Triple negative MDA-MB-231 cells, due to a slower uptake rate showed 
a nearly 4-fold higher IC50 than A2780 cells across all treatment groups, with DOX-MNC-
4c formulation showing the highest cytotoxicity of all the nanoformulations tested. The IC50 





3.3.9 IN VITRO DETERMINATION OF MRI POTENTIAL OF CATIONIC MNCS 
 
Figure 3.11: In vitro evaluation of MRI potential of DOX-MNC-4c formulation. T1 and T2 
images of phantom gels of A2780-WT and MDA-MB-231 cells incubated with different 
concentrations of DOX-MNC-4c formulation. The contrasts of the cellular phantom gels 
were compared with those obtained from serial dilutions of the formulation in absence of 
cells  
 
 In the next step, we evaluated the MRI potential of DOX-MNC-4c formulation was 
evaluated in both the cell lines mentioned in the previous section. Following 24h incubation 
with the said formulation at concentrations equivalent to 0.009, 0.018 and 0.09 mM Fe, 
the cell viability was determined by trypan blue assay and 9 million live cells per group 
were mixed uniformly with molten agar and cooled to mimic soft tumor mass. These gels 
were then scanned in Siemens 3T human scanner to obtain T1 and T2-weighted contrasts 




measurements. The formulation did not show any change in positive (T1) contrast. The 
negative (T2) contrast, on the other hand showed a dose dependent increase. The cellular 
phantom gels also showed significant dose-dependent increase in contrast. A2780 cells 
showed a greater contrast compared to MDA-MB-231 cells due to comparatively higher 
uptake in A2780 cells. It is noteworthy that the contrast obtained for the cationic MNC is 
significantly higher in comparison to that obtained with the anionic MNCs discussed in the 





3.4. DISCUSSION  
 In spite of significant advances made in the field of nanomedicine for cancer therapy, 
numerous problems continue to plague the successful entry of these promising drug 
delivery systems into clinical use. A major cause of this impediment is insufficient 
characterization and lack of understanding of the interactions of various nanoformulations 
in vivo. Although the enhanced permeability and retention (EPR) effect is viewed as a key 
motivation for the use of nano-scale drugs to treat solid tumors, physiological barriers 
posed by the tumor microenvironment hamper uniform delivery of nanoparticles in 
amounts sufficient to eradicate cancer. Nanoparticle size, shape and surface charge (zeta 
potential) have been seen as key factors interacting with physiological tissues and thus 
affecting the uptake of the particles. Predominantly, zeta potential or surface charge 
density of the nanoparticles significantly affects their intracellular uptake. Even relatively 
small positive zeta potential has been shown to cause more than two folds increase in 
intracellular uptake as well as transvascular flux of the nanoparticles.
25
  PLK-based 
nanocarriers, by virtue of their high cationic nature, have shown significant increase in 
cellular uptake of such nanocarriers in vitro as well as in vivo. Cationic nanoparticles made 
from these polymers have shown significant anti-angiogenic properties in animal models
26
 
due to the enhanced uptake and accumulation of these intravenously administered 
cationic systems in the tumor tissue. Poly (L-lysine) serves as a good polymer for 
development of nanocarriers capable of interacting favorably with the cell membranes to 
achieve enhanced drug delivery.  
 Development of MNPs for cancer theranostics requires development of nanoparticle 
cores with superior magnetic properties, which are governed by their core size. A precise 
control over the nucleation and growth phases during the synthesis of core MNPs is a 




decomposition method provides this control over particle size, thereby enabling synthesis 
of larger MNPs, which are known to show higher T2 relaxivity. The prolonged in situ 
tempering of the formed MNPs at high temperatures further enhances the magnetization 
saturation of the resulting MNPs. Size distribution of the cores so formed is also a critical 
parameter. In the ramp and soak technique, which was similar to the techniques described 
in the precious chapter, this separation was achieved by heating the reactants at 150°C 
(nucleation temperature deduced in chapter 2) for 2hrs during which time maximum 
amount of Fe(acac)3 was reduced by the solvent to form nuclei. The subsequent ramp in 
temperature to reflux initiated the growth phase, which utilized the remaining precursor for 
increasing the core particle size. This method resulted in a broad size distribution. Hot 
injection method offered significant advantages over this conventional method. The fast 
injection of the precursor in a solvent, which was already at reflux, induced a high degree 
of super-saturation, resulting in a transient burst of nucleation as the temperature dropped 
to about 165°. As the temperature rose rapidly once again to reflux it prevented any further 
nucleation and promoted uniform growth of the formed nuclei. This entire step was very 
short and lasted for about 10 minutes only and led to large-sized nanoparticles above 
13nm and with a very narrow size distribution. 
 The prolonged high temperature annealing of the formed MNPs imparts superior 
magnetic properties to the MNPs formed by both methods. However, several factors affect 
the magnetic properties, most predominant being the core diameter and size distribution. 
In the nanometer regime, the MNPs comprise of single domains and hence exhibit 
properties different than those of the bulk material. In such clusters of single-domain 
MNPs, the magnetic moment of each particle interacts with its neighbors and the field to 
align in the direction of the magnetic field. The magnetization at which all the moments 
are aligned is referred to as the saturation magnetization (Ms).
27




injection method exhibited nearly 3-fold higher Ms compared to those obtained from the 
ramp soak method. Even in comparison to the once commercially available Feridex
®28
, 
the MNPs obtained by hot injection method had higher Ms. This is predominantly due to 
the particle size and narrow size distribution of the core particles. The complete absence 
of hysteresis indicated absence of any remnant magnetization upon removal of the 
magnetic field, thereby confirming their superparamagnetic nature. 
 MNCs were prepared by formation of coordination complexes between the MNP 
surface and the pendant primary amino groups of the PLK-b-PEG copolymers. Due to the 
absence of strong hydrophobic surfactants such as oleic acid and oleylamine coating the 
MNP surface, this synthesis could be carried out by a completely hydrophilic process 
similar to the process described in Chapter 2. The resulting cluster size was dictated by 
the r.u. of l-lysine in the PLK block. The block length also affected the colloidal stability of 
the MNCs. In a sharp contrast with the MNCs stabilized by anionic block copolymers in 
the previous chapter, the cationic MNCs showed significant stability thus suggesting that 
the coordination complex between the primary amino group and MNP surface is 
significantly stronger than that between the carboxylate group and MNPs. Hence, none of 
the clusters showed complete loss of stability. MNC-1 clusters however, showed an 
increase in Deff over the period of one month. This increase can be attributed to the lack 
of compactness in the MNCs (Figure 2) formed by the shortest copolymer (PLK r.u. 10). 
.Compared to the other MNCs, MNC-1 also had significantly less polymer content, which 
also indicates incomplete surface coverage and hence a high propensity to lose colloidal 
stability. In comparison, MNC-4 clusters, which were synthesized from PLK50-b-PEG113 
and MNPs with core size 14.4nm, showed only marginally higher polymer content than 
MNC-1 and yet this formulation showed significantly higher colloidal stability. This 




Copolymers with a larger PLK block imparted significantly greater interactions with the 
MNP surface, thus covering a greater MNP surface area, thus preventing agglomeration 
and loss of colloidal properties.   
 As mentioned in Chapter 2, relaxivity is an important property of MNPs. It is a measure 
of the MRI potential of the contrast agent. Numerous factors such as method of MNP 
synthesis, MNP core size, the type of stabilizing agent and the MNP content in the cluster, 
all cumulatively affect relaxivity of MNP-based MR contrast agents. This reflects in the T2 
relaxivity (r2) of the MNCs as mentioned in Table 3.2. In spite of having the highest MNP 
content amongst the four different types of clusters synthesized, MNC-1 showed the 
lowest r2 values. The lack of compactness of the MNC-1 clusters is a prime cause of this 
result. MNPs are known to exhibit higher r2 when held together closely in clusters. The use 
of hydrophilic polymers further enhances r2 by increasing not only the diffusion but also 
the retention time of water molecules in close proximity with the MNP surfaces.
29-31
 As a 
result, in clusters with same core MNP sizes, the composition of the cluster, cluster size 
and the resulting compactness governed the diffusion and retention of water molecules in 
the interior of the clusters and hence also the relaxivity. MNC-4 clusters exhibited the 
maximum r2 relaxivity due to a large core size, largest cluster size and effectively 
maximum water retention in the core.  
 DOX loading onto the MNCs was achieved by conjugation of the modified DOX-HZN 
molecule to the pendant –NH2 groups on the MNC clusters. DOX molecule can be 
activated at two sites, the 3’-amino and the 13-keto position. However, DOX ligated at 3’-
amino group has reduced anti-cancer activity due to energetically unfavorable 
intercalation of DOX in the minor groove of DNA.
32
 Conjugates obtained by modification 
at 13-keto position do not cause any change in the activity of the molecule. Hence we 




sensitive DOX-HZN molecule Further, the DOX-HZN was conjugated to the SPDP-
modified MNCs via thioether ester over the traditional disulfide linkage due to the 
previously reported reduced stability of the disulfide bond under physiological conditions.
33
 
The disulfide bond is susceptible to reductive mechanisms such as those of molecules 
such as glutathione and other thiol containing molecules in the liver and plasma, which 
can lead to premature release of the molecule and undesired toxicity. We intended to 
achieve drug release selectively in the acidic environments of the lysosomal-late 
endosomal compartments. Stimuli-responsive systems are specifically designed in order 
to achieve rapid release only under specific conditions such as pH. The acid labile linkers 
such as cis-aconityl
26, 32
 or hydrazone linkers
34, 35
 exhibit sufficient extracellular stability 
and prevent the encapsulated payload from leaching during circulation. Such strategies 
are also advantageous from the point of reducing the drug dose, as the likelihood of 
maximum dose reaching the target tissue is very high in comparison to the passive slow 
diffusion of the drug from the nanocarriers, which is governed primarily by hydrolysis. Drug 
conjugation also imparts considerable control over the amount of drug loaded in the 
nanocarriers. This control is absolutely essential in case of nanocarriers carrying multiple 
modalities such as diagnostic and therapeutic payloads. An optimum drug: MNP ratio 
needs to be achieved in the development of co-encapsulating theranostic nanosystems in 
order to achieve a good contrast in the target tissue while ensuring that the DOX levels 
are also sufficient to achieve a therapeutic effect.  
 Shielding of the ε-amino groups by thiol end groups marginally reduced the 
positive zeta potential of the formulations. However, it did not affect the charge-
induced intracellular uptake of the MNCs in human ovarian and triple negative 
breast cancer cells. The MNCs were internalized as early as 1h-post incubation. 




clusters significantly. The higher uptake of the formulations translated into 
significant intracellular toxicity of the formulations. 
 DOX is an anthracycline antibiotic used in the treatment of a wide variety of 
malignancies such as breast, ovarian, sarcomas, lymphomas, and acute luekemias. 
Intracellular free DOX accumulation varies from one cell line to another. However, most 
cells achieve intracellular steady-state levels within 2–8 hr.
36
 In addition to intracellular 
accumulation, doxorubicin’s mechanism of action is also variable for different cell types. 
For instance, Fulda et al.
37, 38
 concluded that DOX induces the apoptotic death signal in 
different ways depending upon the cell line. Also, in comparison to the free drug 
(DOX.HCl), DOX encapsulated within or bound to nanovehicles is expected to show a 
slower onset of action, which is governed by the release profile of the drug from the 
nanocarriers. Although in this case, the cationic MNCs show significantly faster uptake 
within the first three hours, the pH-triggered release of DOX is a relatively slow mechanism 
as seen in the in vitro drug release studies (Section 3.3.5 and Figure 3.6). All these 
factors contribute to the slower onset of cytotoxicity and hence a higher IC50 compared to 
the free drug. The different formulations exhibit different cytotoxic potential depending on 
the %LC of DOX. This trend was seen in both cell lines, though was more prominent in 
MDA-MB-231 cells wherein DOX IC50 values decreased with increase in DOX loading. We 
attribute this difference to the DOX: MNP ratio in the three formulations.   A lower DOX 
%LC or more MNP content can sterically hinder the exposure of the hydrazone linkage to 
acidic pH and thus can retard DOX release. Nonetheless, the systems successfully 
function as a pH controlled drug release nanoformulation, which by virtue of a sustained 
release can prolong the therapeutic effect. 
 While MNPs larger than 7nm are predominantly negative contrast agents, the cluster 




weighted MR capability. DOX loading did not affect the MR potential of the MNCs. The 
core MNPs used in MNC-4 clusters were above 13nm in diameter. The resulting high Ms 
and significantly high r2 relaxivity values translated into superior negative contrasts of the 
clusters embedded in agar phantom gels. The significantly higher cellular uptake of the 






 In summary, we successfully synthesized MNP cores devoid of any hydrophobic 
surfactants and in the 14-20nm-size range by a one-step direct injection method. 
Compared to the conventional ramp-soak method, the cores were highly monodisperse. 
The larger 14nm MNPs showed stronger magnetic susceptibility and had a higher Ms 
compared to the 9.3nm cores, which had a broader size distribution. PLK-PEG polymers 
form a stable complex with MNP surfaces depending on the lysine block-length. The 
cluster size also governed the relaxivity of the formulations. In comparison to the relaxivity 




), MNC-4 formulation stabilized by PLK50-b-PEG113 showed 
significantly higher relaxivity values. The cellular uptake of these formulations was 
facilitated by their interaction with the negatively charged cell surface and subsequent 
endosmolytic uptake. Compared to anionic formulations discussed in the previous 
chapter, cationic MNCs showed a significantly higher cellular uptake. This can induce 
significant toxicity in the cells. Modification of the free cationic side-chain primary amino 
groups by heterobifunctional linker SPDP and subsequent reduction by DTT to introduce 
thioester functionality significantly reduced the toxicity of the cationic formulation. DOX 
modified by hydrazone linker was conjugated onto these thiol end groups to form a stable 
thioester conjugate which would cleave only at the hydrazone linkage at an acidic pH with 
no effect of redox conditions. Introduction of the pH sensitive linker resulted in a sustained 
release of DOX exclusively in the acidic pH. End group modification also reduced the zeta 
potential of the formulations, which in turn also altered the uptake of the formulations 
depending on the degree of modification.  
 The formulations showed differential uptake in A2780 ovarian cancer and MDA-MB-
231 triple negative breast cancer cells. This difference in uptake also influenced the 




4a, which had the least %LC also showed significantly higher IC50 values in both the cell 
lines. This difference can be attributed to the higher MNP content in the 4a formulation, 
which can shield the cleavage of the hydrazone bond and further prolong the release of 
DOX from the clusters. Finally, the higher cellular uptake also resulted in significantly 
higher MRI potential of the cationic formulations. The formulations resulted in higher 
negative contrasts at lower Fe concentrations compared to the anionic formulations. Thus 
we can conclude that cationic polymers are capable of forming very stable stimuli-
responsive theranostic MNCs without any modification of the polymer to introduce 





3.6 FUTURE DIRECTIONS 
 This work holds tremendous potential in development of protein theranostics. PLK-
PEG, by virtue of this positive charge can efficiently condense proteins and nucleic acids 
onto itself. We have initiated initial studies to load anti-oxidant enzymes such a superoxide 
dismutase (SOD) and catalase, which show tremendous potential in neurodegenerative 
disorders.  
 Previous work in our group has already demonstrated the ability of MNCs to alter 
enzyme kinetics in response to an alternating (AC) magnetic field.
39
 We intend to study 
the effect of such AC fields on the structural integrity of these clusters. Our initial work has 
shown promising results. However, additional confirmatory studies are required before the 
phenomena can be revealed. 
 Finally, in vivo pharmacokinetics of the DOX-conjugated MNC will be evaluated in 
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 Superparamagnetic iron oxide nanoparticles (MNPs) are well known for being able to 
shorten the transverse relaxation time of water protons and have been used as a negative 
contrast agents in MRI.
1
 Recently, aggregated or assembled MNPs are drawing greater 
attention in MRI applications because they can provide even higher contrast than 
individually dispersed MNPs.
2-6
 For biomedical applications such as diagnostics and drug 
delivery, several characteristics of MNPs such as core particle size, cluster size, surface 
charge, colloidal stability and biocompatibility of stabilizing compounds are of critical 
importance since these control the various pharmacokinetic parameters of the MNPs in 
vivo. 
 Different methods have been used to automate and precisely control the process of 
formation of uniform magnetic nanoclusters (MNCs) such as spray drying
7
, mixing with a 
conventional high speed homogenizer
8
, Confined Impinging Jet (CIJ) mixer
9, 10
 and Multi-
Inlet Vortex Mixer (MIVM)
11
. In comparison to thermodynamically controlled processes 
such as dialysis and emulsification-evaporation
12
, which are slow and result in drug/matrix 
separation and low drug loading, kinetically controlled techniques such as flash 
nanoprecipitation with the MIVM and jet impingement have been shown to result in high 
drug loading and formation of the stable complexes.
13-16
 The CIJ mixer and MIVM show 




size distributions, ability to control the particle size and particle composition and enhance 
drug loading capacity.
14
 These kinetically controlled methods of self-assembly were 
chosen for their ability to induce mixing and resultant precipitation in significantly lesser 
time than the characteristic precipitation times of organic/inorganic materials.
17
 These 
kinetically controlled processes have two requisites. First is the creation of a region of 
highly turbulent energy dissipation. High-energy dissipation occurs for impinging jets 
because the kinetic energy of each jet stream is converted into a turbulent-like motion 
through collision and redirection of the flow in a very small volume. Second requisite is to 
ensure that the process streams for mixing pass through the high intensity region. The 
first step ensures the proper scale for mixing and the second ensures that the desired 
molar flow ratios are preserved during the rapid mixing process.
11
 
 Rapid precipitation of organic and inorganic components of nanoparticles at high 
supersaturation requires controlled homogenous mixing to control the particle size 
distribution, which is possible to achieve in a Multi-Inlet Vortex Mixer (MIVM). The four-
stream MIVM allows control of both, the supersaturation and the final solvent quality by 
precisely varying stream velocities with the help of precisely defined Reynolds numbers 
(Re). The Reynolds number is defined as the ratio of momentum forces to viscous forces 
and consequently quantifies the relative importance of these two types of forces for given 
flow conditions.
18
 Reynolds numbers frequently arise in fluid dynamics and are used to 
characterize different flow regimes within a similar fluid, such as  
• Laminar flow: Occurs at low Reynolds numbers, where fluid viscosity is dominant, 
and is characterized by smooth, constant fluid motion; 
• Turbulent flow: Occurs at high Reynolds numbers where inertial forces are 




 The MIVM design enables mixing of streams of unequal volumetric flows, which is not 
possible with alternate confined impinging jet (CIJ) mixing geometries, thus making it a 
more versatile method with a potential for complete automation, high degree of 
reproducibility and control of critical parameters such as particle size and distribution.  
 We first employed the MIVM to control the cluster formation process of MNPs with the 
help of Pluronic amphiphilic tri-block copolymers. As mentioned earlier, the magnetic 
properties and MRI potential of MNPs such as T2 relaxivity is enhanced when they are 
packed into compact and stable clusters.
19
 We studied the effect of numerous factors such 
as MNP and polymer content at different mixing speeds which were controlled by adjusting 
the Re. Subsequently, we also attempted to co-encapsulate a hydrophobic anti-cancer 
agent paclitaxel (PTX) with these MNCs formed by kinetically controlled flash 
nanoprecipitation in a MIVM. The results showed that MIVM served as an ideal method 
for rapid and formation of large volumes of MNCs with precise control over the cluster 
size. Pluronic F127 by itself or in combination with Pluronic P123 efficiently encapsulated 
the oleic acid coated MNPs (OMPs) alone to form very well defined MNCs. However, the 
tri-block Pluronic polymers showed a potential limitation. Negligible to no paclitaxel loading 
was achieved when using F127 alone. Inclusion of P123 as a stabilizing polymer 
increased the encapsulation efficiency, but the % loading of PTX albeit, was still very low. 
Nonetheless, the excellent control over cluster formation is very encouraging and warrants 





4.2 MATERIALS AND METHODS 
4.2.1 Materials 
 Iron (III) acetylacetonate (Fe(acac)3), Benzyl ether, nitric acid (TraceSELECT), ICP 
grade standards for Fe (Fluka) were purchased from were purchased from Sigma-Aldrich 
(St. Louis, MO), Ethanol (200 proof), tetrahydrofuran (anhydrous), n-hexane, acetone 
(histology grade), chloroform (anhydrous), acetonitrile (HPLC grade), methanol (HPLC 
grade) and other HPLC grade solvents were purchased from Thermo Fisher Scientific 
(Waltham, MA). Pluronic F127 (M. wt 12,600, PEO100PPO65PEO100) and Pluronic P123 
(M.wt. 5750, PEO20PPO70PEO20) were kindly provided by BASF (Florham Park, New 
Jersey). Paclitaxel (PTX) was purchased from LC Labs (Woburn, MA). 
 
4.2.2. Design of a Multi Inlet Vortex Mixer (MIVM) 
 




 The MIVM is made from a fiberglass composite material, which is resistant to organic 
solvents typically used in the chemical industry.  Four external inlets lead vertically 
downwards to the four inlet streams (1.1mm diameter) that open tangentially in the 
boundary of the central mixing chamber (5.9mm). The final product exits the mixing 
chamber at the center as shown in Figure 4.1.  
 The theory behind the functioning of the MIVM is that the different flow rates and hence 
the different energies from each stream contribute separately to drive fast micromixing 
into the chamber. In MIVM different volumetric flow rates in each stream, defined by the 
Re, can be run and still obtain good mixing. One of the advantages of using the MIVM is 
that the final fluid phase is mostly aqueous. Therefore, the stability of the nanoparticles 
increases in solution by depressing the rate of Ostwald ripening, when the solubility of the 
precipitating species is high enough to permit this process. The importance of the vortex 
mixer is that a turbulent region can be created to form and precipitate homogeneous 
nanoparticles. The momentum of the four inlet streams through the mixing chamber 
creates the turbulent region. Once in the confines of the mixing chamber, the four fluid 
streams mix by convection energy (macro scale).  Turbulent eddies formed in the mixing 
chamber (meso scale) result in formation of daughter vortices by turbulent diffusion. 
Eventually, molecular diffusion occurs in the turbulent eddies and eliminates region of 




 The inlet velocities are selected by choosing an appropriate Re, inlet velocities, and 
physical properties of the inlet streams. The inlet velocities depend on the desired 
Reynolds numbers and volume fractions in the mixing chamber. The four inlet flow rates 
can be controlled using mechanical pumps. Re depends upon the inlet stream velocities 
(ui) and kinematic viscosities (νi) of the inlet streams and is defined as
11




   Re = Dmixer [u1/v1 +u2/v2 + u3/v3 + u4/v4]   Eqn 4.1 
where Dmixer is the diameter of the mixer 
4.2.3 METHODS 
4.2.3.1 Synthesis of oleic acid coated MNPs 
 Oleic acid-coated MNPs (OMPs) were synthesized by thermal decomposition of 
Fe(acac)3 by at method previously described by Sun et al.
21
Briefly, 2mmoles of Fe(acac)3, 
6mmoles of oleic acid, 6mmoles of oleylamine, 10mmoles of 1,2 hexadecandiol were 
dissolved in 20mL benzyl ether in a 3-necked round bottom flask. The mixture was heated 
at 110°C for 30 minutes in order to remove any traces of water in the reaction mixture. 
The temperature was then raised to 200°C at  3°C/min. The reaction was kept isothermal 
at 200°C for 2h following which the temperature was further increased to reflux (~295°C) 
and maintained isothermal for 2.5h. At the end of the reaction, the mixture was cooled and 
precipitated with twice the amount of reagent alcohol. The precipitate was separated by 
centrifugation at 4000 rpm for 45 minutes and washed with reagent alcohol.   The final 
product was dried by rotary evaporation and stored under vacuum for further use. 
4.2.3.2 Preparation of MNCs by flash nanoprecipitation 
a. Determination of critical aggregation concentration (cac) of F127 
 We determined the concentration at which Pluronic F127 (CMC 2.8μM)22  started 
aggregating in a mixture of 9.1%v/v aqueous mixture of tetrahydrofuran (THF) by DLS. 
Briefly, F127 was dissolved at different concentration in 9.1% v/v THF and allowed to rest 
for 15 minutes prior to measurements. The kilo counts per second function of DLS 
measurements was recorded for each dilution and plotted as a function of the 




given solvent system. For all further mixing procedures, the polymer concentration was 
maintained above the cac value. 
b. Determination of supersaturation (S) of paclitaxel 
 Prior to determination of S, the solubility of paclitaxel (PTX) in 9.1% v/v THF was 
determined. Briefly, 10mg of PTX was dispersed in 5mL of 9.1% THF and stirred 
continuously at RT for 72h. The dispersion was centrifuged at 10000 rpm followed by 
filtration of the supernatant through 0.2μm nylon syringe filter. The amount of PTX 
dissolved in the supernatant was determined by HPLC and denoted as Cinf. 
Supersaturation (S) of PTX in the chamber was determined as a ratio of the total drug 
exiting the mixer (mg) and Cinf. S is a critical parameter to ensure efficient precipitation of 
the drug in the given solvent system along with the other organic components. It is 
recommended to maintain S at values above 40. Similar study was performed for MNPs 




 All organic components, namely Pluronic, MNPs, and PTX (wherever included), were 
dissolved in THF. The MIVM was connected to two high-speed syringe pumps in order to 
obtain two different flow rates for the organic and aqueous phases. One inlet of the MIVM 
was connected to the glass syringe filled with organic solution and placed on one of the 
two pumps. The other three inlets were connected to 140mL syringes filled with DI water. 
The pump flow rates could by controlled separately by computer software to which the 
pumps were connected. We performed different trials by changing the Re, the theoretical 
loading capacity (%TLCMNP) of the MNPs and PTX (%TLCPTX) loading as tabulated in table 
4.1. In all experiments THF: water ratio was maintained at 0.091 (9.1%v/v). The crude 
product exiting the mixer was immediately placed in centrifugal filters (30,000 MWCO) and 




and passed serially through 0.45 and 0.2μm nylon syringe filter. The dead micelles, i.e. 
Pluronic micelles without any MNPs  encapsulated in them were removed by magnetic 
separation to obtain the final product.  







44 11 6300 
A2 9 4 8400 
A3 9 4 12000 
A4 15 8 12000 
A5 8 10 12000 
A6 4 15 12000 
A7 8 7 12000 
B1 20% P123+ 
80% F127 
10 5 12000 
B2 5 5 12000 
 
4.2.3.3 Characterization of MNCs 
a. DLS: The particle size and zeta potential of the MNCs so formed was determined by 
DLS, as described in chapters 2 and 3. The total solid content of the aqueous formulation 
was determined by TGA and the formulations were diluted to 1mg/mL in DI water for DLS 
analysis. 
b. Composition: The composition of blank formulations (without PTX) was determined by 
TGA by a method described in the previous chapters. The total polymer content was 




(LOI). In case of PTX loaded MNCs, PTX %LC was determined by HPLC connected to a 
reverse phase C18 column (Phenomenex, Torrance, CA) column and a diode array 
detector. Briefly, the 0.1mg of the lyophilized formulation was dispersed in acetonitrile and 
sonicated for 45 minutes following which the sample was centrifuged at 10000 rpm. The 
supernatant was diluted with mobile phase (Acetonitrile: water 55:45) and injected to 
obtain a peak at 8 minutes with a method run time of 10 minutes.  
c. Colloidal stability of MNCs 
 Colloidal stability of the MNC formulation was determined on 1mg/mL solutions of 
MNCs in DI water and phosphate buffered saline (PBS; 10mM; 0.14mM NaCl) at room 
temperature (RT) and 37°C. The particle size and PDI of the formulations was measured 
over the period of one month. 
4.2.3.4 Evaluation of MRI contrast capacity in phantom gels 
 MRI contrast capacity of formulations B1 and B2 was determined by embedding the 
formulations in 2% agar gels in 10mM PBS and taking scans in a 3T human MRI scanner 





4.3 RESULTS AND DISCUSSION 
4.3.1 SYNTHESIS OF OLEIC ACID COATED MNPS 
 
Particle size of MNPs obtained by thermal decomposition of Fe (acac)3 in presence of 
oleic acid and oleylamine surfactants were analyzed by TEM. MNPs so formed had a core 
size of 6.3 ± 2nm. We further determined the amount of hydrophobic coating on the core 
particles by TGA. The MNPs had a surfactant coating of 22.6% w/w. 
 A surfactant-mediated synthetic approach was adopted for this project since we aimed 
to form the clusters by flash nanoprecipitation by using amphiphilic Pluronic block 
copolymers. In this synthesis, 1,2 hexadecandiol was added as a reducing agent for the 
thermal decomposition of Fe(acac)3. The oleic acid and oleylamine acts as a surfactant 
during the synthesis for the formation of the iron oleate nuclei at 200°C, which act as the 
seeds growth of the crystals. These hydrophobic coatings also act as ligands for anchoring 
of the central PPO block of the Pluronic moieties. Benzyl ether was chosen for its high 
Figure 4.2. TEM image of magnetic nanoparticles coated with hydrophobic fatty acid 




boiling point (~295°C). This allowed for the rapid annealing of the MNPs once the growth 
is complete. It has been extensively reported that amphiphilic block copolymers such as 
Pluronic stabilize MNPs by a ligand exchange mechanism wherein the polymer exchanges 
with the hydrophobic surfactant on the crystal surface.
23, 24
 Surfactant-mediated synthesis 
enables precise control over the size of the cluster in a two-step process wherein the initial 
cores in the 3-6 nm range are further used as seeds to grow particles as large as 50nm.
21
  











cac : 1.63 mg/mL at 9.1% THF




4.3.2 PREPARATION AND CHARACTERIZATION OF MNCS BY MIVM 
 Prior to MNCs preparation the critical aggregation concentration (cac) of Pluronic F127 
was determined by DLS. Pluronic had a cac value of 1.63 mg/mL in the selected solvent 
systems comprising of 9.1% v/v THF in water. Hence, for all trials, care was taken to 
maintain the polymer concentration in the mixing chamber above the cac value. 
 Different trials, as mentioned in table 4.1, were conducted for formation of MNCs by 
MIVM.  As shown in figure 4.3, the crude formulation consists of a mixture of desired 
MNCs, un-encapsulated MNPs, dead micelles i.e. micelles with only drug and no MNPs 
encapsulated (shown by empty black circles) and un-encapsulated crystalline drug (PTX).  
Scheme 4.1. MNC purification process post MIVM. A Scheme showing magnetic 
separation of final product from a crude mixture. B Different components of the crude 





 The TEM images of the final products obtained after magnetic separation are shown 
in Figure 4.3. It can be seen that at lower Re values, the mixing was inefficient. As a result, 
there was a significant population of MNPs, which were either individually or at least very 
loosely held together by the polymer (figures 4.5A and B). In contrast, Re values above 
10,000, resulted in distinct, well-defined MNCs (figures 4.5C and D). As observed from 
the DLS data (Figure 4.6), all formulations showed particle sizes in the 50-150nm ranges 
Figure 4.4. TEM images of the different purified MNCs formulations obtained from 
different trials in Table 4.1 A.  Formulation A1 obtained at Re 6300 B. Formulation A2 




and good PDI. Formulations A1 and A2 in particular, showed lower Deff due to the 
presence of a large population of individual and loose MNPs stabilized by Pluronic F127. 
 The cluster size was governed by the targeted %LCMNP in the formulations prepared 
at Re 12000. Also, introduction of a more hydrophobic P123 polymer resulted in an 
increase in cluster size while the PDI was reduced significantly. Zeta potentials of the 
formulations were in the -15mV to +10mV range hinting at a mild surface charge.  We 
further determined the composition of selected formulations prepared at Re 12000 by TGA. 
For this study, PTX loading was determined separately by HPLC and that along with the 







































surfactant content were deducted from the total loss of ignition (LOI) to obtain the polymer 
content in the clusters. As seen in Figure 4.7, the targeted loading capacities of MNPs 
(%TLCMNP) dictated the composition of the formulations. Polymer type did not affect MNP 
encapsulation. However, incorporation of P123 polymer resulted in an increased in drug 
loading (%LC). However, the MNC formulations did not have high PTX loading.   
 Inclusion of P123 has been shown to significantly increase the %LC of PTX and other 
hydrophobic drugs in Pluronic-based micellar systems.
25-28
 Hence we had anticipated a 
similar effect with MNC formulations as well. However, the effect was only marginal. We 
speculate that the hydrophobic block of Pluronic is insufficient to encapsulate both MNCs 
as well as PTX and hence MNC encapsulation predominates over PTX. 
.Figure 4.6. % composition of MNCs prepared by MIVM at Re 12000 





















Polymer F127     F127   +20% P123           +20% P123
Re         12000                       12000       12000            12000
%TLCMNP 9       4 10                                5




 Further, we conducted extensive colloidal stability studies of formulation A4 in PBS 
(pH 7.4;10 mM) and DI water at room temperature (RT) and physiological temperature. 
The formulation was stable over the entire period of the study with minimal increase in 
both size as well as PDI (Figure 4.8).  
 
















































4.3.3 MRI CAPACITY OF MNCS PREPARED BY MIVM 
 
 Finally, we studied the MRI potential of two MNC formulations prepared from a blend 
of P123 and F127 (1:4 wt%) with 10% (Formulation B1) and 5% (Formulation B2) 
%TLCOMP respectively. MNCs were prepared at Re 12000. We prepared serial dilutions of 
the MNCs in 2% w/v molten agar gel. After the gels solidified at RT, MRI scans were taken 
in a 3T Siemens human MRI scanner. The protocol for T1 and T2-weighted images was 
similar to that followed in the previous chapters. As seen in figure 4.9, the contrast 
intensities were governed by %LCMNP. Formulation B1, with 10% TLC showed stronger 
negative contrast at lower concentrations than formulation B2 which had a 5% TLC.  
Interestingly, the formulations also exhibited superior T1 (positive) contrasts as well at 
higher concentration. It should be noted at MNPs less than 7nm core sizes (USPIOs) have 
been successfully used as T1 contrast agents. The MNPs used in this case were 6.3nm 




and hence showed an enhanced positive contrast as well. Further, the compact cluster 





 The advent of nanotechnology in the field of medicine and healthcare has initiated a 
radical change in the treatment of various diseases, especially those which, till now were 
perceived as fatal and untreatable. Several research studies have provided significant 
proofs of the concept by demonstrating unprecedented therapeutics efficacy of these 
nanoparticles loaded with the same therapeutic agents currently used in clinical practice, 
albeit with limited efficacy and severe side effects. However, large-scale production of 
uniform-sized nanoparticles of organic and inorganic hydrophobic compounds by an 
economical, scalable process is a considerable challenge. Flash nanoprecipitation is an 
advanced technique that relies on fast mixing of two or more streams to create 
supersaturation. In this technique dissolved solute/ solutes and stabilizing amphiphilic 
polymer are rapidly mixed with an anti-solvent to create supersaturation over a time period 
shorter than the typical nucleation and growth time scales for the hydrophobic 
components. The rapid nucleation and uniform growth of the nanoparticles is curbed by 
the uniform adsorption of the amphiphilic block copolymers on the particle surface. The 
process results in very narrow particle size distributions.  
 An understanding of rapid precipitation of the dissolved components requires an 
understanding of the role of macro-, meso- and micromixing on the development of 
supersaturation. Different types mixing devices have been developed and characterized, 
such as stirred-tank precipitators
29
 and impinging-jet precipitators
17
. Johnson and 
Prud’homme have studied the dependence of mixing time on a critical process parameter 
called the Reynolds number (Re) and geometry in a Confined Impinging Jet mixer (CIJ).
20
 
The MIVM overcomes a prime shortfall of the CIJ such as the requirement of equal flow 
rate of the solvent and anti-solvent streams entering the device. The ability to modulate 




The choice of Re dictates the performance of the MIVM and is independent of the 
configuration of the inlet streams. Above a certain threshold Re value, usually about 2000, 
very uniform mixing can be obtained for simple reaction mixtures. This threshold changes 
with the type of application. For nanoparticle formation Re value above 5000 usually 
provides highly uniform mixing and results in nanoparticles with significantly low PDI 
values. In case of MNCs formed by MIVM, this threshold Re value in the range of 5000-
6000. 
30
 The physicochemical properties of the solute encapsulated in the clusters plays 
a significant role in the efficiency of cluster formation. The solubility of the various 
components of the organic anti-solvent stream such as the drug, the MNPs and the 
polymers are significantly different and thus it is essential to select an appropriate Re such 
that all the components precipitate simultaneously upon super saturation in the mixing 
chamber. In addition, the concentration of the organic solutes in comparison with that of 
the stabilizing amphiphilic polymer was also a critical parameter. Thus, MNCs prepared in 
trial A1, showed a significant population of loosely held MNPs, which were individually 
stabilized by Pluronic following mixing at a Re 6,300. The PDI of this formulation was low 
most likely due to the presence of a significant proportion of individual highly 
monodisperse 7nm MNPs. This population of individually stabilized MNPs or ‘loose MNCs’ 
decreased significantly upon reducing the MNP concentration in the THF stream to 20 
wt% of that in Trial A1 and increasing Re to 8400. Further increase in Re to 12,000 and 
beyond resulted in complete absence of ‘loose MNCs’ with significant improvement in PDI. 
As the momentum of the mixing streams increased, it increased the mixing speed thereby 
prompting simultaneous precipitation of the MNPs and polymer and causing the polymer 
to stabilize the cluster promptly and efficiently. Any further increase in Re up to a maximum 





The negligible %LCPTX in all trials conducted with F127 only can be due to two factors. 
First is the type of polymer being used and second is the precipitation rate of the drug in 
the mixing chamber. Encapsulation of hydrophobic payloads within micellar systems or 
related core-shell structures comprising of a hydrophobic core and hydrophilic shell is 
governed by the properties of the amphiphilic polymers used for formation of the 
nanostructures. Pluronic F127 is a triblock copolymer with a relatively small central 
hydrophobic poly (propylene oxide (PPO) block having a molecular weight of 3775 Da (65 
PO r.u.). MNPs with fatty acid ligands on the surface are known to be stabilized by a 
process known as ligand exchange.
31-33
 As known from the previous two chapters and as 
discussed in the literature,
33
 there exists a hierarchy of binding of different functional 
groups with catechol showing the maximum ligand exchange with oleic acid from MNP 
surfaces followed by phosphates, amines and lastly carboxylates. Given the structure of 
the central PPO block of Pluronic and absence of any of these functional groups, we 
believe that the efficient micromixing in the mixer further accentuates the strong 
hydrophobic interactions between the PPO block and the oleic acid brushes on the MNP 
surface and it is these interactions that result in the formation of stable and well-defined 
spherical MNCs. However, in doing so, the PPO blocks get completely utilized by the 
MNPs leaving absolutely no hydrophobic polymeric region available for entrapment of 
PTX. Attempts were made to reduce MNP feed and increase PTX feed (trial A6). However, 
these attempts resulted in a high proportion of dead micelles and unentrapped free PTX 
with only a marginal increase in %LCPTX. Given the high HLB of Pluronic F127 (HLB 22), 
it is also very likely that upon reaching supersaturation in the mixing chamber, PTX 
precipitates rapidly leading to separation stabilization by the polymer and thus minimal co-
entrapment in the MNCs. In order to decrease the HLB of the polymeric system, 20 wt% 
Pluronic P123 (M.wt. 5750, HLB 8, PPO block M.wt. 3775) was mixed with 80 wt% of F127 




capacity of hydrophobic drug in resulting mixed micellar systems due to a decrease in the 
overall.
26-28
 This approach resulted in a significant increase in PTX loading. However, from 
the point of therapeutic efficacy and balance between the two functional components, this 
%LC was not sufficient and highlighted the limitations of Pluronic polymers for synthesis 
of co-encapsulated nanosystems such as the MNCs prepared here. An amphiphilic di-
block copolymer with a larger hydrophobic block of at least 6 KDa may be required to co-
encapsulate both the hydrophobic components in appreciable amounts in order to achieve 
the desired theranostic goals. 
 It should be noted here that %LCMNP could be controlled easily by changing MNP 
concentration in the THF stream. This was evident when the MRI potential of the MNCs 
obtained from Trials B1 and B2 was studied in phantom gels. MNCs synthesized in Trial 
B1 with 10 wt% concentration of MNPs in THF stream resulted in 39 wt% MNP content in 
comparison with Trial B2 wherein the MNP content in the THF stream was 5 wt% and 
resulted in 22 wt% MNP content (Figure 4.7). Interestingly, these MNCs showed 
significantly higher r1 signals as well. MNPs, specifically, USPIOs in the core size range 
of 4-7nm are known to undergo both R1 and R2 relaxation resulting a dual-modal contrast 
capability.
34-36
 This finding further expands the scope of biomedical applications of these 
MNCs beyond tumor contrast and drug delivery agents. Such MRI contrast agents can 
also function effectively as blood pool agents in cardiovascular and cerebrovascular 






 . Flash precipitation or MIVM involves rapid nucleation at rates less that 50ms, growth 
and kinetically induced polymeric stabilization of the nanoparticles. We attempted to 
design theranostic magnetic nanoclusters by co-encapsulating anticancer agents PTX 
along with oleic acid coated MNPs (OMPs) stabilized by Pluronic block copolymers during 
the rapid micro-mixing of the organic solvent stream containing dissolved polymer, MNPs 
and PTX into miscible anti-solvent streams at time scales in the order of 1-2ms.  MNCs 
fabricated by MIVM displayed uniform spherical structure and had a narrow size 
distribution and relatively low polydispersity. By changing the Reynolds number (Re), the 
cluster size and size distribution could be controlled easily. Given the higher HLB of 
Pluronic F127, inclusion of a relatively hydrophobic Pluronic P123 enabled successful 
encapsulation of Paclitaxel along with the MNPs. Although, considerably less than 
conventional micellar systems, the obtained PTX loading was in line with our anticipation 
given the relatively smaller hydrophobic blocks of Pluronic F127 as well P123. These 
resulting compact MNC formulations produced a higher negative T2-weighted contrast 
under a 3T MRI scanner indicating at significantly higher relaxivity (r2) values. Thus, we 
report the successful fabrication of a biocompatible theranostic system with potential 
applications in cancer therapy wherein the site-specific chemotherapeutic efficacy and 






3.5 FUTURE DIRECTIONS 
 The ability of MNCs prepared by MIVM to function as both T1 and T2 contrast agents, 
as shown in the phantom gel results is a highly desirable feature and hence we propose 
that the same core size be used. While Pluronic block copolymers resulted in stable MNCs 
by MIVM, the polymer structure was the main factor limiting the co-encapsulation of PTX 
and MNPs. Hence future studies will be directed towards studying the effect of polymers 
with longer hydrophobic blocks. Given the advantages of polypeptide-based polymers, we 
propose to design MNCs stabilized by poly (phenyl alanine)-PEG polymer. Given the 
highly hydrophobic nature of poly (phenyl alanine), synthesis of the diblock copolymers 
may require a longer PEG block, such as that with M. wt 10,000 in order to balance a poly 
(phenyl alanine) block of more than 50 r.u. Subject to successful loading of both MNPs 
and significant amounts of PTX or any other anti-cancer agents, we also propose 
extensive in vitro and in vivo studies to establish the theranostic potential of these MNCs 
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 The superparamagnetic properties of magnetic nanoparticles (MNPs) have continued 
to attract the attention of scientists from various field for more than three decades. These 
concerted efforts have resulted in numerous applications of magnetic iron oxide 
nanoparticles as noted in the previous chapters. Of particular interest are the biomedical 
applications of MNPs. The ability to precisely control the sizes of MNPs from a few 
nanometers to a few tens of nanometers further expands the scope of these biomedical 
applications. These MNPs can be manipulated by an external magnetic field gradient. The 
magnitude of such a manipulation depends largely on the size of the magnetic cores. This 
‘remote control’, combined with the fundamental penetrability of magnetic fields into human 
tissue can be exploited in numerous applications such as those involving the transport 
and/or immobilization of magnetic nanoparticles, or of magnetically tagged biological 
entities. MNPs or polymer-stabilized formulations thereof can be developed to deliver a 
wide variety of therapeutic payloads such as an anticancer drug, or a regiment of 
radionuclide atoms to a targeted region of the body, such as a tumor. The magnetic 
nanoparticles can be made to transfer of energy in the form of heat from the exciting field 
to the nanoparticle. This has led to their use as hyperthermia agents, producing toxic 
amounts of thermal energy in targeted bodies such as tumors; or as adjunct therapy in 
combination with chemotherapy and radiotherapy.  
 These and many other possibilities are available in nanomedicine as a result of the 
special physical properties of MNPs. Of all these application, the ability of MNPs to serve 
as MRI contrast agents has attracted tremendous attention from the theranostic view point. 




that shows minimal toxicity, sufficient drug loading capacity and most importantly a precise 
balance between the two components i.e. MNPs (diagnostic) and chemotherapeutic 
agents. Achieving this balance is critical to the success of MNPs as co-encapsulated 
theranostic agents, and certainly poses significant challenges in the development of MNPs 
for cancer theranostics.  
 This dissertation was aimed at designing a biodegradable theranostic nanosystem 
capable of simultaneous drug delivery of anti-cancer agents and MRI contrast agents i.e. 
MNPs which serve as excellent T2- contrast agents. Based on the published literature on 
development of MNPs as theranostic agents, it can be concurred that there are critical 
factors for the successful development of a MNP-based theranostic system. They are:- 
a. The physicochemical characteristics of the core MNPs 
b. The selection of the stabilizing polymer 
 Accordingly, our efforts were focused on synthesizing MNP cores with enhanced 
magnetic properties followed by a comprehensive evaluation of different block copolymers 
as potential stabilizing and cluster forming components of the resulting MNCs. Given the 
continued emphasis of your group on development of biocompatible drug delivery 
technologies, we employed biocompatible and biodegradable polymers in these projects.  
In Chapter 1 we first modified a simple on-pot procedure for synthesis of MNPs by thermal 
decomposition of the organometallic precursor Fe(acac)3. The magnetic properties of 
MNPs, which are essential for their MRI contrast function, are governed by the chemical 
nature and oxidation state of the MNP crystal along with the size of the MNPs. We 
successfully demonstrated that we can control the crystal size by precisely controlling the 
rate of heating of the reaction mixture. The rate at which the reaction mixture was heated 
controlled the two critical staged of crystallization i.e. nucleation and growth. Thus the 




 The stabilization of these MNPs were carried out by coating with completely 
hydrophilic anionic poly (glutamic acid)-b-poly (ethylene glycol) polymers with different 
poly (glutamic acid) block (PLE) lengths. However, the clusters so formed were unstable 
in physiological media resulting in aggregation and loss of colloidal properties. This was 
attributed to the PLE block length and the weak coordination complex formed between the 
carboxylate endgroups of the polymer and the MNP surface, which was easily displaced 
by the physiological electrolytes that have a higher affinity for MNP surface. This 
necessitated the structural modification of the polymer to incorporate bisphosphonate 
containing end groups, which are known to form very strong coordination complexes with 
MNP surfaces. Inclusion of bisphosphonate containing end groups on the PLE block 
significantly enhanced the colloidal stability of the MNCs in physiological conditions. The 
degree of conjugation (Dconj) of the bisphosphonate-containing ALN molecule on the PLE 
block dictated the stability of the clusters with maximum stability obtained at a Dconj of 19 
and a cluster size of approximately 70nm.  
 Cisplatin was successfully conjugated on the MNCs via electrostatic interactions with 
the available carboxylate groups at pH 9.5. The release rate was also controlled by Dconj. 
MNCs with highest Dconj also exhibited the slowest release profile. Overall, the MNCs 
exhibited a sustained pH dependent release profile which was significantly faster at the 
acidic pH. The Dconj and the resulting cluster size, along with the size of the core MNP 
particles controlled the magnetic properties of the MNCs. In addition, inclusion of cisplatin 
also positively affected the T2 relaxivity of the resulting MNC formulations. The 
incorporation of the Pt metal resulted in close proximity with the MNPs resulted in a metal 
cluster effect which is speculated as a reason for the increase in relaxivity of the MNCs 




 These anionic MNCs had very low nonspecific cellular uptake in ovarian cancer cells. 
This is a highly desired feature in nanoformulations as it enables site specific targeting of 
the nanoformulations thereby significantly reducing the undesired side effects due to 
uptake in the healthy tissue as well. We targeted this formulation exclusively to ovarian 
cancer tissue overexpressing LHRH receptor. The MNCs were decorated with synthetic 
LHRH peptide. LHRH conjugation enhanced the cellular uptake significantly. The effect 
was more pronounced in cisplatin resistance ovarian cancer (A2780-CisR) cells than the 
wild type cells (A2780-WT). This active targeting strategy successfully translated into 
enhanced anticancer efficacy wherein the targeted formulations reduced the IC50 by 
almost half in comparison to the non-targeted MNCs. LHRHr targeting and the resulting 
increase in target-specific uptake of the MNPs significantly enhanced the in vitro MRI 
contrast of the formulation when measured in ovarian cancer cells embedded in agar 
phantom gels. 
 Following the successful evaluation of the anionic biocompatible polymer PLEX-b-
PEG113 as a surface stabilizer for theranostic MNCs, we studied the potential of a cationic 
block copolymer in development of stable of MNCs for cancer theranostics (Chapter 3). 
For this purpose, we employed classical poly (l-lysine)-b-poly (ethylene glycol) block 
copolymers of different l-lysine repeating units (X = 10, 50 or 100). The MNPs synthesis 
was modified to further enhance the magnetic properties without compromising on the 
larger core size and greater saturation magnetization. (Ms). MNCs stabilized by PLKX-b-
PEG113 polymers. The cationic block copolymers stabilized the MNPs more efficiently than 
the anionic PLE-based polymers discussed in Chapter 1. However, similar to the anionic 
block copolymers, the stability of the resulting clusters was dictated by the PLK block 
length. Nonetheless, the resulting cationic MNCs did not exhibit any instability in 




The MNCs so developed exhibited significantly higher T2-relaxivities which increased 
depending on the MNP size as well as the Deff of the clusters.MNC-3 and MNC-4 had r2 
values significantly higher when compared to the once commercially available T2-contrast 
agent Feridex
®
. The therapeutic functionality was introduced onto the most stable MNC-4 
clusters in the form of anti-cancer agent doxorubicin (DOX). DOX was conjugated onto 
the MNCs at the pendant side chain primary amino group via a pH sensitive hydrazine 
bond using hetero-bi-functional linker SPDP. The utilization of this end terminal 
significantly reduced the charge induced toxicity of the formulations. A maximum of 2.5 
wt% DOX conjugation was achieved on the MNCs. The pH sensitive hydrazine bond 
successfully prevented premature release of the chemotherapeutic agent in the 
physiological medium. As desired, the drug was released rapidly in a sustained manner in 
acidic pH. The cationic MNCs had significantly higher cellular uptake; almost 20-folds 
higher when compared that of the targeted anionic MNCs discussed in the previous 
chapter. Of the two cell lines tested, triple negative breast cancer MDA-MB-231 cells 
exhibited a relatively slower rate of uptake than the A2780-WT ovarian cancer cells. 
Confocal microscopy of the ovarian cancer and triple negative breast cancer cells revealed 
that post-internalization, the clusters were lodged in the lysosomal vesicles, thus 
supporting the strategy adopted for triggering the drug release from the clusters. Finally, 
the DOX-loaded pH sensitive MNCs exhibited cytotoxicity efficacy consistent with that 
expected from a stimuli-responsive sustained release nanoformulation. The IC50 values of 
the formulations was dependent on the drug loading. DOX-MNC-4c formulation was 
further tested for its MRI contrast potential in vitro by incubating it with the above 
mentioned cell lines for a 24h period. Cationic MNCs, by virtue of a higher cellular uptake 
exhibited significantly stronger T2-weighted contrast in agar phantom gels. Thus, the 
cationic polymers are more efficient in stabilizing bare uncoated (without oleic acid) MNPs 




synthesized by thermal decomposition have seldom been stabilized via hydrophilic routes 
and hydrophilic. We showed that in comparison with the co-precipitation technique for 
synthesis of MNPs, the MNCs formed here were significantly superior from the point of 
stability, cluster integrity and magnetic properties. Based on the observations in Chapters 
2 and 3, it can also be concluded that the strength of the coordination complexes between 
the MNP surface and the polymers is dictated by the available functional groups and that 
the strength of these complexes increases as follows –COOH < -NH2 < (PO(OH)2)2. 
In Chapter 4, we studied the effect of multi-inlet vortex mixing (MIVM) or flash 
precipitation on cluster formation and co-encapsulation of MNPs and hydrophobic anti-
cancer agent paclitaxel (PTX). MIVM technique is based on the principal of kinetically 
controlled supersaturation and the resulting kinetically controlled precipitation of MNPs 
into highly monodisperse MNCs stabilized by amphiphilic block copolymers.  In sharp 
contrast to the MNPs and polymers used in the previous chapters, here we employed the 
widely used thermal decomposition technique to coat the MNPs with hydrophobic 
surfactants oleic acid and oleylamine in situ while the polymers were triblock amphiphilic 
Pluronic block copolymers. 
 The clustering formation is governed by four critical factors namely  
a. The flow rate of the opposing streams during the mixing process (Reynolds 
number Re) 
b. The final ratio of organic and inorganic solvents in the mixing chamber, which leads 
to supersaturation and precipitation 
c. The concentration of the organic components in the miscible organic fraction and 
the critical aggregation concentration (cac) of all the organic components in the 
final mixed solvent system in the chamber 




The cluster formation process showed maximum efficiency at Re between 9000 
and 12,500. Beyond 12,500 the cluster formation showed no significant improvement. 
Re controls the supersaturation of the system and hence the onset and rate of 
precipitation of the organic components. The Re was optimized to 12000. Any further 
increase in Re did not cause any changes in the efficiency. Polymer characteristics 
play a significant role in MNC formation. Since the cluster formation is caused by 
interaction of the hydrophobic block of the polymer and the hydrophobic surfactants 
coating the MNPs, the hydrophobic block length and thus the overall HLB of the 
polymer played a critical role in MNC formation as well as co-encapsulation of PTX 
along with the MNPs. With Pluronic F127 and P123, the hydrophobic blocks do provide 
ample hydrophobic environment for co-encapsulating significant amounts of PTX, 
most likely due to the presence of MNPs, which utilize most of the hydrophobic blocks 
for stabilization into clusters. Nonetheless, in comparison to single polymer F127, a 
4:1 blend of F127 and P123 resulted in an increase in co-encapsulation of PTX. Thus, 
MIVM provides a highly efficient technique for formation of MNCs with low 
polydispersity. Due to technical difficulties, the drug loading could not be maximized. 
Nonetheless, the results have provided a good understanding into the variables that 
are critical to the enhancement of drug loading. 
Thus, to summarize, we successfully studied the physicochemical factors affecting 
formation of MNP-based theranostic. In doing so, we successfully developed highly 
stable theranostic MNCs from three different types of block copolymers namely, 
anionic, cationic and non-ionic block copolymers. This success and the insights gained 
into the development of MNPs as MRI contrast agents warrant further research into 
the in vivo characterization of these different theranostic nanosystems. 
 
